For a fraction of a second, the future is still open. The ball can fall cleanly through the net, glance off the rim, or bounce toward the baseline. A person who has watched enough basketball begins predicting the outcome before impact. The eyes catch the angle. The body anticipates the rebound. A player moves before the ball arrives.

A modern video model can generate this scene beautifully. It can reproduce the arena lights, the flex of the rim, the ripple of the net, even the disappointment on a fan’s face. Yet beauty answers the easiest question. The harder question arrives before impact: where will the ball go, and what should the player do now?

That gap between drawing the future and preparing for it has become one of the largest bets in artificial intelligence.

Language models became powerful by predicting symbols. World models are chasing a more unforgiving target: the next state of a scene, the consequence of an action, and the uncertainty between the two. From November 2025 through June 2026, six prominent US companies pursuing different versions of this idea raised $4.525 billion across their latest publicly announced or credibly reported rounds. NVIDIA, AMD, Alphabet, Amazon, Adobe, and Autodesk have entered through models, chips, cloud agreements, venture investments, and workflow partnerships.

The phrase “world model” makes the movement sound more unified than it is. Underneath it sit several competing beliefs about intelligence. One camp wants to generate the world in pixels. Another wants to ignore pixels and predict in a compressed internal space. A third teaches agents inside imagined futures. A fourth builds persistent 3D environments that software can inspect. A fifth begins with the robot and works backward from action.

They are climbing the same mountain from different sides. Capital is funding every trail because the prize is larger than better video. A machine that can rehearse consequences can create its own training experience. It can test a decision before taking it. Eventually, it can act in the physical world with less human supervision.

The race begins with a deceptively simple question: what does a machine need to know about reality in order to choose well?

Reality Has a Higher Standard

The idea reaches back long before generative AI. In 1943, psychologist Kenneth Craik proposed that the mind carries a “small-scale model” of external reality and uses it to try possibilities before acting. Reinforcement learning later turned that intuition into machinery. An agent observes an environment, takes an action, sees what changes, and builds an internal representation of those transitions.

The model never needs to contain the whole world. A driver approaching an intersection can ignore the motion of every leaf. The other car, the possible paths, the uncertain intent of its driver, and the consequences of braking belong in the decision. Intelligence comes partly from knowing what can be discarded.

In the strict control-theory sense, a world model represents how an environment changes, often after an action, so an agent can predict or plan. The commercial label has expanded far beyond that definition. Video generators predict observations. Meta’s Joint Embedding Predictive Architecture predicts compressed representations. World Labs constructs spatial state. Robot models from Physical Intelligence and Skild AI produce actions, sometimes without exposing a separately inspectable simulator.

This distinction changes how investors should read a demonstration. A renderer promises that the future will look plausible. A simulator promises that the future will respond plausibly when something changes. A planner promises a useful action. Each step raises the cost of being wrong.

An impossible reflection in a commercial video can be edited. A collision error in a factory simulation can waste days of engineering. A wrong command from a robot can damage equipment or hurt someone. The label may be shared; the product contracts are radically different.

For any company selling simulation or planning, one test cuts through the language: if the agent takes a different action, does the model predict the resulting state well enough to improve the decision?

Video generation has yet to clear that bar consistently. OpenAI’s original Sora research report argued that large video models showed a path toward general-purpose simulation. The same report documented failures in object state, glass shattering, and long-duration coherence. Since then, video has become much more convincing. The strongest published tests still find a gap between visual realism and dependable physical prediction.

WorldModelBench found that standard video-quality scores often miss violations of physical laws. Physics-IQ found no statistically significant relationship between visual realism and physical understanding among the models it tested. In a separate 2D collision-and-motion testbed, scaling improved familiar cases and new combinations of familiar elements while failing to produce reliable out-of-distribution extrapolation. The models behaved more like expert imitators than discoverers of universal laws.

This is the tension at the heart of the market. Video models are learning more about the world as they get better at generating it. The knowledge can still break precisely where a machine needs it most: after an unfamiliar intervention.

A beautiful world proves that the renderer works. Simulation begins when changing the cause changes the consequence correctly.

Five Beliefs About Tomorrow

The modern story starts in 2018, when David Ha and Jürgen Schmidhuber published World Models. Their agent compressed an environment into a learned internal space, then trained inside what the authors called its “dream.” The visual output was crude by current standards. The idea was radical: an agent could practice inside a model rather than spending every lesson in the real environment.

DeepMind pushed the same principle toward decision-making. MuZero mastered games without reconstructing every detail or receiving their rules. It learned the dynamics required for reward, value, and action. DreamerV3 imagined trajectories inside a compact learned model and trained behavior from those imagined outcomes. Using one configuration across more than 150 tasks, it became the first algorithm reported to collect diamonds in Minecraft from scratch without human data or a hand-designed curriculum.

MuZero and Dreamer carry a less cinematic business lesson: completeness can become a liability. The best internal model may be the smallest one that preserves the consequences needed for a decision. Every irrelevant detail consumes computation. Every omitted critical variable creates failure.

Yann LeCun has built his argument around this trade-off. His Joint Embedding Predictive Architecture avoids forecasting every pixel because the exact future is unknowable and much of it is irrelevant. A model can instead predict a useful representation of a missing region, another view, or a future state. It learns the shape of the world without spending all its capacity on the flicker of leaves or the texture of a wall.

Meta’s V-JEPA work has begun connecting that philosophy to physical control. V-JEPA 2 learned largely from video, then added an action-conditioned predictor trained on a relatively small quantity of robot trajectories. The 2026 V-JEPA 2.1 paper reported that one-step cup-grasp success rose from 60% to 70% versus V-JEPA 2; an eight-step planning configuration reached 80%. It also reported roughly ten times faster short-horizon navigation planning than its SD-VAE baseline. The manipulation evaluation used ten trials per skill, so these results are signals from a laboratory rather than deployment evidence. Even within that narrow frame, they reveal something important: a machine can learn representations from watching the world and later turn them into plans without generating a photorealistic movie of the future.

The video camp is making the opposite wager. Rather than discard visual detail, it wants scale to absorb the structure hiding inside it. Google DeepMind’s Genie 3 generates navigable environments as a user moves through them. Runway’s GWM-1 family extends real-time video generation into explorable worlds, avatars, and action-conditioned robot rollouts. Odyssey is building interactive simulations. Luma describes its ambition as models that can generate, understand, and operate in the physical world.

Their raw material is abundant. The internet contains an enormous visual record of falling objects, moving bodies, flowing water, human gestures, street scenes, tools, machines, and rooms. If language models extracted structure from text at scale, perhaps video models can extract intuitive physics from motion at scale.

Fei-Fei Li and World Labs approach the problem through space. Her thesis of spatial intelligence begins with a fact language models can easily obscure: people live in three dimensions. We navigate rooms, infer depth, understand occlusion, and manipulate objects. World Labs’ Marble turns text, images, video, or rough layouts into persistent 3D environments. Those environments can export Gaussian splats, visual meshes, and coarse collider meshes for existing tools.

Marble is a meaningful step beyond a fixed clip because the user can move through the result and take the geometry elsewhere. Its collider mesh does not transform it into a validated physics engine. World Labs has been unusually clear about that boundary. In its functional taxonomy, renderers create what people see, simulators preserve state and dynamics that software can use, and planners decide what to do. The long-term ambition is to bring those functions together. The current product begins with space.

NVIDIA is attempting a broader fusion. Cosmos 3 combines reasoning, world generation, and action generation across multiple forms of input. Omniverse supplies an environment for simulation. Isaac supplies robotics tools. GPUs and networking provide the computation. This route does not ask learned models to replace classical physics immediately. Neural systems can generate scenes, sensor data, rare events, and candidate futures while deterministic engines enforce the constraints engineers already trust.

That hybrid may dominate the next few years. It can create economic value before anyone builds a universal simulator.

Physical Intelligence and Skild AI start closer to the machine that must move. They are training robot foundation models across tasks and, in Skild’s case, across different bodies. Their systems sit beside the strict world-model category. A successful policy must exploit regularities in how actions change an environment, but an observation-to-action policy can encode those regularities without predicting future states in a separately inspectable simulator.

The difference may sound philosophical until money enters the picture. Investors have valued Physical Intelligence above $5 billion and Skild above $14 billion. Those prices already assume substantial progress beyond today’s bounded demonstrations. They are wagers that learning across tasks, environments, and robot bodies will eventually produce an economic machine brain.

One phrase now contains at least five beliefs: dream inside compact dynamics, predict in latent space, scale video into simulation, build spatial worlds, or learn action directly. The eventual winner may combine all five. The market has begun paying long before that convergence is proven.

The Money Arrived Before the Proof

The financing did not build slowly. It arrived in waves.

In November 2025, Luma AI announced a $900 million Series C at a reported valuation above $4 billion. Around the same time, Bloomberg reported that Physical Intelligence had raised $600 million at a $5.6 billion valuation. In January 2026, Skild AI announced a $1.4 billion Series C at a valuation above $14 billion. Runway followed in February with $315 million at $5.3 billion. Eight days later, World Labs announced $1 billion in new funding. By June, Odyssey had raised $310 million at a $1.45 billion valuation.

Together, those six latest rounds total $4.525 billion. The sum is deliberately narrow; it covers selected US-headquartered companies rather than the whole market. Its composition says more than its size.

Capital is backing the forgiving end of the market and the unforgiving end at the same time. Runway and Luma can sell creative generation now while financing a larger simulation ambition. World Labs can enter design and media workflows through 3D creation. Odyssey can turn interactive environments into a product before solving universal physics. Physical Intelligence and Skild are priced against a future labor market whose revenue remains gated by reliability in the real world.

The public companies circling these startups are also buying different forms of optionality.

NVIDIA has the broadest position. It supplies the dominant accelerated-computing platform, builds Cosmos, Omniverse, and Isaac, and has invested in World Labs, Runway, Skild, Luma, and Odyssey. Its advantage comes from participating across several technical routes. Its risk comes from assuming too much of the future compute pool while AMD and hyperscalers build alternatives.

AMD Ventures has backed World Labs, Runway, Luma, and Odyssey. These stakes create strategic access to major multimodal-model developers. They are not evidence of Instinct demand until those companies disclose AMD-based training or inference workloads. The distinction matters for public investors because a venture relationship can validate a category without moving product revenue.

Alphabet owns perhaps the most unusual collection of assets. Google DeepMind has Genie, Dreamer, and years of model-based reinforcement-learning research. Project Genie has been grounded in Street View imagery. Waymo gives Alphabet a separate embodied-AI business and a potential source of future learning loops, although public evidence does not show its driving logs training Genie. CapitalG led Physical Intelligence’s 2025 financing, while GV backed Odyssey. Alphabet has research, distribution, venture exposure, and an autonomous-driving business; the world-model economics may still remain buried inside a company of its size.

Amazon’s participation in Odyssey reveals the cloud strategy more cleanly. Odyssey named AWS its preferred cloud provider and said it would optimize for Trainium. Amazon can fund the application and compete for the workload it creates.

Autodesk has the clearest disclosed bridge into an existing workflow. Its $200 million investment in World Labs includes a strategic advisory role and plans to explore integration with Autodesk design software. If that work becomes a product, world generation gains access to architects, designers, engineers, and media creators who already pay for spatial tools. The model does not need to become general intelligence to save them time.

This is where the capital story becomes more interesting than the funding total. Venture investors are betting on standalone model companies. Strategic investors are positioning chips, clouds, and software around those models. If the frontier commoditizes, much of the durable value can still flow to the companies that own computation, distribution, workflows, and deployed machines.

The deepest bet is therefore larger than any startup valuation. World models could turn video inference, simulation, and robot learning into persistent computational workloads. Every generated world can be explored. Every exploration produces more states. Every policy can be tested across thousands of variations. The appetite for computation grows with the number of futures a machine can afford to rehearse.

Rehearsal Becomes a Business

The world-model market will earn revenue in the reverse order of its ambition.

Creative work comes first because creative errors are cheap. A studio can use generated video for previsualization. An advertising team can explore concepts before a shoot. A game developer can sketch a world before artists build it. A designer can generate spatial alternatives while a person chooses what survives. Runway and Luma can fund long-term research with products whose current value is visible in a single session.

The next market begins when generated environments become rehearsal spaces.

Robotics companies need rare failures that are dangerous or expensive to collect physically. Autonomous-vehicle systems need edge cases that appear only after millions of miles. Factories need to test layouts before moving equipment. Architects need environments that remain coherent while they are changed. A useful simulator can reduce real-world training hours, expose policy failures earlier, and widen the range of conditions an agent sees before deployment.

Perfection is unnecessary. Economic usefulness arrives when the simulator improves a measurable outcome. If synthetic experience increases robot success, lowers testing costs, or catches a design error, the model has earned its place in the workflow.

This is why hybrid systems have the strongest near-term position. Learned models can supply variation; CAD systems, physics engines, and digital twins can supply constraints. The neural model does not need to rediscover every engineering law from video before customers benefit. It needs to generate the uncertainty and diversity traditional tools handle poorly.

By 2029, the market should begin judging world models by intervention accuracy and sim-to-real performance. Video quality will remain commercially useful, but the strategic benchmark will shift: when an action changes, does the predicted outcome change correctly, and does training on that prediction improve behavior outside the simulator?

That transition favors companies with proprietary action-and-outcome data. Internet video shows what happened. Robot trajectories, driving logs, simulation rollouts, and human interaction traces show what an agent did and what changed afterward. A deployed fleet or a high-volume workflow can turn each failure into another training case.

Distribution then becomes part of the intelligence. A model inside Autodesk can learn from design workflows. A robot model inside a working fleet can collect new trajectories. A simulation platform tied to NVIDIA’s tools can sit beside training and deployment. A benchmark leader without a workflow receives less feedback and becomes easier to replace.

Through 2029, the strongest businesses will sell useful incompleteness: creative rendering with paying users, hybrid simulation connected to engineering or robotics, and compute platforms that earn revenue across several architectures. Universal reality engines can wait. Customers will pay for smaller worlds that solve expensive problems.

Physical action comes last because its errors are unforgiving. A household robot can succeed nineteen times out of twenty and still be unusable if the twentieth failure breaks a glass beside a child. Long tasks compound small mistakes. Hardware wears out. Safety certification takes time. Customer environments resist standardization.

Industrial work will move sooner. Warehouses, factories, laboratories, and logistics sites can constrain the environment and define success clearly. “General” robot models may first earn money through bounded jobs such as sorting, inspection, material handling, or repetitive manipulation. Their intelligence can generalize more than traditional automation while the workplace limits the chaos they must survive.

Revenue therefore moves from forgiving outputs to unforgiving ones: pixels first, simulation next, physical action last.

The Scarce Asset Is Consequence

The long-term thesis begins where the near-term product ends.

David Silver and Richard Sutton describe an approaching “era of experience”, in which agents improve through sustained interaction rather than depending mainly on static human-created data. A world model gives that agent somewhere to practice between encounters with reality.

Imagine a warehouse robot that fails to grasp a new package. The failure creates a trajectory: the camera view, the attempted movement, the contact, the slip, and the final state. A world model identifies where its prediction diverged. Simulation generates variations around that failure—different angles, lighting, packaging, friction, and timing. The policy practices against those variations. The improved robot returns to the warehouse and produces new evidence.

Deployment feeds simulation. Simulation improves the policy. The policy returns to deployment.

This loop is the real long-term moat. The LLM boom competed for human-created text. Physical AI will compete for trajectories recording what an agent did, what changed, and where its prediction failed. Companies with machines in the world can collect data unavailable in passive video. Companies with simulation can multiply each physical lesson. Companies that own both can compound faster.

The architecture may eventually blend today’s camps. A system could render observations for people, maintain a compressed state for reasoning, simulate counterfactual futures, and generate actions for machines. NVIDIA’s Cosmos 3 is moving toward a combination of reasoning, generation, and action. World Labs expects the borders among renderers, simulators, and planners to narrow. Meta is showing how latent prediction can feed robot planning. Runway is extending video generation into action-conditioned rollouts.

The winner will be the company that closes the experience loop. Until deployment data improve the simulator and the simulator measurably improves the deployed policy, “unified world model” remains option value rather than operating proof.

Three failures could break the investment thesis. Video scaling may remain trapped in plausible imitation, forcing customers to gather near-exhaustive deployment data. Generated environments may fail to improve real policies, leaving classical simulators in control of high-value engineering work. Robotics may remain constrained by hardware, maintenance, safety, and customer integration after model quality improves.

If those conditions persist, the category can still expand while most value accrues to chips, clouds, existing simulation software, and deployed fleets. Independent model labs would face the same pressure language-model companies already feel: immense training costs, rapid imitation, and uncertain differentiation.

For public-market investors, NVIDIA currently offers the broadest exposure, Alphabet the widest collection of internal options, Autodesk the clearest workflow bridge, Amazon a cloud-and-silicon route through Odyssey, and AMD a portfolio of strategic relationships whose hardware payoff remains unproven. None deserves a valuation change solely because “world models” appears in an investor deck. The signal will come from workload growth, product integration, customer adoption, and evidence that simulated experience changes real behavior.

Private investors need an even sharper question. A vivid demonstration can hide a weak business. The useful test is whether intervention predictions hold over the required horizon, whether simulation improves a customer workflow or real policy, how much deployment data remain necessary, and who owns the feedback when the model fails. Revenue from a current product is far more valuable than a financing round sustaining a product customers may want later.

The defining metric will be decision usefulness per dollar.

Before the Robot Moves

Return to the basketball suspended above the rim.

The renderer creates the arena. It makes the shot look real.

The simulator carries the ball forward. It predicts the miss and the direction of the rebound.

The planner chooses a path. The robot moves before the ball arrives.

Capital is funding all three moments. Over the next few years, rendering should produce the clearest revenue and hybrid simulation the strongest enterprise pull. Robot-planning companies may continue attracting the richest private valuations, with operating proof lagging until reliability improves. Over the longer term, these functions can converge inside systems that learn continuously through action and consequence.

The decisive breakthrough will come from a machine that can imagine the wrong move, understand what follows, and choose differently before reality makes the mistake expensive.

That is the deeper wager behind the world-model boom.

AI learned to speak by predicting the next word.

Now it is learning to move by predicting the next world.

The company announced a public blockchain, a new generation of tokenized stocks, 24/7 markets, decentralized lending, perpetual futures and AI agents that can trade. Robinhood called the event “The World Is Flat.” The name sounded like marketing until Robinhood Chain went live and capital began moving.

Within a week, daily transactions had climbed from roughly 680,000 to 7 million. Daily active users rose from about 33,000 to 194,000. Token Terminal tracked nearly $250 million of liquidity, including approximately $70 million of bridged ETH and $178 million of USDG. On Uniswap, daily volume approached $500 million.

Then crypto did what crypto always does. The memes arrived.

Much of the early volume came from speculative tokens rather than tokenized stocks. Critics saw a familiar circus: incentives, cheap gas, market makers and traders chasing whatever had started moving. Vlad Tenev saw the same thing and laughed. On X, the Robinhood co-founder wrote that while Robinhood Chain was being built as “the best chain for RWA,” it apparently “works great for memes too.”

I think the market is reading that joke too narrowly.

The meme activity revealed Robinhood’s most valuable advantage. The company can point users, liquidity providers, developers and market makers toward a new piece of infrastructure and make it feel alive almost immediately. Most blockchains spend years begging for that kind of attention. Robinhood switched it on in days.

The first week was never the destination. It was a demonstration of force.

Robinhood is turning itself from an app that sells access to financial markets into a company that owns more of the market itself. Robinhood Chain is the clearest expression of that ambition. And because the chain is an Ethereum Layer 2 built with Arbitrum technology, its launch also strengthens a second thesis: Ethereum is becoming the default operating system for institutional onchain finance.

I am bullish on both HOOD and ETH because they occupy different positions in the same transition. Robinhood owns distribution and the customer relationship. Ethereum owns the settlement ecosystem, liquidity gravity and technical standards that increasingly sit beneath digital finance.

DeFi is the future of market structure. Robinhood Chain is where a major public fintech finally began acting like it.

The brokerage is disappearing into the chain

Robinhood began by making stock trading feel simple. The interface hid the machinery behind the trade: exchanges, clearing, custody, market makers, settlement schedules and banking relationships. That model won millions of customers, but Robinhood still depended on infrastructure owned by other companies.

Its recent strategy has been a steady march inward.

Bitstamp added institutional crypto distribution. Robinhood Banking and the Gold Card pulled more of the customer’s financial life into one account. Robinhood Strategies moved the company into managed money. Private-market funds created access to assets that traditional retail investors rarely see. Rothera, Robinhood’s prediction-market venture with Susquehanna, gave the company more control over product selection and pricing.

Tenev explained the logic on Robinhood’s first-quarter 2026 earnings call. Vertical integration, he said, gives Robinhood “end-to-end control of the customer experience, including pricing and selection.” On the same call, he described a coming tokenization “supercycle” and said Robinhood wants to apply crypto infrastructure to assets with real-world utility.

Robinhood Chain joins those ideas together.

A brokerage earns from the activity that passes through its interface. A financial network can participate in issuance, trading, settlement, lending, collateral, data and application activity. When Robinhood places tokenized assets on infrastructure it operates, seeds liquidity around them, distributes them through its wallet and allows developers to build with them, each product becomes part of a larger economic loop.

That loop can compound.

More assets attract more liquidity. More liquidity attracts traders. Traders create fees and price discovery. Deeper markets make the assets more useful as collateral. Lending creates another reason to hold capital onchain. Developers gain a larger customer base, which encourages them to build applications that bring in still more users.

The brokerage interface remains important, but the chain begins to absorb the economic activity behind it. Robinhood can keep the consumer experience familiar while moving more of the machinery onto programmable rails it helps control.

Wall Street has spent decades separating trading, settlement, custody and lending into different systems with different operating hours. DeFi collapses those functions into software. An asset can trade, settle, move into a wallet, enter a lending pool and become collateral inside the same digital environment. The market remains open while the software enforces the rules.

That architecture is structurally better. It is faster, globally accessible and easier for developers to extend. Robinhood’s bet is that customers will eventually use it without caring whether the activity is called crypto, brokerage or DeFi. They will care that their capital can do more.

The Stock Token is the bridge

Robinhood’s tokenized stocks provide the first bridge between the business it already dominates and the financial network it wants to build.

The product has two generations, and they should not be confused.

Classic Stock Tokens, launched in 2025 for European customers, are derivative contracts offered through Robinhood Europe on Arbitrum One. They track the price of the referenced securities without granting ownership rights in those shares.

The new Stock Tokens on Robinhood Chain are tokenized debt securities issued by Robinhood Assets (Jersey) Limited. They provide economic exposure to referenced securities but do not grant legal or beneficial ownership of the underlying shares.

A token referencing Apple is therefore different from an Apple share held in a conventional brokerage account. The investor owns a financial claim created through Robinhood’s legal and product structure. Issuer, custody and jurisdiction risk remain part of the package.

The innovation appears after issuance. Eligible users can hold the new Stock Tokens in Robinhood Wallet, trade them through decentralized venues including Uniswap, and eventually deploy them into lending or collateral markets. The asset can leave a closed brokerage interface and enter an open financial network.

That changes the product from a price tracker into programmable capital.

A conventional stock position mostly sits still until its owner sells, borrows against it through a broker or collects a dividend. A well-designed tokenized position can move across wallets and applications, settle against stablecoins and interact with lending protocols continuously. Developers can create new products around it without waiting for Robinhood to build every feature itself.

Uniswap arrived on Robinhood Chain from day one with v2, v3, v4 and UniswapX. Chainlink, Alchemy, BitGo and other infrastructure providers were already integrated. Arbitrum’s stack gave Robinhood approximately 100-millisecond block times and the ability to tune execution around financial applications.

Robinhood did not invent a new blockchain architecture. It assembled a functioning financial market from proven components, then attached that market to one of the largest retail investing brands in the world.

That is the more powerful achievement.

The memes proved the distribution engine

The most common bearish reading of Robinhood Chain’s first week is also the easiest: the volume was speculative, gas was subsidized and meme coins dominated attention.

All three observations are true. I reach the opposite investment conclusion.

New financial networks have a brutal cold-start problem. Assets need liquidity before users will trade them. Liquidity providers want users before committing capital. Developers want both. A technically elegant chain with empty pools is still an empty chain.

Robinhood broke that loop immediately.

Hayden Adams, the founder of Uniswap, pointed to nearly $500 million of 24-hour volume as Robinhood Chain briefly became one of Uniswap’s largest networks. Token Terminal recorded rapid growth in users, revenue and transactions while block time fell toward 100 milliseconds. The system absorbed the launch surge without an obvious performance breakdown.

Meme coins acted as the accelerant. They gave traders a reason to bridge, market makers a reason to quote, and applications a reason to integrate. The same pools, wallets, bridges and routing infrastructure can later support Stock Tokens, stablecoins and lending markets.

Speculation has often financed the early infrastructure of crypto. Bitcoin mining created a security industry before institutions accepted Bitcoin. NFT trading stress-tested wallets and marketplaces before major brands understood digital ownership. Stablecoin demand grew inside crypto trading before banks recognized its usefulness for global settlement.

Robinhood is using the same pattern with unusually strong distribution. The company can let speculative activity build liquidity while it introduces regulated financial products into the same environment.

The trend I would watch is the migration of that liquidity, not whether memes disappear. If bridged ETH and USDG stay, lending pools deepen, and Stock Tokens become useful collateral, Robinhood will have converted temporary excitement into permanent financial infrastructure.

The opening week showed that Robinhood can create the conditions for that conversion. Few fintech companies can.

Ethereum is becoming Wall Street’s chain

Tom Lee has spent much of the past year making an aggressive claim: Ethereum is the future of finance.

In a May 2026 thread on X, the Fundstrat co-founder argued that Ethereum has “ultimate” product-market fit for Wall Street tokenization, AI and agentic systems, and stablecoin payments. In public interviews, he has said Wall Street has already chosen Ethereum as the principal environment for building tokenized finance.

Lee is financially interested in the outcome. He chairs BitMine, whose strategy centers on accumulating ETH. His conviction comes with exposure. It also lines up with what institutions are doing.

Coinbase built Base as an Ethereum rollup. Robinhood built its chain with Arbitrum and settles within the Ethereum ecosystem. Uniswap, Chainlink and the dominant EVM developer stack were ready on day one. Stablecoins and tokenized assets already use Ethereum and its rollup ecosystem as core infrastructure. When financial companies want their own execution environment, they increasingly customize Ethereum rather than abandon it.

This is how a platform wins.

Institutions do not need every transaction to happen on Ethereum mainnet. They need a trusted settlement ecosystem, deep liquidity, mature security assumptions, battle-tested smart-contract standards and a large developer base. Rollups let them keep those advantages while gaining lower fees, faster execution and control over product design.

Ethereum’s modular design once looked like fragmentation. It now looks like the architecture institutions were waiting for.

A bank, exchange or fintech can operate a branded chain without building a stand-alone blockchain or persuading the market to adopt an entirely new technical stack. It can inherit Ethereum’s liquidity and standards while tailoring the customer-facing experience. Coinbase and Robinhood are showing the template. Others will follow because the alternative is more expensive and carries greater execution risk.

The fee impact on Ethereum may arrive more slowly than the adoption headlines. Robinhood controls its sequencer and customer economics; Uniswap earns from trading; Arbitrum supplies the technology. Yet ETH value accrual is larger than a single month of settlement fees. Every successful rollup keeps assets, developers and institutions inside the Ethereum economy. ETH remains the native collateral and reserve asset at the center of that system.

This creates a powerful long-term flywheel. More institutional chains bring more assets onchain. More assets deepen liquidity. Deeper liquidity attracts applications and capital. As the financial value secured by the ecosystem grows, demand for the asset underpinning its settlement and collateral system grows with it.

The market still tends to evaluate ETH as a crypto token competing for transaction fees. I see an emerging claim on the infrastructure of global digital finance.

Robinhood Chain strengthens that claim.

HOOD is becoming more than a brokerage stock

Robinhood’s public-market identity still carries the baggage of its origin story. Investors remember meme stocks, payment for order flow and pandemic-era trading. The company today is broader, more profitable and far more ambitious.

Robinhood ended the first quarter of 2026 with 4.3 million Gold subscribers. It has expanded into retirement, banking, credit cards, advisory products, futures, prediction markets, private markets, institutional crypto and international distribution. Each product increases wallet share. Robinhood Chain can connect those products through a shared financial backbone.

The market is accustomed to valuing brokerages on accounts, assets, trading volumes and interest income. A network deserves a different lens. Networks gain value when each additional user, asset and application makes the rest of the system more useful.

Robinhood already has the users. Bitstamp adds institutional reach. The wallet creates self-custody distribution. Stock Tokens supply financial assets. USDG supplies settlement liquidity. Uniswap supplies open markets. Morpho and other lending protocols can turn those assets into productive collateral.

This is why I think HOOD has one of the strongest platform stories in public fintech.

The chain does not need to generate billions in direct fees next quarter. Its near-term job is to deepen Robinhood’s moat and increase the number of economic relationships the company owns. A customer who trades, saves, borrows, earns yield and holds tokenized assets inside the same ecosystem is more valuable and harder to lose than a customer who occasionally buys a stock.

Internationally, the opportunity is even larger. Billions of people live outside the United States yet want exposure to U.S. financial assets. Traditional access is fragmented by local brokers, market hours, settlement systems and capital requirements. Tokenization lets Robinhood package that exposure for continuous digital markets, subject to local regulation.

The company that makes those markets simple can become the default financial account for a global generation. Robinhood has the brand, product instincts and risk appetite to attempt it.

I would rather own that option before Wall Street fully recognizes Robinhood as infrastructure than after the revenue model becomes obvious.

The rough edges are signs of an early standard

Tokenized securities still carry technical problems that traditional markets solved through decades of infrastructure and regulation.

RWA.xyz found that Robinhood’s Classic Stock Tokens required custom accounting for reverse splits and distribution-driven changes in net asset value. Standard ERC-20 indexing could overstate supply because third-party systems did not understand Robinhood’s multiplier mechanics. Across 21 mismatched tokens, RWA.xyz calculated a roughly 56% discrepancy before adapting its methodology.

That finding does not weaken the tokenization thesis. It shows where the next generation of market infrastructure must be built.

Corporate actions need shared standards that wallets, exchanges, data providers and lending protocols can read. Robinhood and Superstate have already contributed to a proposed ERC standard for scaled display amounts. The ecosystem is finding the problem, proposing a standard and improving interoperability in public.

This is how financial infrastructure evolves. The early internet had incompatible browsers, broken links and competing protocols. The winners were the companies and standards that improved while usage kept growing. Tokenized finance is moving through the same compressed process.

The thesis would break if Robinhood cannot move activity beyond incentives, if regulators close major markets to tokenized products, or if Stock Tokens remain too legally or technically constrained to become useful collateral. Those are real tests. They are also measurable over time.

The current trend points the other way: more assets are moving onchain, stablecoins are expanding, financial companies are building Ethereum-aligned networks, and DeFi protocols are becoming embedded inside consumer products.

The financial internet has found its distribution engine

The first week of Robinhood Chain looked like a crypto spectacle because speculation is loud. The deeper story was quieter.

A major public fintech launched its own Ethereum rollup. It brought users, stablecoins, tokenized securities, liquidity venues, lending infrastructure and developers together on day one. It demonstrated that a brokerage can become a programmable financial network without forcing customers to learn the machinery underneath.

That is where finance is going.

DeFi will not remain a separate corner of crypto. Its core ideas—continuous markets, self-custody, programmable collateral, transparent settlement and open financial software—will be absorbed into mainstream products until the boundary disappears. Robinhood understands this earlier than most traditional financial companies.

HOOD gives investors exposure to the company packaging that future for consumers. ETH gives investors exposure to the settlement ecosystem institutions keep choosing to build upon.

I am bullish on HOOD because Robinhood is accumulating the pieces of a global financial superapp and now owns a programmable financial rail beneath it. I am bullish on ETH because Ethereum is becoming the neutral financial infrastructure connecting stablecoins, tokenized assets, institutional chains and DeFi.

The meme coins will come and go. The rails will remain.

Robinhood is building on those rails, and it intends to own the station.

Source notes

1. Robinhood, “Robinhood Accelerates Global Expansion with Robinhood Chain Mainnet…”, July 1, 2026.

2. Arbitrum, “Robinhood Chain mainnet is live, built with the Arbitrum Platform”, July 1, 2026.

3. Uniswap Labs, “Uniswap is Live on Robinhood Chain”, July 1, 2026.

4. Token Terminal, “Robinhood Chain’s first week in data”, July 2026.

5. Robinhood Markets, Q1 2026 earnings-call transcript, May 2026.

6. Vlad Tenev’s July 2026 X remarks were cross-checked against contemporaneous reporting by Crypto.news.

7. Tom Lee, X thread on Ethereum’s product-market fit, May 18, 2026.

8. Binance, Tom Lee keynote on Ethereum and tokenization, December 4, 2025.

9. RWA.xyz, “Robinhood’s Tokenized Stocks: The Good, The Bad, and The Fix”, 2026.

This article is for informational purposes only and is not investment advice. The author may discuss securities, crypto assets and financial products that involve substantial risk.

In the first, a professional watches an AI assistant finish the first draft of a task that once consumed an afternoon. Her company is spending heavily on automation, but her own role is becoming more valuable because she knows how to direct the system, catch its mistakes, and turn its output into a decision. Her retirement account is rising with the same semiconductor and cloud stocks powering the tool. A summer cruise that looked indulgent a year ago now feels affordable.

Across town, another household opens a different set of apps. A recent graduate has sent out dozens of applications for jobs that used to train people into a career: junior analyst, entry-level developer, marketing assistant, support specialist. Interviews are scarce. Rent is due. The grocery order moves from a familiar brand to a private label. A planned clothing purchase becomes a trip to an off-price store. The family is still spending, but every dollar has been given a harder job.

Both households appear inside the same consumer-spending number. Both live under the same unemployment rate. Both contribute to an economy that may still be growing.

Their private economies are moving in opposite directions.

That is the K-shaped economy. The upper arm compounds through asset ownership, scarce skills, business scale, and access to the technologies raising productivity. The lower arm bends under weaker bargaining power, fragile entry-level work, expensive necessities, and debt. Artificial intelligence did not create America’s fault lines in wealth, housing, education, or market access. It is beginning to press on all of them at once.

The investment story follows from that split. The companies selling the machinery of AI can thrive. So can the platforms serving households enriched by the boom. At the same time, merchants that help pressured consumers stretch a paycheck can gain traffic and market share.

One economy can produce record demand for data-center cooling and stronger demand for closeout merchandise. One stock market can support premium cruises while the same country produces more private-label grocery baskets.

The K is already becoming visible. Investors can own both arms.

The first rung of the career ladder is shaking

A K-shaped economy rarely announces itself with a recession siren. It appears first as a contradiction.

The June 2026 employment report looked subdued rather than disastrous. The United States added 57,000 payroll jobs. Unemployment held at 4.2%. Average monthly payroll growth over the preceding year was only 36,000, labor-force participation slipped to 61.5%, and April and May gains were revised down by a combined 74,000 jobs.[1]

Those numbers describe a labor market that is cooling. They do not describe what it feels like to be trying to enter one of the occupations AI can already touch.

The New York Fed reported that unemployment among recent college graduates aged 22 to 27 reached 5.6% in March 2026, up from 3.6% in March 2019.[2] Stanford Digital Economy Lab researchers then found something more specific in ADP payroll data: workers aged 22 to 25 in the most AI-exposed occupations experienced a 16% relative employment decline after the researchers controlled for firm-level shocks. Experienced workers in the same occupations remained comparatively stable. The damage was concentrated where AI looked automative; in work where AI augmented people, the same decline did not appear.[3]

This distinction may become one of the defining economic lines of the next decade.

An experienced lawyer can ask a model for a first-pass analysis and recognize the missing precedent. A senior engineer can use generated code and see the architectural flaw. A seasoned marketer can turn a synthetic draft into a campaign. Judgment makes the machine useful.

A junior employee was often paid to produce that first pass while learning how experts think. If software now produces the draft, summary, research memo, basic code, or scripted support response, the company can demand experience before it has created enough places for people to acquire it.

The ladder does not disappear all at once. The first few rungs become farther apart.

The evidence still calls for restraint. New York Fed research using Lightcast job postings found little indication that AI exposure alone caused a distinct fall in vacancies after ChatGPT’s release.[4] High interest rates, the post-pandemic technology correction, remote work, and slower white-collar hiring also shaped the market. AI is an accelerant, not a complete explanation.

Yet the direction matters. A technology can transform bargaining power before it produces mass unemployment. Companies need only discover that one experienced worker with AI can supervise work previously distributed across several junior seats.

That is how a productivity story becomes a distribution story.

The machine rewards the people who can afford to build it

AI adoption has moved beyond demos. Census Bureau survey data from late 2025 and early 2026 found that 18% of U.S. firms used AI in at least one business function. Larger companies adopted it more aggressively, so the employment-weighted adoption rate reached 32%.[5]

The gap between those two figures reveals the corporate version of the K.

A large enterprise can pay for models, cloud capacity, security, data preparation, consultants, workflow redesign, and employee training. It can spread those fixed costs over millions of transactions. It may even own proprietary data that makes a general model more useful inside its business.

A smaller company often buys the finished capability as a subscription. It receives some productivity gain, but the infrastructure margin flows elsewhere—to the chip designer, the networking vendor, the cloud platform, the power-and-cooling supplier, or the software company controlling distribution.

Aggregate productivity data fit this capital-deepening story, even though they cannot isolate AI as the cause. Nonfarm business labor productivity rose 2.8% year over year in the first quarter of 2026, while unit labor costs increased only 0.5% over four quarters. For 2025 as a whole, labor productivity rose 2.2%, including a 0.9-percentage-point contribution from capital intensity.[6]

Output can grow faster than labor hours when companies invest in computing, software, automation, and redesigned workflows. The first claim on those gains usually belongs to whoever owns the scarce capital.

This is the industrial logic explored in The Next Architecture of Intelligence. The first AI trade was scale: more accelerators, more networking, more data centers, more electricity, more cooling. Even if the next architecture eventually makes intelligence cheaper, today’s deployment wave remains a resource race.

That race pulls the upper arm of the K higher.

The stock market turns technology gains into household divergence

The ownership of the AI boom is even more concentrated than its use.

Federal Reserve distributional data show that in the first quarter of 2026, the wealthiest 1% owned 50.2% of corporate equities and mutual-fund shares. The next 9% owned another 37.2%. Together, the top 10% by wealth controlled 87.4% of the equity pool. The bottom half owned 1.1%.[7]

When the market assigns hundreds of billions of dollars of value to AI infrastructure and platforms, the gains do not arrive evenly. They land first in portfolios that already hold the most financial assets.

That creates a loop. AI expectations raise the value of the companies expected to build or monetize the technology. Rising portfolios make affluent households feel more secure. Those households keep investing and spend more freely on travel, convenience, services, and experiences. Their spending supports corporate earnings, which can reinforce asset prices.

New York Fed researchers found that since 2023, real net worth for the top income percentile grew more than 25%, while growth for the middle 40% remained below 10%. They also found that lower-income households consistently faced higher inflation than middle- and higher-income households beginning in late 2022.[8]

The same economy was therefore delivering faster wealth growth to people who owned financial assets and a harsher inflation mix to people whose budgets were dominated by necessities.

This extends the argument in The Rich-Person Password. Access determines who compounds with innovation. In private markets, wealth gates can reserve early exposure for accredited capital. In public markets, access is formally broader, but ownership remains so concentrated that a technology-led rally still produces a sharply unequal wealth effect.

AI becomes more than a software story at that point. It becomes a mechanism for distributing claims on future income.

Two consumers now walk through the same economy

By early 2026, the divergence had begun to show up at the cash register.

Bank of America’s aggregated card and deposit data found that January card spending rose 2.5% year over year for higher-income households, compared with 1.0% for middle-income households and 0.3% for lower-income households. After-tax wage growth showed an even wider split: 3.7% for the higher-income cohort, just under 1.6% for the middle, and 0.9% for the lower.[9]

A Moody’s Analytics estimate put the top 10% of earners’ share of consumption at 49.2% in the second quarter of 2025.[10] That estimate is debated, and other methods produce a lower share. The precise number matters less than the direction supported across several datasets: affluent households have supplied a disproportionate share of incremental spending, while lower-income households have become increasingly price-sensitive.

Debt narrows the choices available to the lower arm. New York Fed data show $18.8 trillion in household debt in the first quarter of 2026, including $1.25 trillion in credit-card balances and $1.69 trillion in auto loans. Some 4.8% of outstanding debt was in delinquency, while the annualized flow into early credit-card delinquency remained elevated at 8.6%.[11]

This does not mean the pressured household stops consuming. Life rarely permits that. Food, school supplies, soap, work clothes, and transportation still have to be purchased.

The household changes stores. It changes brands. It waits for a deal. It buys a smaller pack, accepts yesterday’s fashion at a discount, consolidates shopping trips, or pays for a membership that promises lower unit costs.

That is why a K-shaped economy can create two profit pools instead of one winner and one wasteland.

A previous Signal Before Consensus piece, Why Investors Should Reconsider the “Avocado Toast” Generation, argued that Millennials should be understood through economic pathways rather than as one average consumer. The K-shaped framework pushes that idea further. Even within the same generation, one household may be an AI-using manager with rising assets while another is a renter juggling debt and a more fragile career ladder. Age no longer tells investors enough. Ownership, income resilience, and bargaining power do.

Follow the money up the K

The upper arm begins in a data center.

Before an AI assistant can save an employee an hour, a chain of companies has to turn electricity into computation. Nvidia (NVDA) supplies the leading accelerated-computing platform for training and inference. Fiscal 2026 revenue reached $215.9 billion, up 65%.[12] The risk is equally large: hyperscaler spending can slow, custom silicon can improve, export controls can tighten, and a valuation built around scarcity can compress when supply catches up.

The clusters also need alternatives and connective tissue. Broadcom (AVGO) combines custom AI accelerators with networking that helps the largest cloud customers optimize their own systems. Its Q2 fiscal 2026 AI semiconductor revenue reached $10.8 billion, up 143% year over year.[13] That growth comes with customer concentration and lumpy program timing.

Arista Networks (ANET) supplies the high-speed Ethernet switching and software that allow thousands of machines to operate as one cluster. First-quarter 2026 revenue rose 35.1% year over year.[14] Its opportunity sits inside the traffic explosion; its risk sits in dependence on a small number of very large customers and competition from integrated vendors.

Then the computation becomes a heat and power problem. Vertiv (VRT) supplies power conversion, thermal management, and service for dense data-center infrastructure. First-quarter 2026 organic sales in the Americas rose 44% on data-center demand.[15] Vertiv is the physical reminder that “the cloud” is a building full of electrical constraints. Project timing, capacity expansion, cyclicality, and valuation can still punish investors if the buildout outruns demand.

Amazon (AMZN) sits above this machinery and inside it. AWS sells compute, custom chips, models, and AI services; Amazon’s retail and advertising operations can use automation at enormous scale. AWS first-quarter 2026 sales grew 28% to $37.6 billion.[16] The company’s planned 2026 capital spending of roughly $200 billion raises the central question of the upper arm: how much future return is already embedded in today’s investment?

The wealth created around this buildout produces a second set of beneficiaries.

Interactive Brokers (IBKR) is a technology-led toll collector on global market participation. Client equity reached $789.4 billion in the first quarter of 2026, up 38% year over year.[17] Rising asset values and activity can support the platform, while market declines, lower interest income, or subdued trading can reverse the effect.

Royal Caribbean (RCL) captures the experiential side of affluent resilience. First-quarter 2026 adjusted EBITDA rose 21%, bookings carried record prices, and onboard spending exceeded the prior year.[18] A cruise ship may look far removed from an AI rack, yet the financial connection runs through the household balance sheet. When portfolios rise and high-income wages remain strong, premium experiences retain pricing power. Fuel, leverage, geopolitics, travel disruption, and a market correction remain the obvious breaks in that chain.

These companies occupy different points along one river of money: capital spending flows into NVDA, AVGO, ANET, and VRT; cloud and platform economics accrue to AMZN; financial wealth and affluent spending can reach IBKR and RCL.

Follow the paycheck down the K

The lower arm begins with a different question: who can make a constrained dollar feel larger?

Walmart (WMT) has the broadest answer. Its purchasing scale supports price leadership, while delivery, marketplace, membership, and advertising improve the profit mix. Fiscal 2026 revenue rose 4.7% to $713.2 billion, and global advertising grew 46%.[19] Walmart can attract a household trading down on groceries and another household paying for fast delivery. Tariffs, wages, food disinflation, and the difficulty of protecting margins during a price war remain real risks.

Off-price retail turns somebody else’s forecasting error into the customer’s bargain.

TJX Companies (TJX) buys branded excess inventory and sells it at discounts commonly advertised at 20% to 60%. Fiscal 2026 comparable sales rose 5%, with every division growing at least 4%.[20] Ross Stores (ROST) offers a similar treasure-hunt model with a lower-income customer skew; first-quarter 2026 comparable-store sales rose 17%.[21]

Their appeal grows when the shopper still wants a recognizable brand but refuses the full-price channel. Their vulnerability appears when attractive inventory becomes scarce, freight costs rise, fashion bets miss, or pressure on the customer becomes severe enough to reduce traffic altogether.

Ollie’s Bargain Outlet (OLLI) pushes the same logic into closeouts and “extreme value.” First-quarter fiscal 2026 net sales rose 14%.[22] Its store expansion adds a growth engine, while inconsistent deal flow and execution risk can make the model uneven.

Dollar General (DG) is the more fragile expression of the lower arm. Its small rural stores and heavy consumables mix matter when transportation, time, and budgets are tight. First-quarter 2026 traffic rose 1.4%, operating profit rose 10.8%, and same-store sales rose 2.0%.[23] Yet the company serves a customer with very little room left to trade down. Shrink, labor costs, tariffs, and a shrinking basket can overwhelm thin margins. Consumer stress can create traffic and destroy profit in the same quarter.

That distinction is essential. A weak consumer does not automatically produce a strong discount retailer. The durable winners have purchasing power, inventory discipline, useful locations, and enough margin flexibility to share savings with the customer without surrendering the economics of the business.

A few companies can stand in the middle

Some businesses do not need to choose one household.

Costco (COST) sells thrift in a format affluent consumers enjoy. The membership fee converts loyalty into recurring, high-margin income. Bulk economics appeal to value seekers; product quality, convenience, and the treasure-hunt assortment keep wealthier households engaged. Fiscal third-quarter 2026 net sales rose 11.6%, adjusted U.S. comparable sales rose 6.8%, and digitally enabled comparable sales rose 20.8%.[24]

Walmart increasingly spans the K for similar reasons. Food and low prices anchor the lower arm. Delivery, Walmart+, marketplace breadth, advertising, and Sam’s Club reach households higher up the income ladder.

Amazon also crosses the split. AWS and advertising sit firmly on the upper arm, while retail selection, logistics, and price comparison serve cost-conscious consumers. Its enormous capital commitment makes the stock a more direct wager on the upper arm, but the consumer platform still sees both households.

These bridge companies may be especially valuable when the macro story is right but the timing is unclear. They can gain from divergence without requiring an investor to predict which side accelerates first.

Build the barbell before the slogan becomes consensus

The cleanest portfolio expression is a barbell rather than a heroic bet on one macro outcome.

On one end sit the scarce inputs and scalable platforms of AI: NVDA, AVGO, ANET, VRT, and AMZN. They benefit while companies continue buying the capacity required to automate and augment work.

Alongside them sit businesses exposed to rising assets and affluent resilience: IBKR and RCL.

On the other end sit the merchants of trade-down: WMT, TJX, ROST, and OLLI, with DG reserved for investors willing to accept greater operational and customer stress. COST and WMT can act as bridge holdings because they serve both the household protecting a budget and the household paying for convenience.

The construction still requires valuation discipline. A correct social observation can become a terrible stock purchase when the price assumes flawless execution.

AI infrastructure companies can suffer if hyperscalers pause capital spending, customers move toward custom chips, inference becomes dramatically more efficient, or a shortage turns into excess capacity. Premium-consumption companies can weaken quickly after a market correction because the wealth effect runs in both directions. Value retailers face tariffs, wages, shrink, and customers whose budgets may become too strained even for the cheapest discretionary purchase.

The thesis should therefore be monitored through behavior rather than repeated as a slogan. Watch hyperscaler capital-expenditure guidance and AI revenue conversion. Follow networking, power, and cooling backlogs. Track employment outcomes for young workers in exposed occupations, spending and wage growth by income cohort, credit delinquencies, value-retail traffic and margins, and premium-travel pricing.

The shape of the K will show up in those numbers before it becomes obvious in GDP.

The K can bend

The strongest objection is that the consumer split remains real enough to investigate and too contested to declare permanent.

Bank of America and New York Fed data show meaningful divergence by income. Moody’s estimates an extraordinary concentration of spending. Other transaction-based and government-derived measures suggest lower-income consumption held up better through 2025 and that the top decile’s share is well below 49%. Stripe Economics argues that the clearest K appears in corporate profits and equity returns, while the consumer split remains less conclusive.[25]

AI causation deserves the same caution. Stanford’s payroll evidence is striking, but Federal Reserve job-posting research has yet to show a broad AI-specific collapse. Interest rates, remote work, immigration, demographics, and post-pandemic normalization also shape hiring.

Diffusion could narrow the K. Cheaper AI may help small businesses compete. Productivity gains may eventually lift real wages. New occupations may absorb displaced workers. A generation that learns to use AI early may turn apparent vulnerability into an advantage.

Those possibilities do not erase the investable pattern already in front of us. The high-confidence claim is that AI currently rewards scarce capital, scale, and experienced judgment. The high-confidence consumer claim is that affluent spending remains resilient while value-seeking behavior has strengthened. The uncertain part is how quickly those forces harden into a lasting social structure.

Owning both arms is a way to invest through that uncertainty rather than pretending it does not exist.

The cash flows tell the story

Return to the two phones on Friday night.

One displays a rising brokerage balance, an AI assistant, and a travel booking. The other displays unanswered job applications, a credit-card balance, and a search for the lowest price.

The screens look unrelated. The cash flows connect them.

The data center behind the assistant sends revenue toward Nvidia, Broadcom, Arista, Vertiv, and Amazon. The portfolio gains around the boom can send assets and activity toward Interactive Brokers and discretionary spending toward Royal Caribbean. The tighter paycheck sends traffic toward Walmart, TJX, Ross, Ollie’s, Dollar General, and Costco.

This is the uncomfortable elegance of the K-shaped investment thesis: the same technological wave can strengthen the companies building the future and the merchants helping people survive its uneven arrival.

The upper arm favors NVDA, AVGO, ANET, VRT, AMZN, IBKR, and RCL. The lower arm favors WMT, TJX, ROST, OLLI, and, at higher risk, DG. COST and WMT possess the rare ability to serve both.

Investing in this split does not require celebrating it. It requires seeing where capital, wages, and household spending are moving before the average statistics make the divergence impossible to ignore.

The K is more than a letter laid over a chart. It is two American nights unfolding at once.

Sources and research notes

1. U.S. Bureau of Labor Statistics, The Employment Situation—June 2026.

2. Federal Reserve Bank of New York, New York Fed to Release Research on the Role of Remote Work in Youth Unemployment.

3. Stanford Digital Economy Lab, Canaries in the Coal Mine?.

4. Federal Reserve Bank of New York, Do Job Postings Show Early Labor-Market Effects of AI?.

5. U.S. Census Bureau, AI Use at U.S. Businesses.

6. U.S. Bureau of Labor Statistics, Productivity and Costs—First Quarter 2026 and Total Factor Productivity—2025.

7. Federal Reserve Distributional Financial Accounts via FRED, Q1 2026 equity ownership table.

8. Federal Reserve Bank of New York, Explaining the K-Shaped Economy: What’s Behind the Divide?.

9. Bank of America Institute, Consumer Checkpoint: Weathering the Storm.

10. Federal Reserve Bank of Dallas, Consumption concentration may be up, adding slightly to economic fragility.

11. Federal Reserve Bank of New York, Quarterly Report on Household Debt and Credit—Q1 2026.

12. Nvidia Investor Relations, Fiscal 2026 results.

13. Broadcom Investor Relations, Q2 FY2026 results.

14. Arista Networks Investor Relations, Q1 2026 results.

15. Vertiv Investor Relations, Q1 2026 results.

16. Amazon Investor Relations, Q1 2026 results.

17. Interactive Brokers, IBKR Fact Sheet.

18. Royal Caribbean Group, Q1 2026 earnings release.

19. Walmart Investor Relations, FY2026 Q4 earnings release.

20. TJX Investor Relations, Q4 and FY2026 results.

21. Ross Stores Investor Relations, Q1 2026 Form 8-K.

22. Ollie’s Bargain Outlet, Investor home and Q1 FY2026 results.

23. Dollar General Investor Relations, Q1 2026 results.

24. Costco Investor Relations, Q3 FY2026 results.

25. Stripe Economics, K-shaped economy?.

Disclosure: This article is for research and educational purposes and is not individualized investment advice. The author may hold securities discussed. Public-company fundamentals, prices, and risks can change quickly; readers should review current filings and valuation before investing.

That view still looks right. Google DeepMind has moved from AlphaFold 2 to AlphaFold 3, AlphaProteo, AlphaGenome, and Isomorphic Labs. OpenAI has made its own moves through Eli Lilly and Retro Biosciences. Microsoft is building BioEmu for protein dynamics. NVIDIA is turning digital biology into an infrastructure market. Anthropic is trying to make Claude useful inside the daily workflow of scientists.

The pattern is too broad to dismiss as branding. The leading AI companies are looking at biology because biology has started to look, at least from a distance, like an information problem. DNA has sequence. Proteins have sequence and structure. Cells have states. Disease perturbs a system. Drug discovery searches through an enormous space of possible interventions. Experiments generate feedback.

Once you see biology that way, it becomes tempting to believe the same forces that scaled language models can scale scientific discovery.

That optimism has real evidence behind it. But the best version of the thesis needs a stricter sentence attached to it:

AI may make biology more programmable, but biology will punish anyone who confuses programmability with control.

The progress is real

The strongest case for optimism begins with AlphaFold.

Protein folding was never a toy benchmark. For decades, figuring out the three-dimensional structure of a protein could require years of experimental work. Then AlphaFold changed the default expectation. DeepMind later released predicted structures at enormous scale, turning one of biology’s central bottlenecks into a shared scientific resource.

That gave the AI-for-science thesis something rare in technology investing: a visible scientific win.

AlphaFold 3 pushed the story further. In 2024, Google DeepMind and Isomorphic Labs said the model could predict the structure and interactions of proteins, DNA, RNA, ligands, antibodies, and other molecules. Their own description was careful but still striking: for interactions between proteins and other molecule types, AlphaFold 3 showed at least a 50% improvement over existing methods, with some categories doubling prediction accuracy. The model was also made available through AlphaFold Server for non-commercial research.

That does not make drug discovery easy. It does shift the frontier from isolated protein shapes toward molecular relationships, which is closer to where drug discovery actually lives. A drug works because a molecule binds, a pathway changes, an antibody recognizes a target, or a mutation alters expression. If AI can reduce the cost of exploring those relationships, it can raise the return on experimental capital.

DeepMind’s newer systems point in the same direction. AlphaProteo designs protein binders and has shown wet-lab success across several targets, while also failing on at least one difficult target. AlphaGenome moves into regulatory genomics, trying to predict how DNA variants affect gene regulation across long sequence contexts. The company is no longer making a single protein-folding claim. It is building layers of a larger biological model.

This is why Demis Hassabis matters in the story.

In my earlier essay, Demis Hassabis’s 37 ideas about AI, science, and the next human era, I argued that his deepest theme is the move from chatbots to discovery engines. Hassabis keeps returning to the same idea: AI should become the “ultimate tool for advancing human knowledge.” In his worldview, AlphaFold is a prototype for a broader scientific machine. Protein structure was one layer. The next layers are interactions, regulation, cell state, disease mechanisms, and drug response.

On CBS’s 60 Minutes, he pushed the optimism much further. Drug development, he said, takes roughly ten years and billions of dollars for one drug; AI could perhaps reduce parts of that process to months or weeks. He then made the quote that now hangs over every AI-biology discussion: “one day maybe we can cure all disease with the help of AI,” perhaps “within the next decade or so.”

That sounds extreme. It is easier to understand if you see where Hassabis is coming from. He is not thinking mainly about a chatbot answering medical questions. He is thinking about search, simulation, hypothesis generation, and experimental loops. His career runs from games to reinforcement learning, from AlphaGo to AlphaZero, from protein structure to scientific reasoning. In games, the system can search a defined space, evaluate outcomes, and improve through iteration. Hassabis’s biology thesis is that parts of science can gradually acquire that same loop: a model proposes, an experiment tests, the data returns, and the next proposal improves.

That is the dream. In narrow domains, the dream is already becoming practical.

Why Silicon Valley is so tempted by biology

The tech industry tends to approach a domain by asking whether it can be represented digitally, searched computationally, and improved through feedback. Biology now gives better answers to those questions than it did twenty years ago.

Sequencing costs collapsed. Cryo-EM improved. Single-cell and spatial omics can measure biological state at extraordinary resolution. CRISPR makes perturbation experiments more programmable. Robotic labs can run experiments at scale. Public databases have accumulated protein structures, gene-expression profiles, molecular screens, clinical trial records, and literature.

For a software person, that looks familiar. A messy human activity becomes digitized. Once digitized, it becomes searchable. Once searchable, it becomes optimizable. After that, someone tries to turn it into a platform. Advertising, maps, media, finance, logistics, code, and customer support all followed some version of that path.

So when the AI world looks at biology, it sees a giant, under-optimized search problem with enormous economic value.

A good molecule can be worth billions. A validated target can define a company. A better assay can redirect a research program. A faster way to design proteins can create an entire platform. If AI can make discovery even modestly faster, the market does not need science fiction to justify investment.

This is also why the infrastructure companies care. NVIDIA does not need to know which AI-designed drug wins. If biology becomes a computation-heavy industry, demand can flow into GPUs, BioNeMo, NIM microservices, model serving, simulation, chemistry, genomics, imaging, and private-cloud deployments. Cloud providers get paid before the drug works. Lab-software companies get paid before approval. Data platforms get paid while pharma is still deciding which targets to pursue.

That investment stack is more robust than a simple “AI will cure cancer” trade. The early money may accrue to compute, cloud, lab automation, data infrastructure, workflow software, and companies with proprietary feedback loops. The higher-upside layer is more fragile: AI-native drug discovery companies, protein-design platforms, longevity programs, and full-stack biology companies that must eventually survive clinical reality.

That is why I still like the broad thesis from A Bigger AI War Is Starting: life sciences may become one of the most important credibility tests for frontier AI.

But credibility cuts both ways.

Biology is two orders more complex than the software analogy suggests

Here is where many scientists start to roll their eyes.

Tech people see information. Biologists see context.

That difference explains much of the disagreement. In software, the same input usually produces the same output. If the program fails, you can reproduce the bug, inspect the stack trace, patch the code, and ship the fix. The system is built by humans, and its abstractions were designed to be legible.

Biology did not inherit those conveniences. A gene is not a function call. A protein is not a fixed machine part. A cell is not a container for code. A disease is not a single bug. The same molecule can behave differently across tissue types, developmental stages, immune states, microbiomes, genetic backgrounds, drug combinations, sex, age, and environment. A pathway that matters in a dish may disappear in a mouse. A result in a mouse may fail in a human. A clean target in one cancer subtype may become irrelevant when the tumor evolves around it.

This is why the “two orders of magnitude” complaint has force.

One hidden order is biological organization. Molecules sit inside cells; cells inside tissues; tissues inside organs; organs inside organisms; organisms inside environments. Each level changes the behavior of the level below it.

Another hidden order is measurement. In software, logging a system often means recording the thing you need. In biology, the measurement can distort the system, miss the relevant time point, average away the important subpopulation, or capture a proxy that looks precise while hiding the causal mechanism.

That is why AI can look brilliant in one biological layer and fragile in another. A model can predict a structure and still fail to predict toxicity. It can design a binder and still fail on delivery. It can optimize affinity and still create immunogenicity. It can identify a target and still fail because the disease mechanism is downstream, redundant, compensated, or patient-specific. It can generate a therapy and still run into manufacturing, dosing, biodistribution, reimbursement, trial design, or regulation.

Scientists have learned to respect these traps because biology has spent decades embarrassing clean theories.

Jennifer Doudna’s skepticism fits here.

In a Bloomberg interview, Doudna pushes back against the claim that AI will simply cure everything. Her reply to the idea that ChatGPT might deserve a drug-sales royalty was only two words: “Good luck.” On Larry Ellison’s claim that AI could generate personalized cancer vaccines in 48 hours, her answer was equally grounded: if that were true, everyone would be happy, but she does not see that day yet.

Her most important point is simple: cancer is not one disease. It is hundreds of diseases. Every oncologist knows this, but the phrase “AI will cure cancer” tends to compress that reality into a slogan.

Doudna is not anti-technology. She uses AI tools. She sees value in data organization, reporting, guide-RNA design, DNA-sequence modeling, and running fewer, better experiments. In Scientific American, she described AI as transforming parts of CRISPR science, from guide-RNA design to DNA-sequence modeling, and said the convergence of AI and gene editing can help scientists run “fewer experiments but the right ones.”

That phrase is the sober version of the AI-biology thesis: fewer experiments, better chosen.

It is a long way from that to “all disease cured in ten years.”

The data bottleneck is real

The biggest misunderstanding in AI biology may be the word “data.”

Tech people hear “biology has lots of data” and imagine the internet. Biologists hear the same phrase and ask what kind of data: which assay, tissue, species, cell state, protocol, time point, batch, negative control, patient population, and failed experiment?

Biology has a lot of data, but much of it is the wrong shape for AI.

Public biological datasets were usually created for human scientific questions rather than machine-learning consumption. They are uneven, biased toward successful experiments, biased toward fashionable targets, biased toward easier measurements, and often difficult to compare across labs.

The negative results are especially valuable and especially missing. Failed compounds, failed screens, failed protocols, and failed clinical hypotheses often remain inside companies or disappear into the file drawer.

This matters because models need to learn what fails. A drug-discovery model trained mostly on published success is like an investor trained only on winning pitch decks. It may learn the language of confidence without learning the base rate of failure.

The experimental substrate also matters. A large share of biological data still comes from simplified systems: 2D cell cultures, immortalized cell lines, animal models, narrow assays, and measurements that capture a slice of the disease rather than the disease itself. These systems are useful. They can also mislead. A tumor in the body is a spatial ecosystem, with nutrient gradients, hypoxia, immune interactions, stromal cells, clonal diversity, and resistant subpopulations. A flat plate of cells can remove the very context that determines whether the drug works.

That is why organoids, organ-on-chip systems, spatial biology, perturbation atlases, patient-derived models, and automated labs matter so much. They are data infrastructure. They are attempts to generate the kind of biological evidence AI can actually learn from.

Doudna’s example about the genome is powerful for the same reason. The human genome was sequenced around the turn of the century. Yet more than two decades later, scientists still do not understand the function of a large share of genes even in much simpler organisms. The instruction-book metaphor is useful, but it can mislead. We have the letters. We do not have the operating semantics.

AlphaGenome itself admits some of this. DeepMind says the model can analyze up to one million DNA letters and predict thousands of molecular properties, but it also says the model is not designed or validated for personal genome prediction or direct clinical use. It can predict molecular outcomes, while complex traits and diseases involve developmental and environmental factors outside its direct scope.

That caveat should be printed on the wall of every AI-biology investor. Prediction at one layer is progress. Translation across layers is the hard part.

Doudna’s CRISPR lesson: the bottleneck moves to delivery and access

CRISPR has already produced real medical miracles. Victoria Gray became the first patient treated with CRISPR for sickle cell disease in 2019, and Casgevy later became an approved therapy. The case of baby KJ Muldoon is even more dramatic: a fully personalized in-vivo CRISPR therapy for a rare metabolic disease, designed and delivered on an emergency timeline.

Those stories prove that programmable biology is no longer only a metaphor. They also reveal the next bottleneck.

Casgevy costs around $2.2 million per patient. KJ’s personalized therapy cost roughly $800,000 and depended on an unusual coalition of academic, public, and philanthropic support. Doudna’s question is the right one: how do you save more children like KJ without requiring a heroic one-off operation every time?

AI can help, but the job is more prosaic than the hype. It can help design guides, screen off-target risks, interpret sequence effects, support delivery design, automate documentation, triage actionable rare variants, and help researchers choose experiments more efficiently. The hard parts of CRISPR therapeutics still include delivery, immune response, tissue targeting, dosing, manufacturing, safety monitoring, reimbursement, and ethics.

Those are system problems, not chatbot problems.

Doudna’s caution about designer babies belongs in the same frame. Editing a single disease-causing mutation can be rational when the disease mechanism is clear and the suffering is severe. Editing traits like intelligence or height is a different category. Those traits are polygenic, context-dependent, developmentally mediated, and socially dangerous. Changing a few genes does not guarantee a predictable long-term outcome.

Her answer to the Gattaca question is the best kind of scientific realism: the future is probably somewhere in the middle, hopefully closer to heaven.

Hassabis and Doudna are less opposed than they look

The easy version of this debate puts Hassabis on one side and Doudna on the other. That is too simple.

Hassabis is the ambitious system-builder. Doudna is the experimental scientist who has watched a breakthrough technology fight its way toward real patients. One speaks from the frontier-lab view of AI as a general discovery engine. The other speaks from the translational reality of making biology safe, deliverable, affordable, and ethically usable.

Both are describing real parts of the same machine.

Hassabis is right that AI can change the search process. AlphaFold already did. AlphaFold 3, AlphaProteo, AlphaGenome, BioEmu, ESM3, and the next generation of closed-loop lab systems will probably change it again. If AI can propose better hypotheses, prioritize better experiments, and help scientists explore a larger design space, it can reshape the economics of research.

Doudna is right that summarization is not discovery, that cancer is not one disease, that simulation cannot replace every kind of testing, and that the field needs better data rather than louder promises.

The most investable synthesis is this: AI will not abolish biology’s complexity. It will make parts of that complexity searchable.

That is still a huge statement. Searchability is how new industries begin. Once a domain becomes searchable, companies can build tools, platforms, workflows, and feedback loops around it. The winners may be the companies that turn biological complexity into a compounding data asset rather than a one-time prediction demo.

What investors should watch

The next phase of AI biology should be judged less by press releases and more by feedback loops.

The key question is whether an organization can test its ideas, learn from the results, and improve the next round faster than competitors. A model that generates a plausible molecule is useful. A company that repeatedly turns model output into experimental learning has a different kind of asset.

That shifts the investor’s attention toward proprietary experimental data, especially failed assays and negative results that never reach the public literature. It also makes wet-lab integration harder to fake. If the loop between model and experiment is slow, brittle, or outsourced in fragments, the moat may be weaker than the pitch deck suggests.

Biological fidelity will matter more as the field matures. Data from patient-derived organoids, spatial biology, perturbation screens, and clinically relevant models may beat larger but weaker datasets. Translational depth will matter too, because delivery, toxicity, manufacturability, dosing, regulatory strategy, and trial design separate scientific demos from medicines.

Workflow adoption deserves attention for a less glamorous reason: it may commercialize first. Tools that help scientists read, design, document, analyze, and coordinate research can create value before any AI-designed blockbuster reaches the market.

This is why the investment map needs layers. NVIDIA and the cloud platforms benefit if biology becomes more computational. Alphabet has a unique full-stack position through DeepMind and Isomorphic Labs. Microsoft, AWS, and Anthropic can win through scientific workflow and infrastructure. Lab-automation, data, and omics platforms can become the rails for the field. AI-native drug companies carry the most dramatic upside, but they also carry the full burden of clinical failure.

The real prize is not a single AI miracle drug. It is a new research operating system where models, labs, data, and scientists form a faster learning loop.

That connects back to The Next Architecture of Intelligence. The transformer era proved that scale can create surprising intelligence from statistical learning. Biology may demand the next layer: models that combine scale with search, memory, simulation, causal experimentation, and real-world feedback.

It also connects to The Billionaire Bet on Reversing Aging. Longevity investing is really a bet that cell state can become more programmable. AI may accelerate that bet, but the same warning applies: resetting a cell marker is not the same as safely resetting an organism.

The right level of optimism

The AI industry is right to be excited. Biology is becoming more measurable, more programmable, and more computational. The progress from AlphaFold to AlphaFold 3 to protein design and genome modeling is meaningful. The movement of talent and capital into AI life sciences is a real signal. The potential market is enormous.

The scientists are right to be skeptical. Human biology is not software. Disease is layered, adaptive, heterogeneous, and contextual. Better predictions do not automatically become approved therapies. Data quality, experimental design, delivery, toxicity, manufacturing, regulation, and access remain hard.

The right forecast should hold both ideas at once.

AI will probably not cure all disease in ten years. It may still make the next ten years one of the most important decades in the history of biological discovery.

That is the investment story worth watching: not a straight line from chatbot to cure, but a slow conversion of biology from an artisanal search process into a machine-assisted learning system.

The prize is not certainty.

The prize is better experiments.

And in biology, better experiments are how the future starts arriving.

Now the category is being repriced as financial infrastructure.

Kalshi has gone from a regulatory curiosity to a potential IPO candidate. Polymarket has become a global information brand, with Intercontinental Exchange, the owner of the NYSE, agreeing to invest up to $2 billion at roughly an $8 billion pre-money valuation. Robinhood has already turned prediction markets into a product surface inside its app through Kalshi. Meta, according to reporting from NPR and The New York Times, is building a prediction market app of its own called Arena.

The question for investors is no longer whether prediction markets are real.

The question is where the durable economics land.

Do they belong to the regulated exchange?

The consumer app?

The crypto-native liquidity venue?

The social graph?

The data distributor?

Or do event contracts become another commoditized product that every finance app eventually offers?

My answer: prediction markets will produce several winners, but the strongest long-term moat probably belongs to the player that combines regulation, liquidity, distribution, and trusted resolution. Right now, Kalshi is closest to that position in the U.S. real-money market. Polymarket still has the stronger cultural brand. Robinhood may become the most important consumer distribution layer. Meta has the most users, but also the hardest trust problem.

That sounds messy because the market itself is messy. This is at least four businesses wearing the same label.

The old dream finally found its moment

Prediction markets have been around forever in tech years.

The pitch was always beautiful: if people put money behind beliefs, the market price becomes a cleaner signal than punditry, polling, or corporate forecasting. A contract trading at 67 cents means the crowd assigns roughly a 67% probability to the event.

For a long time, the idea was better than the business.

The old versions were too academic, too thinly traded, too constrained, or too legally awkward. The markets that did exist often had poor liquidity and narrow communities. They were fascinating to read and hard to scale.

Then several things changed at once.

The 2024 election made prediction markets part of mainstream conversation. Crypto rails made global collateral and settlement easier. Retail trading apps trained millions of people to understand options, derivatives, and probability-shaped interfaces. Sports betting made real-time outcome speculation socially normal. AI made market creation and resolution cheaper. And the Kalshi court fight opened the door for U.S.-regulated event contracts in a way that did not exist before.

A prediction market only works when enough people care about the question, trust the rules, and can access the venue. The category finally has all three.

Polymarket: the cultural liquidity machine

Polymarket’s edge is simple: it became the place people check when they want to know what the internet thinks will happen.

That is a very different position from being a broker or a regulated exchange. Polymarket behaves more like a live probability layer for the news cycle. It turns every question into a price: elections, sports, geopolitics, crypto, celebrity drama, technology launches, court cases, macro releases.

The product is addictive because it makes uncertainty visible.

During a breaking news cycle, a traditional article says, “Analysts are divided.” Polymarket says, “The market moved from 34% to 52% in two hours.” That price movement becomes content. Media outlets quote it. Traders react to it. Social feeds amplify it. Then the market gets more liquid.

That feedback loop is Polymarket’s real asset.

ICE’s investment makes the point even clearer. ICE said it would become a global distributor of Polymarket’s event-driven data and explore future tokenization initiatives with the company. That turns Polymarket from a consumer trading venue into a data product. If event probabilities become financial sentiment indicators, then Polymarket prices can be sold, embedded, licensed, and referenced.

The weakness is the same one Polymarket has always had: regulatory footing.

Polymarket settled with the CFTC in 2022 for offering off-exchange event-based binary options and had to block U.S. users. Its later acquisition of QCEX, a CFTC-licensed exchange and clearinghouse, gave it a path back into the U.S., with a 2025 CFTC no-action letter around certain event-contract reporting and recordkeeping requirements. That is progress, but it does not erase the complexity.

Polymarket’s moat is cultural liquidity and crypto-native speed. Its challenge is turning that into a regulated, durable, U.S.-accessible exchange business without losing what made it fast.

That is not easy.

Crypto products often win because they move faster than institutions. Exchange businesses win because customers believe the rules will hold under stress. Polymarket now has to become more institutional without becoming boring.

Kalshi: the regulated exchange with IPO gravity

Kalshi is the cleaner institutional story.

It is CFTC-regulated. It fought the election-contract battle and won a key legal opening. It has become the preferred partner for financial platforms that want exposure to prediction markets without building the exchange themselves. Robinhood’s prediction markets hub runs through KalshiEX. That matters because Robinhood brings consumer distribution while Kalshi supplies the regulated market structure.

Kalshi’s growth has been remarkable.

Recent reporting puts Kalshi at a $22 billion valuation after a $1 billion Series F round led by Coatue, with participation from firms including Sequoia, Andreessen Horowitz, Paradigm, Morgan Stanley, and ARK Invest. Kalshi has also reported massive growth in trading activity, with annualized trading volume cited around $178 billion and institutional trading volume up sharply. CNBC reported that CEO Tarek Mansour said Kalshi is thinking about an IPO, though not in 2026.

If Kalshi goes public in 2027 or 2028, it will not be sold as a cute betting app. It will be sold as a new derivatives exchange.

That distinction matters for valuation.

A consumer betting app gets valued on user growth, retention, take rate, and regulatory risk. An exchange gets valued on liquidity, clearing, market data, institutional adoption, compliance, and operating leverage. CME, ICE, Nasdaq, and Cboe have shown how powerful exchange economics can be when a venue becomes the default place to trade a specific category.

Kalshi wants investors to see event contracts that way.

The risk is that public markets may ask a tougher question than private investors: how much of the volume is structurally durable?

Sports contracts appear to be a major driver of recent growth. That is exciting because sports create frequent, high-engagement markets. It is also dangerous because sports sit directly in the conflict zone between federal derivatives regulation and state gambling regulation. Nevada, New Jersey, Illinois, and other states have challenged Kalshi. The company argues that its contracts sit under federal CFTC oversight, while state regulators argue that some products resemble sports betting.

That fight is the biggest open variable.

If Kalshi wins the federal preemption argument, it has a real regulatory moat. If states can significantly restrict sports-style event contracts, some of the growth story becomes less clean.

The other problem is market integrity.

Prediction markets are uniquely vulnerable to insider information. If a market asks whether a company will announce layoffs, whether a politician will resign, whether a product launch will be delayed, or whether a regulatory action will happen, somebody may know before the market does. Kalshi has been emphasizing KYC, employer information, and surveillance. It has to. Institutional users will not treat event contracts as a serious asset class if they think the market is structurally easy to game.

So Kalshi’s moat is regulation plus exchange infrastructure. Its challenge is proving that the category can scale beyond sports and elections into something Wall Street uses all year.

Robinhood: the distribution layer with asymmetric upside

Robinhood does not need prediction markets to become the whole company.

That is exactly why it is dangerous.

For Kalshi, prediction markets are the business. For Robinhood, they are another product tile next to stocks, options, crypto, retirement, credit cards, and futures. Robinhood can make event contracts feel like a natural extension of retail trading.

That gives Robinhood a powerful hand.

Robinhood already has millions of users who understand risk-taking interfaces. Its customers are used to small-dollar trading, real-time prices, and markets that feel like social events. A contract on March Madness, Fed rates, Bitcoin, CPI, or an election outcome fits the emotional cadence of the app.

The company’s first attempt at Super Bowl contracts hit a CFTC roadblock in February 2025. It then returned with a broader prediction markets hub through Kalshi, launching markets such as March Madness and Fed-rate contracts. Robinhood’s approach is pragmatic: it does not own the exchange, so it lowers regulatory and infrastructure burden. It can test demand, keep the interface, and let Kalshi handle the market venue.

That also limits Robinhood’s moat.

The Kalshi partnership is reportedly non-exclusive. If prediction markets become a standard brokerage product, Interactive Brokers, Webull, Coinbase, Schwab, DraftKings-like hybrids, and other platforms can eventually add similar access. Robinhood’s advantage is speed, UX, and customer base, not ownership of the core exchange.

But this may still be a very good business for Robinhood.

A broker does not need monopoly economics to benefit from a new asset class. Options helped Robinhood because they increased engagement, revenue per user, and daily habit. Prediction markets could do something similar. They are simpler than options, more topical than stocks, and easier to understand than many crypto products.

For public-market investors, Robinhood may be the cleanest way to express the retail-distribution side of the thesis. It has prediction market upside without depending entirely on the category.

That makes HOOD interesting even if Kalshi captures the exchange economics.

Meta: the biggest audience, the hardest trust problem

Meta’s reported prediction market project is the most interesting and the most misunderstood.

According to NPR and The New York Times, Meta is building a standalone app called Arena. It would likely use play money rather than real money at launch. Internal documents reviewed by NPR reportedly describe Llama generating markets from trending topics, recommending markets to users, and resolving outcomes in near real time.

This is Meta’s playbook in one sentence: take a behavior that is working elsewhere, remove the friction, automate the expensive parts, and push distribution through the social graph.

Meta has tried this before. Forecast, its earlier prediction app, launched in 2020 and shut down in 2022. NPR reported that internal documents cited the operational cost of manual question curation as a reason Forecast died. Arena appears to be the rebuild with AI replacing the expensive human layer.

That is smart.

Question creation is one of the hidden costs of prediction markets. Someone has to decide what questions matter, write them clearly, define resolution criteria, prevent duplicates, moderate manipulation, and settle disputes. If Llama can generate thousands of timely markets from what people are already discussing on Facebook, Instagram, Threads, and WhatsApp, Meta can create a much broader prediction layer than Kalshi or Polymarket.

Meta also has the largest distribution advantage in the category. More than 3 billion people use at least one Meta app daily. If even a tiny fraction tried Arena, it could become the largest prediction app by registered users almost immediately.

But users are not liquidity.

That is the key point.

Play-money markets are good for engagement, polling, games, and community forecasting. They are weaker as truth machines. Real money disciplines prediction because being wrong costs something. Points can still create ranking incentives, but they do not create the same arbitrage pressure. If Meta wants Arena to become an information product with prices that investors, journalists, and institutions trust, the lack of money is a problem.

Then comes the bigger issue: trust.

Would users trust Meta’s AI to resolve politically sensitive markets? Would regulators tolerate a social media platform creating, recommending, and resolving markets around elections, wars, public health, protests, corporate news, and cultural controversies? Would journalists cite an Arena probability if the market is shaped by recommendation algorithms instead of open financial liquidity?

Meta’s biggest edge is also its biggest liability.

It knows what people are talking about. It knows what keeps them engaged. It can personalize the feed. It can push prediction prompts into massive social loops. That is powerful. It is also exactly what makes regulators, academics, and media critics nervous.

Meta can win the attention version of prediction markets. It can turn forecasting into a social product. It may even create a valuable dataset about crowd beliefs. But unless it moves into real-money contracts through a regulated partner or license path, Arena is more likely to become a social forecasting game than a financial exchange.

That does not mean it is irrelevant. It means Meta’s first win would be engagement, not exchange economics.

The moat question

Prediction markets have several possible moats, and most are weaker than they look.

Liquidity is a moat, but only within a market category. A platform can dominate election markets and still lose sports, macro, crypto, or entertainment. Liquidity follows attention, and attention moves.

Brand is a moat, but only until users can get better prices or easier access somewhere else. Polymarket has the brand among internet-native forecasters. Kalshi has the regulated credibility. Robinhood has the consumer finance relationship. Meta has mass-market attention. None of those brands automatically wins every market.

Regulation is a moat, but it can become a trap. Kalshi’s CFTC-regulated status helps partners like Robinhood. It also puts Kalshi directly in the federal-versus-state fight over sports and event contracts. Polymarket’s U.S. path through QCEX helps, but its crypto-native history still creates scrutiny. Meta can avoid money at first, but then it avoids the strongest source of forecasting accuracy.

Distribution is a moat, but only if the product can convert attention into reliable markets. Meta and Robinhood have distribution. Kalshi and Polymarket have stronger category authenticity. The winner needs both.

Data may become the best moat.

If prediction markets become a new type of financial sentiment feed, the most valuable product may not be trading fees. It may be probability data. ICE’s Polymarket investment points in that direction. A live market-implied probability for elections, policy, sports, geopolitics, inflation, recession, product launches, or corporate events can become an input for media, risk models, trading systems, and enterprise dashboards.

That is where the category starts to look less like gambling and more like Bloomberg.

Who is best positioned?

If I had to rank the players by long-term position, I would separate them by role.

Best positioned to own the U.S. regulated exchange layer: Kalshi

Kalshi has the clearest path to becoming the CME of event contracts. It has regulation, liquidity, institutional momentum, a Robinhood distribution partner, and IPO gravity.

Its risk is concentration in legally controversial high-volume markets, especially sports. It also has to prove that institutional event trading becomes a durable year-round asset class rather than a hype cycle around elections and major sporting events.

If Kalshi clears those hurdles, it has the strongest standalone company story.

Best positioned to own global cultural probability: Polymarket

Polymarket has the brand, the crypto-native user base, and the cultural reflex. It is where the internet looks when it wants a fast probability on the story of the day.

ICE’s investment gives it institutional validation and a potential data-distribution engine. The U.S. return through QCEX could dramatically expand its addressable market.

Its risk is that the very thing that made it fast, open, and internet-native may be hard to reconcile with full institutional trust.

Best positioned to monetize retail distribution: Robinhood

Robinhood may not own the exchange, but it can own the user interface for millions of retail traders.

That is a good place to sit if prediction markets become a common product rather than a single destination. Robinhood can add markets, earn fees, increase engagement, and treat event contracts as another reason users open the app.

Its ceiling is lower than Kalshi’s if exchange economics concentrate. Its risk is lower because prediction markets are an extension, not the entire company.

Best positioned to make prediction social: Meta

Meta can scale a points-based prediction app faster than anyone. It can use AI to create and resolve markets at huge volume. It can attach prediction to social discussion, trending topics, creator content, and news.

But Meta has the weakest claim to “market truth” unless it adds real money or a regulated partner. Play-money prediction markets can be fun and informative, but they do not carry the same weight as prices backed by capital.

Meta’s opportunity is enormous. Its trust problem is even larger.

The investment angle

For public-market investors, the direct plays are limited.

Kalshi and Polymarket are private. A Kalshi IPO could become one of the first pure-play public tests of prediction markets as exchange infrastructure. If that happens, the S-1 will matter more than the hype. Investors should look at revenue mix, take rate, sports exposure, institutional volume, market concentration, regulatory expenses, surveillance costs, and repeat behavior outside election cycles.

Polymarket’s public-market angle currently runs through ICE. ICE is not a pure prediction-market stock, but its investment says something important: the owner of the NYSE sees event probability data as a real financial product. That may matter more than the minority stake itself.

Robinhood is the most obvious public equity expression of consumer adoption. If event contracts become another high-engagement trading category, HOOD benefits through usage, brand relevance, and revenue per active trader.

Meta is the option value play. If Arena works, it could create a new social behavior layer. If it fails, it becomes another experimental app in Meta’s long list of clones, trials, and shutdowns. For META shareholders, the prediction-market project is interesting but not thesis-defining.

My base case

The long-term winner will not be the company with the most questions.

It will be the company whose prices people trust enough to quote, trade, hedge, and build products around.

That points toward a layered market:

• Kalshi wins regulated U.S. real-money event contracts.

• Polymarket wins global culture, crypto-native liquidity, and probability-as-media.

• Robinhood wins consumer brokerage distribution.

• ICE and other infrastructure players turn event data into institutional products.

• Meta builds a huge social forecasting product, but its first version will probably be more engagement engine than financial market.

The category’s largest prize is not “betting on everything.”

The largest prize is becoming the probability layer of the internet.

Every market, media story, policy debate, sports season, Fed meeting, product launch, election, court case, and geopolitical crisis has an implied probability. Today those probabilities are scattered across polls, odds, analyst notes, options markets, social feeds, and vibes. Prediction markets compress them into a visible price.

That price will not always be right. Markets can be manipulated. Thin markets can be silly. Sports volume can masquerade as institutional adoption. AI-resolved markets can create new trust problems. Regulators can still change the rules.

But the direction is clear.

The world is getting more uncertain, and investors, consumers, journalists, and institutions want live probabilities rather than delayed explanations.

That is why prediction markets matter.

The moat will belong to whoever turns that demand into trusted liquidity.

Right now, Kalshi has the best shot at building the regulated exchange. Polymarket has the best shot at owning the culture. Robinhood has the easiest path to mass retail usage. Meta has the largest distribution but the hardest path to credibility.

If I had to pick the long-term center of gravity, I would pick Kalshi for the exchange layer and Polymarket for the information layer.

If I had to pick the public company that benefits soonest without needing to own the whole category, I would watch Robinhood.

And if I had to pick the wild card, it is Meta. Arena may fail as an app. But the idea behind it will not go away: prediction markets are no longer just markets. They are becoming a new format for social attention.

Not investment advice. Prediction-market companies face substantial regulatory, legal, market-integrity, and product-adoption risks.

Those answers were reasonable. They still are. AI is already making money in those places. You ask it to write emails, clean up slides, generate code, summarize calls, or run a customer support bot, and companies understand the value immediately. Save time. Cut cost. Move faster. That looks like the natural path for AI commercialization.

But lately I keep coming back to a different thought.

The thing that really excites the AI giants may not be sitting on your laptop screen. It may be sitting under a microscope.

Look carefully at what has happened over the past two years. Almost every top AI company is pushing into life sciences, each from a different angle.

Google DeepMind built AlphaFold 3, putting proteins, DNA, RNA, small molecules, and antibodies into one prediction framework. Its sister company, Isomorphic Labs, is working with Novartis, Eli Lilly, and Johnson & Johnson to push AI models into real drug discovery.

OpenAI is working with Lilly on new antimicrobials and with Retro Biosciences on protein engineering for cell reprogramming. Microsoft is building BioEmu to model how proteins move. NVIDIA is turning biology into a market for GPUs, BioNeMo, NIM microservices, and AI infrastructure. Meta’s earlier ESM protein language model work helped seed EvolutionaryScale, whose ESM3 model is trying to make protein generation feel closer to image generation. Anthropic is plugging Claude into scientific workflows through Benchling, PubMed, 10x Genomics, BioRender, and related tools. Amazon Web Services is playing the cloud, model, and automation layer for companies like Bayer and Exscientia.

That signal deserves attention.

The AI giants did not all wake up one morning and develop a sentimental love for biology class. They see a larger opportunity. If AI can move from generating text to generating testable scientific hypotheses, the ceiling changes completely.

Writing an email may save a company a few minutes.

Designing a molecule that eventually enters the clinic can change the fate of an entire company.

That is the lure of life sciences.

After AlphaFold, Google Wants to Turn a Nobel Prize into Drugs

This story has to begin with DeepMind.

When AlphaFold 2 cracked the protein structure prediction problem, a lot of people realized something for the first time: AI could write essays, play Go, recognize images, and also solve scientific problems that had frustrated researchers for decades.

Then came AlphaFold 3, with a much larger ambition. When DeepMind and Isomorphic Labs announced the model in 2024, they said it could predict the structure and interactions of all life’s molecules, including proteins, DNA, RNA, ligands, antibodies, and more.

The phrase “predict structure” sounds abstract. The important part is more practical: drug discovery happens through interactions.

A drug works because it binds to a protein pocket, blocks a pathway, changes a signal, or alters a biological process. An antibody works because it recognizes an antigen. A DNA variant matters because it can change expression, splicing, or disease risk. For decades, scientists have attacked these questions with experiments, experience, luck, and a lot of expensive trial and error.

AlphaFold 3 tries to move part of that search into the computational world.

DeepMind’s own research blog says AlphaFold 3 improved predictions for interactions between proteins and other molecule types by at least 50% versus existing methods, with some categories doubling in accuracy. That does not mean drug-development success rates suddenly jump by 50%. Biology is not that kind of machine. But it explains why Isomorphic Labs has become such an important Alphabet asset.

The logic is simple.

DeepMind produces the scientific breakthrough. Isomorphic tries to turn the breakthrough into drug programs.

The company started a collaboration with Novartis in 2024, initially focused on three difficult small-molecule targets, then expanded the work in 2025. Its Lilly collaboration focuses on undisclosed small-molecule targets. Its Johnson & Johnson partnership goes broader, covering multiple targets and multiple modalities, including small molecules and biologics.

The message is direct: Google does not want AlphaFold to remain a citation machine or a scientific trophy. It wants to know whether AI can become the engine of a new kind of drug company.

That is why Alphabet’s line of attack is so interesting. Alphabet is doing something more ambitious than selling cloud compute to pharma or adding a few science plugins to a general chatbot. It has a chain that runs from frontier models to scientific teams, from scientific teams to a drug discovery company, and from that drug discovery company to large pharmaceutical partners.

If AI drug discovery eventually produces a group of major medicines, Alphabet may have one of the earliest full-stack templates.

OpenAI Wants to Prove Intelligence Can Invent

OpenAI’s entrance into life sciences feels more like OpenAI.

It has not yet built a full drug company around the effort. Instead, it is showing examples that support a much bigger claim: models can invent useful things.

In June 2024, Eli Lilly announced a collaboration with OpenAI to use generative AI to discover novel antimicrobials for drug-resistant pathogens. Antimicrobial resistance is one of those global risks that remains strangely underpriced in public attention. Traditional antibiotics can be commercially unattractive, while the science is difficult and the public-health need is enormous. Lilly’s partnership with OpenAI is basically asking: can large models help humans explore antimicrobial chemical space that has been neglected or poorly searched?

The more dramatic case is OpenAI’s work with Retro Biosciences.

Retro works on longevity science, including cell reprogramming. One of its areas of interest involves Yamanaka factors, a set of proteins that can push ordinary cells back toward a younger, stem-cell-like state. The problem is efficiency. Reprogramming takes time, and only a small share of cells complete the journey.

MIT Technology Review reported that OpenAI and Retro built a model called GPT-4b micro to redesign those factors. Preliminary results suggested that model-designed variants improved certain reprogramming markers by more than 50 times compared with the original factors.

We should be careful here. No drug has come out of this yet. No commercial product has come out of it either. It is more like a scientific demonstration.

But the demonstration matters because it hits the exact point OpenAI wants to make. AI can help scientists read papers, write code, and organize lab notes. It may also propose designs that human scientists did not think of, then produce effects that show up in the lab.

That matters to OpenAI far beyond longevity.

If a model can design proteins, it starts to approach the center of scientific discovery. If a model can propose an experimental hypothesis, watch the lab test it, absorb the result, and improve the next proposal, the system starts looking less like a chatbot and more like the early outline of a scientific engine.

From an investment lens, OpenAI’s life-sciences line has strong option value. It does not yet have the clean commercial drug-discovery path that Isomorphic is trying to build. But it has a larger story: general intelligence should eventually accelerate human invention.

That is why OpenAI has to be here. If the AGI story stays trapped in customer support, office work, and coding, enterprise-software valuations will define its imagination. Life sciences gives OpenAI a different story: superintelligent tools might change medicine, aging, disease, and human lifespan.

That story is too large for OpenAI to ignore.

Microsoft and NVIDIA Are Building the Scientific Engine Room

Compared with OpenAI and DeepMind, Microsoft’s life-sciences strategy looks less theatrical. It is also very serious.

Microsoft’s AI for Science team is building BioEmu around one key fact: proteins move.

A lot of people hear about AlphaFold and assume that once you know a protein’s structure, the drug discovery problem is mostly solved. Reality is messier. Proteins wiggle, fold, unfold, expose hidden pockets, shift domains, and occupy different states. A drug’s ability to bind often depends on those moving states.

BioEmu uses generative deep learning to model protein equilibrium ensembles. Microsoft’s research page says BioEmu can generate thousands of statistically independent protein structures per hour on a single GPU. Its training data integrates more than 200 milliseconds of molecular dynamics simulations, static structures, and experimental stability data. It can also predict free energies close to long-timescale molecular dynamics and experimental measurements.

That sounds technical. Underneath it is a business equation.

Traditional molecular dynamics simulation is expensive and slow. Experiments are even more expensive and even slower. If systems like BioEmu can amortize part of that cost into fast model generation, they can change the cost curve of scientific computation.

NVIDIA is looking at a different layer.

Once life sciences enters the model era, the field needs compute, software stacks, deployment tools, and inference services. That is NVIDIA’s home territory.

BioNeMo is NVIDIA’s toolkit for drug discovery and digital biology. It includes models for protein structure, generative chemistry, molecular docking, DNA sequence analysis, and single-cell RNA analysis. NVIDIA is also packaging these capabilities through NIM microservices so drug companies can integrate them more easily in the cloud or on premises.

This is the business NVIDIA understands better than anyone: turn a new computing paradigm into an infrastructure market.

If every large pharma company eventually trains its own molecular models, runs protein dynamics simulations, deploys AI lab platforms, and processes genomic, cellular, chemical, and imaging data at scale, GPU demand will not come only from chatbots. It will also come from animal models, cell images, genome sequences, protein spaces, and chemical universes.

NVIDIA does not need to know which AI-discovered drug wins. If the entire industry believes drug discovery needs more computation, NVIDIA gets to stand near the toll booth.

That is why life sciences may be an underappreciated long-term demand source for NVIDIA. Today, investors stare at data centers and cloud capital expenditure. Five years from now, biological computation could become another durable layer of AI demand.

The Seed Meta Left Behind Is Growing into Programmable Proteins

Meta looks quieter in this race, but its earlier ESM work matters.

ESMFold and the ESM Metagenomic Atlas predicted structures for hundreds of millions of metagenomic proteins, pulling unknown proteins from soil, oceans, microbes, and the human body into a structural map. The people and ideas behind that work later became central to EvolutionaryScale.

EvolutionaryScale’s ESM3 is an ambitious model. It works across protein sequence, structure, and function. The company says ESM3 has 98 billion parameters, was trained with more than 1 x 10^24 FLOPs, and generated a new green fluorescent protein. That protein had only 58% sequence similarity to the closest known fluorescent protein, which the company described as equivalent to simulating more than 500 million years of evolution.

That sounds like science fiction. But it captures the most fascinating part of protein engineering.

Nature has spent billions of years searching through protein space. Humans have mostly modified what nature already gave us. If a model can learn the language of proteins, it may be able to jump into new regions that nature never explored but physics still allows.

That is the imagination behind programmable biology.

Today we generate images with AI and barely think about it. You type a prompt, and the model searches image space for something that fits. One day, a scientist may type a functional constraint, and the model may search protein space for an enzyme, a binding protein, a delivery system, or a cell-therapy component.

Of course, the validation gap is huge. A human can judge an image in a second. A protein has to fold, function, avoid toxicity, and be manufacturable. The lab gets the final vote.

Still, the direction has changed.

In the past, we ordered from the menu nature had already written. Now AI companies want to help write new menus.

Anthropic and AWS Are Going After the Scientist’s Daily Workflow

Life-sciences AI does not have to begin with the design of a new molecule.

Some value will arrive in more ordinary places first: reading papers, drafting protocols, organizing data, searching internal records, generating compliance documents, planning clinical recruitment, and connecting lab notebooks with databases.

Anthropic’s Claude for Life Sciences is aimed at that layer.

It connects Claude to Benchling, PubMed, BioRender, Wiley Scholar Gateway, Synapse.org, 10x Genomics, and related platforms. In practical terms, scientists do not have to drag everything into a blank chat window. AI moves into the tools they already use.

That matters.

Scientific work contains a lot of reading, cleaning, formatting, protocol writing, database querying, first-pass analysis, and regulatory paperwork. The “eureka” moment is precious. The daily friction is relentless. If Claude can remove some of that friction, commercial value may arrive faster than outsiders expect.

Sanofi’s use of Claude points in the same direction. Pharma companies are not treating AI as a lab toy. They are putting it across the value chain, from R&D to internal knowledge work to commercialization.

AWS is doing something similar from the infrastructure side.

AWS worked with Bayer on a six-week project using generative AI to predict chemical reaction conditions. To outsiders, reaction conditions may sound unexciting. To chemists, they matter enormously. Making a molecule often means navigating solvents, catalysts, temperature, pressure, reagents, and sequence of steps. Better prediction can save real time.

AWS also supports Exscientia’s AI-powered drug discovery platform, which combines generative design with robotic lab automation. That loop, where the model proposes a design, robots run the experiment, and the data returns to the model, is one of the most important structures in future drug discovery.

Anthropic and AWS therefore represent a more pragmatic route. Put AI into the daily workflows of researchers and pharma teams. Start by saving time. Move gradually toward scientific discovery.

That path may be less glamorous than “AI designs a new drug,” but it may commercialize faster.

Why Now?

Saying “healthcare is a huge market” is too shallow.

Healthcare has always been huge. Pharma has always been profitable. So why are AI companies rushing in now?

Because several conditions matured at the same time.

Start with the deepest shift: life began to look like language.

Proteins are sequences. DNA is sequence. RNA is sequence. Chemical reactions can be tokenized. Lab protocols are text. Papers are text. Clinical records are full of text. Transformers are very good at learning patterns from large-scale sequences. They do not make biology simple, but they allow AI companies to see many biological systems as things with learnable grammar.

Then came data. Biology finally became large enough.

Sequencing, single-cell biology, spatial omics, cryo-EM, protein databases, high-throughput screening, and automated labs have made living systems more measurable. AlphaGenome can read one million DNA base pairs at a time and predict regulatory signals across tissues and cell types because the scientific world spent years measuring the underlying system.

Even more important, the experimental loop is forming.

In the past, AI models could make suggestions, but scientists still had to arrange experiments slowly. Now robotic labs, automated synthesis, and cloud data systems are shortening the prediction-experiment-feedback-prediction cycle. AI changes drug discovery through that shorter loop, rather than through one magical prediction.

Pharma also needs a new engine.

Large drug companies face patent cliffs. Older drugs lose revenue to generics. New drugs are more expensive to develop. Clinical failure is brutally costly. They need better targets, stronger candidates, smarter trial design, and fewer dead-end experiments. If AI improves even a small part of that process, the economic value can be enormous.

And AI companies need a bigger proving ground.

If AI only writes marketing copy and handles customer service, it is useful but limited. Life sciences gives AI companies a harder exam. Can you propose new hypotheses? Can you design new molecules? Can you improve experimental outcomes? Can you accelerate discovery?

That is why life sciences matters so much.

It is a place where AI can prove that it creates knowledge.

The Talent War Is Becoming Half Scientist, Half Engineer

This race eventually comes down to people.

The AI industry used to fight over machine learning researchers, GPU engineers, distributed-systems experts, and product engineers. Now it needs another kind of person: someone who understands proteins, chemistry, cell experiments, sequencing data, and also knows how to talk to a model team.

There are not many people like that.

A pure AI team may misunderstand experimental noise and mistake beautiful metrics for real biology. A traditional pharma team may understand biology but struggle to turn internal data into a continuously learning AI system. The scarce person is the bridge.

That is why Isomorphic Labs emphasizes multidisciplinary talent. Anthropic is also pulling more life-science expertise into its orbit. In 2026, John Jumper, the AlphaFold co-creator and Nobel laureate, left Google DeepMind for Anthropic. The symbolism is hard to miss.

A person who helped build AlphaFold chose another frontier AI company as his next stop, rather than a traditional pharma company.

That tells us something. Top scientific talent is starting to see AI companies as new scientific institutions. In the past, elite biologists wanted to go to universities, major pharma companies, Genentech, or the Broad Institute. In the future, some may decide the best experimental platform sits inside an AI company, where there is compute, model talent, engineering speed, and a sufficiently unreasonable goal.

For investors, talent flow matters.

Capital follows talent. Platforms form around talent. Partnerships follow talent. The companies that can put AI researchers, computational biologists, medicinal chemists, wet-lab scientists, and product builders into one fast operating rhythm have the best chance of building a true life-sciences AI flywheel.

For Investors, Start with Infrastructure, Then Look at Drug Optionality

If I put this into an investment framework, I would separate it into two layers.

The first layer is infrastructure.

NVIDIA is obviously there. If drug discovery becomes a large-scale modeling, simulation, inference, and data-processing problem, GPU demand grows. Microsoft, Google Cloud, and AWS are there too. Pharma companies need cloud systems to train models, manage omics data, run automated experimental platforms, and call biological foundation models. Lab data and R&D workflow platforms such as Benchling also become more important because AI needs clean access to experimental records to matter.

The advantage of this layer is timing. It does not need to wait for one AI-designed drug to succeed in the clinic. Once the industry adopts the tools, infrastructure gets paid first.

The second layer is platform and drug optionality.

Isomorphic Labs, EvolutionaryScale, Retro Biosciences, Exscientia, Recursion, Insilico, Iambic, and similar companies represent the higher-upside layer. If AI improves candidate quality, shortens discovery cycles, or opens new modalities, the returns can be enormous. The risk is also enormous, because clinical trials still decide the truth.

Biology does not flatter anyone for long.

A molecule can look beautiful in a model and fail in a cell. It can work in a mouse and fail in humans. It can show efficacy and then fail on toxicity. It can make mechanistic sense and still fail commercially. So I would not frame AI drug discovery as “software eating pharma.” The better framing is that AI gives pharma and techbio companies a new discovery lever.

Large pharma can be both customer and winner. Lilly, Novartis, J&J, Sanofi, Bayer, and others have clinical development, regulatory knowledge, manufacturing, and commercialization capacity. If they integrate AI into their R&D systems, AI may strengthen them rather than replace them.

The thing to watch is proprietary feedback loops.

Public data can train powerful foundation models. But long-term advantage in drug discovery often comes from private experimental data: failed compounds, real assay results, cell images, protein engineering logs, synthesis routes, clinical signals, and the tacit knowledge scientists build over years.

Whoever turns every experiment into training signal owns an asset that is hard to copy.

That is the life-sciences version of the AI flywheel.

The Real Bet Is Learning the Operating System of Life

I think the AI giants are after something much larger than another revenue vertical.

They are looking for AI’s next source of legitimacy.

Chatbots brought AI into everyday life. Coding assistants brought AI into software production. Life sciences may bring AI into humanity’s most difficult knowledge-production system: understanding disease, designing drugs, engineering proteins, interpreting genomes, and shortening experimental cycles.

In the short term, much of the value will look ordinary. Read papers faster. Draft protocols faster. Clean data faster. Generate regulatory documents faster. Predict reaction conditions faster. None of that sounds sexy, but pharma will pay for it.

In the medium term, AI should improve the search efficiency of drug discovery: better targets, better molecules, fewer wasted experiments, faster feedback loops.

Over the long term, the exciting possibilities arrive: programmable proteins, AI-designed molecules, genomic regulatory models, automated experimental loops, and semi-autonomous discovery systems.

The path will be uneven. AI will make mistakes. Models will hallucinate. Experiments will fail. Clinical trials will embarrass beautiful theories. Some projects will disappoint. But for investors with a five-year horizon or longer, the question to watch is whether biology is becoming a domain that computation can learn more effectively.

My answer is yes.

Life sciences is slowly moving from experience-driven discovery toward a system driven by data, models, and experimental feedback loops. This transition will not finish overnight, but the direction is clear.

So when AI giants bet on life sciences, they are chasing far more than a short-term theme.

They are fighting for a much larger doorway: whoever learns to read life may define the next generation of scientific productivity.

If the last decade taught AI human language, the next decade may teach it the language of life itself.

That is what makes this race so fascinating.

Disclaimer: This article is for research and educational purposes only. It does not recommend buying, selling, or holding any security, fund, drug asset, or private company. Life-sciences and AI drug-discovery investments carry high risk, including clinical failure, regulatory changes, valuation volatility, and slower-than-expected technical adoption. Make your own decisions based on your own risk tolerance.

That line works because the official label sounds so respectable. Qualified suggests training, judgment, financial literacy, or some demonstrated ability to evaluate risk. In practice, the U.S. private-market gate still leans heavily on income, net worth, institutional status, and proximity to professional finance.

The SpaceX IPO turned that abstraction into a live market lesson. Here was a company that had spent 24 years private, reached infrastructure scale, and entered the public market as one of the most important businesses in the world. Retail investors could finally buy it directly, but only after private investors had spent years compounding inside the gates.

Harvey described requesting ten shares at the $135 allotment price and receiving one. The rest of the order, he said, would have to be filled around $170. His warning was simple: the public was being offered a sliver of the IPO allocation and a much fuller dose of the post-pop price.

That is why the accredited-investor debate has moved from legal plumbing to political economy. The rule began as investor protection. In today’s market structure, it increasingly operates as opportunity rationing: ordinary households are shielded from bad private deals while also being blocked from many of the private companies that define the next growth cycle.

SpaceX made the problem visible. OpenAI and Anthropic could make it unavoidable.

A disclosure rule became a wealth gate

The historical starting point matters because the original fear was real.

The Securities Act of 1933 came after a market collapse that exposed how little ordinary buyers often knew about securities being sold to them. The New Deal answer was disclosure. Washington would not certify which investments were good. Instead, if a company wanted to sell securities broadly to the public, it had to register the offering, publish material information, and accept liability for misleading statements.

Private offerings lived outside that full registration bargain. The Supreme Court’s 1953 Ralston Purina decision framed the exemption around whether offerees could “fend for themselves” and had access to the kind of information registration would disclose. That became the philosophical ancestor of the modern accredited-investor regime.

Regulation D, adopted in 1982, turned that philosophy into a working market system. Rule 506 became the main highway. Under Rule 506(b), an issuer can sell to unlimited accredited investors and up to 35 non-accredited but sophisticated investors, without general solicitation. Under Rule 506(c), created later by the JOBS Act, an issuer can generally solicit, but all purchasers must be accredited and the issuer must take reasonable steps to verify that status.

For individuals, the familiar tests remain: income above $200,000 individually or $300,000 with a spouse or spousal equivalent, or net worth above $1 million excluding the primary residence. The tougher “qualified purchaser” category under the Investment Company Act generally requires an individual to own at least $5 million in investments, a threshold that matters because many private funds rely on qualified-purchaser exemptions.

The definition has been patched. Dodd-Frank excluded the primary residence from the net-worth calculation. In 2020, the SEC added narrow knowledge-based paths, including Series 7, Series 65, and Series 82 licenses and certain knowledgeable employees of private funds. The SEC described the change as a way to recognize investors with “knowledge and expertise,” rather than income or net worth alone.

That was progress. It was also limited progress. The main gate still opens through wealth.

Inflation widened the gate without solving the fairness problem

One irony of the accredited-investor rule is that it has become broader over time without becoming especially smarter.

The thresholds were never indexed to inflation. In its 2023 review, the SEC estimated that households meeting the financial criteria rose from about 1.8% of U.S. households in 1983 to 18.5% in 2022, or roughly 24.3 million households. If the original thresholds had been adjusted by CPI-U through 2022, the $1 million net-worth test would have been about $3.04 million, the $200,000 individual-income test about $607,568, and the $300,000 joint-income test about $911,352.

That fact cuts in both directions. Defenders can say the rule has already expanded far beyond its original reach. Reformers can respond that inflation is a terrible proxy for sophistication. A household does not become better at reading a cap table because home prices rose. A retired couple may qualify because of assets accumulated over a lifetime and still be vulnerable to a slick private-placement pitch. A younger engineer may understand AI infrastructure deeply and remain legally excluded.

The SEC’s own participation data show how dominant the accredited channel has become. From 2009 through 2022, the agency estimated about 9.6 million investor participations in Regulation D offerings. Roughly 99.7% were accredited-investor participations. Only about 27,900 non-accredited investor participations appeared across that entire period.

The scale of the market makes those numbers matter. The SEC estimated that exempt offerings raised about $3.7 trillion in 2022, roughly 270% more than the $1.0 trillion raised through registered offerings. Private markets are no longer a small side room attached to public markets. They are a main room of American capital formation.

That changes the moral weight of the access question.

The IPO now arrives after the steepest climb

The old mental model said that ambitious companies eventually went public early enough for public investors to participate in a long runway of growth. That model has weakened.

Private capital is deeper. Late-stage venture funds, crossover funds, sovereign wealth funds, family offices, corporate investors, and secondary platforms can finance companies for years. At the same time, public-company disclosure costs, litigation risk, quarterly scrutiny, and governance burdens give boards reasons to delay listing.

The result is an inversion. The public market used to be where growth companies came to finance the future. Increasingly, it is where mature private companies come to provide liquidity, establish a trading currency, and let earlier investors realize gains.

SpaceX is the cleanest case because it compresses the problem into one trading day. Retail investors were not excluded only from a tiny seed round where failure risk was extreme. They were largely excluded from direct ownership during the long period when SpaceX moved from audacious private venture to infrastructure-scale company. By the time public investors arrived, the question had changed from “Can I participate in the rise?” to “How much of the rise has already been priced in?”

Harvey’s phrase for the public buyer’s position was harsh: “The leftovers are relegated to the retail investor.” The phrase is useful because it captures the structure of the transaction. Accredited capital buys the uncertain curve. Public capital is asked to buy the narrated outcome.

This does not mean every IPO is bad or every late-stage private investor wins. Space, AI, biotech, and frontier technology can destroy capital as easily as they create it. But the allocation of timing matters. If the most powerful value creation happens behind a wealth gate, then the public market becomes less a democratizing mechanism and more a liquidity event.

OpenAI and Anthropic make the issue larger than SpaceX. Artificial-intelligence leaders require extraordinary capital for compute, data centers, talent, distribution, safety infrastructure, and model training. Private capital has become deep enough to fund that race for years. If these companies remain private through the period when strategic control, platform lock-in, and model capability are established, retail investors may again be invited after the steepest part of the curve.

Brian Armstrong captured the frustration in a June 2026 post calling for a revisit of accredited-investor laws. Companies are staying private longer, he wrote, and retail investors can enter only after IPO, “when much of the upside has already been captured.” His most memorable line was sharper: the rules have often “made it illegal to get richer, unless you’re already rich” — “a regressive tax.”

That phrase is provocative, but it identifies a real economic channel. The rule does not tax income directly. It taxes opportunity. It assigns many of the call options on future growth to accredited capital, then offers public investors the stock after the option has been exercised.

The harm is larger than missed gains

The easy version of the argument says rich people get to buy winners early and ordinary people do not. That is true, but incomplete.

The deeper harm is that the rule distorts the relationship between savings and innovation. Households are told to fund retirement through capital markets. Indexing is treated as the responsible default. Financial-literacy campaigns encourage Americans to become long-term owners of productive assets. Yet a growing share of the most dynamic productive assets sits outside the ordinary investor’s direct investable universe.

This creates a diversification problem. If enormous companies remain private longer, a public-equity portfolio is missing part of the economy. The missing slice is concentrated in areas where intangible assets, network effects, technical talent, and scale can produce very large outcomes: AI, space, fintech, defense, biotech, and infrastructure software.

It also creates a legitimacy problem. The public supports the legal, educational, infrastructure, defense, and research ecosystems that help produce frontier companies. Workers train the models, buy the products, live with the social consequences, and in some cases fund the customer base through public budgets. Direct financial participation is still rationed by wealth.

Finally, it creates a trust problem for markets themselves. When the public sees major wealth creation happening in private and receives access mainly at exit valuations, capitalism starts to look like a club. Capital markets depend on the belief that the game is open enough, rules-based enough, and meritocratic enough to deserve broad participation.

The real protection problem is information

The case for investor protection should be taken seriously. Private markets are risky for reasons that public-market analogies often miss.

Private companies disclose less. Financial statements may be unaudited or unavailable. Secondary shares may carry transfer restrictions. Preferred-stock terms can make common-stock valuations misleading. Liquidation preferences, ratchets, side letters, and information rights can create different economics for different investors at the same headline valuation. Private funds charge layered fees. Marks may move slowly. Exits can take years. Some offerings are fraudulent.

Even sophisticated investors make mistakes under these conditions. A retail investor buying a late-stage private AI company through a secondary platform may see a famous name and a recent valuation but still lack the information needed to understand revenue concentration, compute commitments, safety liabilities, governance rights, dilution, customer churn, or who is selling and why.

So the answer cannot be “open everything.” Wealth thresholds solve real administrative problems: they are easy to verify, difficult to fake at scale, and correlated with capacity to absorb losses. A retiree putting half of her liquid savings into a hyped pre-IPO secondary at a fantasy valuation is a real regulatory concern.

But the defense of protection does not prove the case for a wealth password. The current rule bundles three different ideas — knowledge, loss capacity, and access — and mostly measures one. A person can be wealthy and credulous. A person can be non-accredited and informed. A person can qualify because of retirement assets and still lack bargaining power to demand information from an issuer.

A better regime would protect investors by improving the decision environment, not by pretending that net worth equals judgment.

Reform needs a laddered access system

The practical answer is a laddered access system that ties participation to competence, disclosure, diversification, and loss capacity.

At the broadest level, ordinary investors should be able to access private growth through regulated diversified vehicles: interval funds, tender-offer funds, closed-end funds, or other structures with transparent fees, independent valuation policies, concentration limits, liquidity warnings, and plain-English reporting. Many households should begin with diversified exposure rather than single-name private bets.

The next rung should be knowledge-based qualification. Armstrong suggested a financial-literacy or competency test: pass it and you qualify. That idea deserves serious treatment. A useful exam would cover illiquidity, dilution, liquidation preferences, valuation marks, secondary-transfer restrictions, fund fees, conflicts of interest, fraud indicators, and the difference between preferred and common economics. Passing it would not make anyone immune to losses. It would at least measure the thing the word “qualified” claims to measure.

For direct single-company exposure, access should scale with risk. A knowledge-qualified investor could face annual caps based on liquid net worth or income, with stricter limits for earlier-stage or less-disclosed offerings and more room for late-stage issuers that provide standardized information. The goal is to prevent ruinous concentration while permitting meaningful participation.

Disclosure should be tiered as well. Harvey’s intermediate-tier idea points in the right direction: keep full public-company disclosure for public listings, but create a lighter, standardized disclosure regime for large private companies seeking broad retail-accessible liquidity. That regime could include audited financial summaries above size thresholds, capitalization structure, material debt and compute commitments, related-party transactions, insider-sale activity, risk factors, transfer restrictions, and a plain-English description of investor rights.

Platforms and intermediaries should carry responsibility. If they market private securities to a wider investor base, they should verify eligibility, enforce caps, disclose compensation, present standardized risk labels, and face liability for misleading presentation. Broader access without credible enforcement would democratize exploitation. Broader access with better disclosure and sharper accountability would democratize opportunity.

The guiding principle should be simple: protect people from deception and ruin, not from the possibility of wealth creation.

The next IPO wave will force the issue

SpaceX showed the pattern: a defining company matures in private, accredited capital captures much of the steepest upside, and retail arrives at a price that may be necessary for diversification but less attractive for forward returns.

OpenAI and Anthropic could turn that pattern into a national argument. If AI becomes the general-purpose technology investors believe it may be, then excluding ordinary households from direct early exposure will look less like consumer protection and more like a structural allocation of national upside to private capital.

The accredited-investor rule was born from a noble fear: that ordinary people could be misled into securities they did not understand. The modern fear should be different: that ordinary people will be locked out of companies they understand, use, work around, and help finance indirectly through the economy built around them.

Nearly a century after the Securities Act, America does not need to abandon investor protection. It needs to update the instrument. Disclosure can be strengthened. Fraud can be punished. Concentration can be capped. Competence can be tested. Access can be diversified.

What should disappear is the rich-person password.

Behind the poetry, code, images, and conversation produced by large language models sits a machine doing enormous amounts of linear algebra. Words become high-dimensional vectors. Images become tensors. Those vectors flow through layers of weight matrices. Training adjusts billions or trillions of numbers until the system learns a statistical geometry of language, images, and behavior.

That description strips AI of mysticism without making it less extraordinary. A large model is a gigantic learned transformation. It takes an input point in a high-dimensional space, repeatedly stretches, rotates, compresses, and reprojects it through matrices, then emits the most likely next token, pixel, action, or representation. The miracle is that when the matrices become large enough, the training data broad enough, and the optimization stable enough, this statistical machine begins to look like reasoning.

The question now is whether this architecture is the final form of machine intelligence or simply the first scalable platform that worked.

The answer matters far beyond academic computer science. Transformers turned AI into a compute market, a data-center market, a chip market, a cloud market, and a new operating layer for enterprise software. If the next architecture changes the cost, memory, and learning profile of AI, it could redraw the entire value chain again.

Before the Transformer, AI Remembered One Step at a Time

Before 2017, AI had already gone through several eras.

The early symbolic systems tried to encode intelligence as rules. They worked when the world was narrow and formal: chess positions, expert systems, hand-written decision trees. They broke when reality became messy. The world contains ambiguity, context, common sense, and exceptions. Hard-coding all of that turned out to be impossible.

Neural networks offered a different path. Instead of writing rules by hand, engineers would build a structure capable of learning from examples. A model would start with random weights, make predictions, compare them with correct answers, and use gradient descent to adjust its internal parameters. Intelligence became less like a library of rules and more like a landscape of weights.

Convolutional neural networks became the breakthrough architecture for images. Their key insight was local pattern recognition. A CNN could learn edges, textures, shapes, and eventually objects by applying small filters across an image. That structure matched vision well because nearby pixels are meaningfully related. Images have spatial locality.

Language created a harder problem. Words arrive in sequence. Meaning depends on order, memory, and context. The sentence “the animal didn’t cross the street because it was too tired” requires the model to connect “it” with “animal.” Change one phrase and the reference changes. Sequence models had to carry information across time.

Recurrent neural networks, and later LSTMs and GRUs, became the standard solution. They processed text token by token, passing a hidden state forward like a rolling memory. LSTMs improved the system by adding gates that decided what to keep, what to forget, and what to expose. This helped with longer dependencies and made machine translation, speech recognition, and text modeling more useful.

Yet the architecture had a bottleneck. The model still moved through the sentence sequentially. Token one influenced token two, token two influenced token three, and so on. Training could not fully exploit parallel hardware because the computation depended on time order. Long-range memory also remained fragile. Important information could fade as the sequence grew.

Attention existed before the Transformer as an add-on to encoder-decoder systems. It allowed a decoder to look back at different parts of the input sequence instead of compressing everything into a single hidden state. This was powerful. The model could translate a word by paying attention to the most relevant source words. But attention was still attached to recurrent or convolutional machinery.

Then came the 2017 paper that changed the trajectory of AI.

“Attention Is All You Need” Was an Architecture Shock

In June 2017, Ashish Vaswani and colleagues released Attention Is All You Need. The title sounded almost too simple. The claim was radical: sequence transduction could be built entirely on attention, dispensing with recurrence and convolution.

The paper introduced the Transformer.

Its breakthrough was architectural, economic, and philosophical at the same time. Architecturally, it replaced step-by-step recurrence with self-attention. Economically, it made sequence modeling far more parallelizable on GPUs and later specialized AI accelerators. Philosophically, it suggested that the right general mechanism might scale across tasks with fewer hand-built assumptions.

A Transformer begins by converting tokens into embeddings: vectors in a high-dimensional space. It also adds positional information because a pure attention mechanism needs a way to know order.

Then each token embedding is projected into three different vectors: Query, Key, and Value. These are produced by multiplying the input by learned weight matrices usually called WQ, WK, and WV.

A Query asks: what am I looking for?

A Key answers: what information do I contain?

A Value carries: what content should I contribute if another token attends to me?

The model compares Queries and Keys across tokens, usually through dot products. If one token’s Query aligns strongly with another token’s Key, the attention score rises. After normalization through softmax, those scores become weights. The model then computes a weighted mixture of the Value vectors.

In plain language, every token can look at every other token and decide how much each one matters.

This creates a flexible graph of relationships inside the sentence. In “the horse ran because it was frightened,” the token “it” can attend strongly to “horse.” In code, a variable can attend to its definition. In a legal document, a clause can attend to a definition many paragraphs earlier. The model learns these relationships through data rather than receiving hand-coded grammar rules.

Multi-head attention makes the system richer. Instead of one attention pattern, the Transformer runs several attention heads in parallel. One head might track syntax. Another might track references. Another might track positional patterns. Their outputs are combined and passed through feed-forward networks. Residual connections and layer normalization stabilize the repeated transformations.

Stack enough of these layers, train them on enough data, and the result becomes a general pattern engine. It can translate, summarize, write code, answer questions, generate images when fused with diffusion systems, and control tools when wrapped in an agent loop.

The Transformer became the AI world’s first truly general-purpose architecture. It was the x86 moment for deep learning: a common computational substrate that could scale across modalities and products.

The Transformer’s Power Came From Scale

The success of the Transformer validated Rich Sutton’s “bitter lesson”: in AI, general methods that leverage computation tend to beat systems filled with human-designed knowledge. The Transformer fit that lesson perfectly. It did not require engineers to encode grammar, facts, logic, or world models by hand. It needed data, compute, optimization, and scale.

This created the modern AI industrial stack.

NVIDIA GPUs became the engines because they excel at matrix multiplication. Hyperscale cloud providers became the factories because training and serving frontier models requires huge clusters, high-speed networking, power infrastructure, cooling, and software orchestration. Data became a strategic asset because models improve when they consume more diverse, higher-quality examples. Enterprise software became the distribution layer because language models could be embedded into workflows.

The Transformer’s potential remains enormous.

It is a universal interface for language. It can compress expertise into an interactive assistant. It can turn unstructured data into structured outputs. It can write code, draft memos, inspect contracts, generate synthetic media, orchestrate tools, and make software more conversational. When connected to retrieval systems, APIs, memory, and user-specific context, it becomes a new work layer above existing applications.

But the same architecture that created the boom also created the bottleneck.

The Shortcomings Are Built Into the Machine

The first limitation is compute.

Self-attention compares tokens with other tokens. In the standard form, the attention matrix grows quadratically with sequence length. Double the context and the attention computation grows much faster than double. Engineers have invented many optimizations, but the basic pressure remains: longer context, larger models, and more users require vast memory bandwidth, power, and serving infrastructure.

The second limitation is data hunger.

A human child learns language from a tiny fraction of the text used to train modern language models. A frontier model often needs enormous pretraining corpora, expensive reinforcement learning or preference tuning, and continuous post-training to become useful. The system appears intelligent after it has absorbed an extraordinary amount of human-generated signal.

The third limitation is static learning.

After pretraining, a model’s core weights are mostly fixed. It can use context. It can retrieve documents. It can store external memories. But updating the model’s internal knowledge safely, continuously, and efficiently remains difficult. Naive continual learning can cause catastrophic forgetting, where new training degrades old capabilities. The result is a strange kind of intelligence: highly capable inside a context window, yet still brittle as a lifelong learner.

The fourth limitation is grounding.

Transformers learn statistical structure. They can infer patterns, simulate reasoning, and generate fluent explanations. They also hallucinate because fluency and truth are different objectives. Retrieval, tool use, verification loops, and agent frameworks help, but the base model still lacks the kind of grounded sensorimotor learning that biological systems use from infancy.

The fifth limitation is energy.

The human brain runs on roughly the power draw of a dim light bulb. Training and serving today’s AI systems require chips, clusters, and data centers at an entirely different scale. The gap is more than an engineering annoyance. It shapes margins, deployment models, geopolitical infrastructure, and the ability to put advanced intelligence on edge devices.

These limits do not mean Transformers are a dead end. They mean the current architecture may represent a powerful local optimum: the best architecture we have found for scaling matrix-based pattern learning on modern hardware, while leaving open the possibility that nature already discovered a more efficient algorithm.

That is where cortical columns enter the story.

Cortical Columns: The Brain’s Repeating Microcircuit

The neocortex is the folded outer sheet of the brain associated with perception, planning, language, and abstract thought. A striking feature of the neocortex is its repeated structure. Across different regions, neurons are organized into layers and column-like circuits. Vernon Mountcastle’s work helped make the cortical column one of the central concepts in neuroscience.

A cortical column can be understood as a small vertical processing unit running through the layers of the cortex. It contains groups of neurons connected across layers, plus lateral links to neighboring columns. The exact definition and function remain debated, but the broad idea is powerful: the brain may use many variations of a repeated computational motif.

Jeff Hawkins, Subutai Ahmad, and Yuwei Cui proposed that cortical columns can learn models of the world by combining sensory input with location signals. In their theory, a single column detects a feature together with its location relative to an object. Through movement and repeated sensing, it builds a model of the object. Multiple columns then collaborate through lateral connections, each contributing partial knowledge until the system reaches a stable interpretation.

This is a very different computational philosophy from today’s language models.

A Transformer learns by absorbing a gigantic corpus and compressing statistical relationships into weights. A cortical-column-inspired system suggests a more embodied style of learning: observe part of the world, know where that part sits relative to an object, move or receive new input, update the model, and let neighboring units reach consensus.

The key words are location, movement, partial evidence, consensus, and continuous updating.

That sounds much closer to how humans learn. We do not need to see every chair ever made to understand chairs. We touch, look, move, compare, and build stable object models from sparse experience. We generalize from a handful of examples because the brain appears to carry strong architectural priors about objects, space, causality, and temporal continuity.

If artificial systems could borrow even a small part of that efficiency, the economics of AI would change.

Why Flourish Might Be the Next Breakthrough

Flourish is interesting because it is making the architectural bet explicit.

According to WIRED, Flourish describes itself as a neuro-AI company trying to solve two of AI’s hardest problems: power efficiency and continuous learning. The company is building a system it calls Cortex AI, designed to match more of the computational capacity, learning efficiency, and power budget of the human brain. Thomas Reardon’s stated ambition is a synthetic AI brain running at 50 watts or less.

The company reportedly raised $500 million at a $2.5 billion valuation, with funding from Jeff Bezos and others. Its team includes neuroscientists and AI researchers working side by side. The focus, according to the WIRED reporting, includes cortical columns, connectomics, hippocampus-inspired memory, and models that can learn continuously with far less training data.

The reason this matters is that the Transformer era has become a resource race. More parameters, more tokens, more GPUs, more power, more data centers. That race has produced astonishing progress, but it also creates an opening for any architecture that can produce useful intelligence with lower energy, lower data requirements, and better continual adaptation.

Flourish is trying to attack the constraints at the root.

If Cortex AI can learn continuously, it would address the static-weight problem. Instead of retraining a model in massive batches, the system could update from ongoing experience. If it can use hippocampus-like memory, it could separate fast episodic learning from slower structural learning, closer to how biological memory appears to work. If it can borrow principles from cortical columns, it could improve grounding, object modeling, and abstraction from sparse data. If it can run on tens of watts, it could move powerful AI from data centers into local devices, robots, wearables, vehicles, and industrial systems.

That combination would directly challenge the economic assumptions of the current stack.

A 50-watt AI system would change deployment. Continuous learning would change personalization. Brain-inspired memory would change agents. Efficient object and world modeling would change robotics. A new architecture that reduces dependence on frontier-scale training clusters would shift value from raw compute accumulation toward algorithmic design, neuroscience-derived architectures, and specialized silicon.

This is the bull case for Flourish: it is chasing the part of intelligence Transformers approximate poorly.

How Cortex AI Claims to Solve the Transformer Problems

Cortex AI should be understood as an ambition rather than a proven public product. Flourish has not disclosed enough technical detail to evaluate the architecture rigorously. The right framing is conditional: if the company can translate neuroscience into working silicon and software, the approach could solve several pain points in today’s AI.

First, it targets energy efficiency.

Transformer models burn power because they perform enormous matrix operations across huge parameter sets and context windows. A cortex-inspired architecture would aim to use sparse, modular, event-driven, or locality-aware computation. Biological brains do not activate every neuron at full intensity for every thought. They route activity through specialized circuits. A successful Cortex AI system would likely need similar selectivity: activate the relevant computational columns, memory systems, and pathways rather than the whole machine for every query.

Second, it targets continual learning.

Transformers can adapt through context and external memory, but their internal learning mostly happens during expensive training runs. Cortex AI appears to be aimed at systems that keep learning after deployment. That matters for agents. A useful agent should become better at a user’s workflow over time, remember the consequences of actions, update procedures, and refine its model of the environment without requiring a full retraining pipeline.

Third, it targets sample efficiency.

The human brain learns from sparse, noisy, embodied data. Cortical-column-inspired learning could give AI better priors about objects, space, and causality. Instead of learning every relationship from internet-scale text, a model could infer more from fewer examples by using a structured architecture closer to how perception and memory work in living systems.

Fourth, it targets grounding.

A language model can describe a coffee mug. A grounded system should understand that the mug has a handle, occupies space, can be grasped, can contain liquid, can fall, can break, and looks different from different angles while remaining the same object. Cortical columns, with their emphasis on features at locations and consensus across partial views, point toward this kind of stable object modeling.

Fifth, it targets edge intelligence.

If advanced models can run on laptop-level power, the market expands. AI can leave the data center and become embedded in devices that learn locally. This matters for privacy, latency, cost, robotics, defense, healthcare devices, and consumer hardware. It also changes who captures value. The winners may be companies that own efficient architectures, specialized chips, embedded operating systems, and high-quality local learning loops.

The Skeptical Case Still Matters

Flourish is a bold bet, and bold bets often fail.

Neuroscience has inspired AI many times. Neuromorphic computing has had cycles of excitement. The brain is poorly understood compared with the precision required to build reliable commercial systems. Cortical columns themselves remain scientifically debated. A useful analogy can mislead if engineers copy biology at the wrong level of abstraction.

The Transformer also has a major advantage: it works. It scales. It has an ecosystem. It runs on existing hardware. It has huge developer mindshare, open-source momentum, cloud support, tooling, benchmarks, and business demand. Any challenger architecture must beat a moving target. Transformers are improving in efficiency, context length, multimodality, reasoning scaffolds, retrieval, tool use, and inference cost.

This means Cortex AI does not need to replace Transformers everywhere to matter. A narrower breakthrough would still be valuable. A memory system that improves agents, a low-power model for edge devices, a continual-learning module, or a more efficient world-modeling architecture could become a major component in hybrid systems.

The future may look less like one architecture replacing another and more like a stack: Transformers for language and broad knowledge, retrieval systems for factual grounding, tool-using agents for execution, and cortex-inspired modules for memory, adaptation, perception, and embodied learning.

The Investment Narrative: From Scaling Compute to Scaling Learning

The first AI trade was scale.

More GPUs. More data centers. More tokens. More parameters. More electricity. This trade has obvious winners: NVIDIA, advanced packaging providers, memory suppliers, networking vendors, hyperscale cloud platforms, and companies that can monetize AI copilots across large installed bases.

The next AI trade may be learning efficiency.

If the industry remains on the current path, intelligence keeps getting better but also more capital-intensive. That favors the richest labs and largest cloud platforms. If a new architecture reduces the amount of compute and data required to learn, the economics shift. The scarce asset becomes less about owning the biggest cluster and more about owning the best learning architecture.

This is why Flourish deserves attention. Its bet sits directly at the fault line of the current AI economy. Transformers proved that intelligence can be scaled through computation. Cortex AI is betting that intelligence can be made more efficient by rediscovering some of the brain’s algorithms.

The story of AI evolution therefore has three acts.

The first act was rules. Humans tried to write intelligence directly.

The second act was weights. Machines learned statistical structure through data and gradient descent.

The third act may be architecture. The industry may discover that the next leap requires better computational primitives: memory systems that update continuously, world models that learn from sparse evidence, and modular circuits that achieve more with less energy.

Flourish may fail. Cortex AI may turn out to be too vague, too biological, too early, or too difficult to commercialize. But the question it is asking is exactly the right one: if the brain can learn continuously, generalize from limited data, ground concepts in the world, and operate on about 20 watts, why should artificial intelligence require city-scale infrastructure to approximate a fragment of that ability?

That question will not go away.

The Transformer gave AI its industrial revolution. Cortex-inspired systems are searching for its biological revolution. The next breakthrough may come from the point where those two histories finally meet: the brute-force lesson of scale, and the quiet efficiency of the cortex.

Risk Note

This is a technology and market-structure analysis, not investment advice. Flourish and Cortex AI remain early and technically unproven based on public information. Transformer-based systems continue to improve quickly, and the incumbent compute ecosystem may remain dominant even if brain-inspired modules become useful. Any investment conclusion should be tested against product evidence, customer adoption, technical disclosures, and competitive response.

There was always a little truth inside the stereotype. Millennials did enter adulthood under unusual pressure. Many graduated into or soon after the 2008 financial crisis. Student debt, rent inflation, weak early-career wage growth, and then the post-pandemic spike in home prices all hit them at formative moments.

But the old frame is now too small.

Millennials are no longer a youth trend. Broadly defined as those born between 1981 and 1996, the oldest Millennials are now in their 40s and the youngest are approaching 30. They are entering the phase where income, household formation, housing decisions, parenting costs, insurance needs, retirement planning, workplace authority, and eventual inheritance all start to compound.

That turns them from a cultural punchline into an investment map.

The old media question was whether Millennials were “killing” some legacy industry. Investors should ask a cleaner question now: as this large cohort moves into peak earning, spending, and decision-making years, which companies are becoming the infrastructure of their lives?

The delayed wealth cycle is finally turning on

The Millennial story has always been a story of delay.

Delayed marriage. Delayed homeownership. Delayed children. Delayed savings. Delayed management roles. Delayed wealth accumulation.

That delay created a powerful market impression: Millennials do not have money.

A better read: Millennial wealth arrived unevenly, late, and under pressure. It did arrive.

Federal Reserve distributional wealth data and related demographic work suggest Millennials now control roughly a tenth of U.S. household wealth. That is still far below Baby Boomers and below Gen X, but the direction matters more than the snapshot. Millennials are moving into the age range where assets, equity compensation, retirement balances, and home equity can begin to accelerate.

A 2025 St. Louis Fed analysis also highlighted a less intuitive point: when compared at similar ages, younger families, mainly Millennials and Gen Z, have in some ways accumulated more wealth than Gen X households had at the same stage. Comfort is still uneven across the cohort. The important point is that Millennial wealth looks far more unequal, and more investable, than the old stereotype suggests.

On one side are high-income Millennials in technology, finance, healthcare, entrepreneurship, and professional services. Many bought homes earlier, benefited from stock-market gains, received family help, or built equity in businesses. On the other side are Millennials still squeezed by rent, student loans, credit-card balances, childcare, insurance, and medical costs.

That split is exactly why investors should stop treating Millennials as one average consumer. The better framework is to divide them into economic pathways: the homebuyer, the long-term renter, the new parent, the caregiver, the digital investor, the debt restructurer, the wellness consumer, the frequent traveler, and the AI-using middle manager.

Each path points to a different corner of the public market.

Housing: the largest pain point is also the longest opportunity

If one word explains the Millennial economic experience, it is housing.

Apartment List’s 2025 Millennial homeownership report estimated the Millennial homeownership rate at about 47% in 2024. That is not trivial. Millennials are already a major part of the housing market. But compared with earlier generations at the same age, they reached ownership more slowly.

The reasons are familiar: the financial crisis, student debt, down-payment pressure, the pandemic-era jump in home prices, and higher mortgage rates.

Delayed homeownership compresses demand, pushes households into rentals for longer, and often turns the eventual purchase into a larger upgrade.

For the Millennial who does buy, the home carries more jobs than a roof ever used to. It has to hold a home office, a school district, a commute radius, a place to raise children, and the stability many households spent years trying to reach.

That points directly to large U.S. homebuilders such as D.R. Horton (DHI), Lennar (LEN), PulteGroup (PHM), Toll Brothers (TOL), and NVR (NVR). The broad thesis goes beyond “home prices go up.” The U.S. has a long-running housing shortage, while Millennials and Gen Z are still moving through the household-formation pipeline. Builders with exposure to entry-level and move-up buyers, especially DHI, LEN, and PHM, sit closer to the mainstream Millennial demand curve than pure luxury developers.

The housing chain extends past builders. Builders FirstSource (BLDR) is tied to residential construction inputs. Home Depot (HD) and Lowe’s (LOW) capture repair, maintenance, renovation, and DIY behavior. Trex (TREX) and Masco (MAS) provide more targeted exposure to outdoor living, decking, fixtures, and home-improvement components.

If Millennials rent longer, the investment story moves toward rental housing. AvalonBay (AVB), Equity Residential (EQR), Mid-America Apartment Communities (MAA), and Camden Property Trust (CPT) represent apartment REIT exposure. Invitation Homes (INVH) and American Homes 4 Rent (AMH) represent single-family rental exposure.

The transaction layer matters too. Rocket Companies (RKT) and UWM Holdings (UWMC) are tied to mortgage origination. Fidelity National Financial (FNF) and First American Financial (FAF) sit in title insurance and real-estate transaction services.

Housing, then, works better as a chain than as one trade: construction, rentals, mortgage origination, title insurance, renovation, furniture, and household services. The longer Millennial housing demand is delayed, the longer that chain stretches.

Finance: they trust new rails over old gatekeepers

A common assumption says Millennials became conservative after watching the 2008 crisis.

Many came away with a stranger mix: skeptical of institutions, but still curious about risk.

Distrust of traditional financial institutions did not keep them out of markets. They are natural users of mobile brokerage, ETFs, fractional shares, crypto platforms, thematic investing, financial influencers, newsletters, and social investment narratives.

This generation learned to invest on a phone. Instead of a broker’s office or a phone order, their path runs through apps, YouTube, Reddit, podcasts, Substack, Discord, TikTok, and creator-led financial education.

That changed the distribution system for finance.

Robinhood (HOOD) is the obvious symbol. It goes beyond zero-commission trading. It made finance feel mobile, simple, and behaviorally designed. Coinbase (COIN) is the regulated crypto gateway. Interactive Brokers (IBKR) skews toward active and more sophisticated traders who want global market access. Charles Schwab (SCHW) represents the traditional brokerage world adapting to a new user base.

For the ETF and asset-management layer, BlackRock (BLK) remains one of the central names through iShares and broader institutional scale. For market infrastructure, Intercontinental Exchange (ICE), CME Group (CME), Nasdaq (NDAQ), and Bank of New York Mellon (BK) are closer to the toll roads behind rising financial activity.

On the fintech and payments side, SoFi (SOFI) is a younger-user financial platform spanning lending, banking, and investing. PayPal (PYPL) and Block (XYZ) represent digital payments, merchant services, and personal finance entry points.

The pattern is simple: Millennials are anxious, but they are willing to try new tools. They may not believe in Wall Street as an institution, but they do believe in access, low friction, and self-directed participation.

That puts mobile brokerage, crypto access, ETFs, exchange infrastructure, digital payments, and personal-finance platforms into one connected thesis.

Retirement anxiety is becoming a product category

Another lazy stereotype says Millennials do not save.

Recent data is more interesting. Goldman Sachs Asset Management’s 2024 retirement survey found that many Millennials have personalized retirement plans and a meaningful share believe their retirement savings are on track or ahead. Northwestern Mutual’s 2024 research found that Millennials believe they need roughly $1.65 million to retire comfortably, more than the average estimate among U.S. adults.

The implication points in the opposite direction from the carefree stereotype. They understand that retirement feels expensive, healthcare feels uncertain, traditional pensions are rare, and Social Security may not be enough.

That makes retirement anxiety a product category.

Traditional asset managers will not own the whole opportunity. BlackRock (BLK), Charles Schwab (SCHW), and Bank of New York Mellon (BK) can continue to benefit from long-term allocation flows. But SoFi (SOFI), Robinhood (HOOD), and Intuit (INTU) may also become important because they sit closer to the user’s personal financial operating system.

Boomers often wanted an advisor. Millennials often want a system that connects cash flow, debt, taxes, retirement, investing, and family goals.

That is the long-term opening for fintech and wealth-tech.

Consumption: the real product is time

Millennials are often described as experience consumers. That is true, but incomplete.

They pay for identity, convenience, time, health, and flexibility.

They are the first generation to build adult life around the smartphone. Subscriptions, delivery, e-commerce, digital payments, online reviews, creator recommendations, algorithmic discovery, and app-based services are their default interface for daily life.

So investors should look past the shopping cart and focus on the friction points: which companies make daily life easier?

Amazon (AMZN), Walmart (WMT), Costco (COST), and Target (TGT) sit in household replenishment, e-commerce, and high-frequency retail. DoorDash (DASH), Uber (UBER), and Maplebear/Instacart (CART) represent delivery, mobility, and last-mile convenience. Shopify (SHOP) and MercadoLibre (MELI) represent merchant digitization and e-commerce infrastructure.

The keyword here is time scarcity, not laziness.

As Millennials move through their 30s and 40s, life gets more crowded. Work, children, housing, aging parents, health, finances, and social obligations all collide. Any company that can turn a messy process into a simpler one has a chance to become a lasting consumer gateway.

Health and middle age: the first digital midlife generation

For years, people spoke about Millennials as if they were permanently young.

That era is over.

Millennials are now facing sleep problems, weight management, metabolic risk, skin care, hair loss, fertility, mental health, hormone questions, chronic disease risk, and longevity anxiety.

That creates a large market: digital midlife health.

McKinsey’s 2025 Future of Wellness work estimated the global wellness market at roughly $2 trillion and noted that younger consumers, especially Millennials and Gen Z, are reshaping categories such as functional nutrition, beauty, longevity, wellness experiences, weight management, and personalized health.

The most obvious public company in this lane is Hims & Hers Health (HIMS), which packages hair loss, skin care, sexual health, weight management, and telehealth into a consumer experience built for younger users. LifeMD (LFMD) is another telehealth and prescription-services name. For GLP-1 and metabolic health, Eli Lilly (LLY) and Novo Nordisk (NVO) remain the global anchors.

Fitness and lifestyle health add another layer. Life Time Group (LTH) represents premium health clubs. Planet Fitness (PLNT) represents lower-cost mass fitness. Lululemon (LULU) remains tied to athletic lifestyle. Estée Lauder (EL) is still a major global beauty player. Abbott Laboratories (ABT) and DexCom (DXCM) connect to medical devices, glucose monitoring, and chronic-condition management.

Millennials did not suddenly become wellness-obsessed. They became the first smartphone-shaped, remote-work, delivery-heavy, high-stress middle-aged generation buying health solutions digitally.

Travel: experience spending did not disappear; it segmented

Millennials do value travel and experiences. Deloitte’s 2025 holiday travel survey suggested Millennials were expected to be among the highest-spending holiday travelers, with average budgets around $2,602.

That is not surprising.

Millennials grew up alongside Instagram, Airbnb, low-cost airlines, points cards, remote work, digital nomadism, boutique hotels, and short-term rental platforms. Travel is leisure, but it is also identity, family memory, and social currency.

The direct exposures are online travel platforms: Booking Holdings (BKNG), Airbnb (ABNB), and Expedia (EXPE). Hotel groups such as Marriott (MAR), Hilton (HLT), and Hyatt (H) benefit from loyalty programs, premium experiences, and the professionalization of travel. Airlines such as Delta Air Lines (DAL) and United Airlines (UAL) remain important windows into U.S. travel demand.

The travel thesis also reaches beyond travel companies. American Express (AXP) captures premium card spending and travel benefits. Visa (V) and Mastercard (MA) sit underneath the global payments layer.

The opportunity comes from the way they combine travel, points, card perks, hotel loyalty, remote work, and family vacations into one spending system.

Debt: financial pressure opens another investment line

If housing, investing, travel, and wellness are the upward story, debt is the pressure valve.

Experian data showed the average U.S. consumer credit-card balance was around $6,730 in the third quarter of 2024, while Millennials averaged about $6,932, up from the prior year. That is below Gen X, but it is still enough to reveal stress.

High rent, high rates, childcare, insurance, healthcare, student loans, and credit-card interest pull Millennial cash flow in too many directions.

There are two investment categories here.

The first is credit and consumer finance. Capital One (COF), Synchrony Financial (SYF), and American Express (AXP) are tied to credit cards and consumer lending.

The second is debt restructuring, personal loans, and collections. LendingClub (LC), SoFi (SOFI), and Enova International (ENVA) are tied to personal lending, refinancing, and online credit. Encore Capital Group (ECPG) is a representative name in debt purchasing and collections.

This part of the map deserves the most caution. Credit growth can be profitable, but it can also turn into credit losses when the economy slows. I would rather watch platforms that help users reorganize debt, lower interest costs, and improve cash flow than simply assume more borrowing is good.

Millennials do have spending power. But their cash flow is often pulled in many directions at once.

Parents, children, and the new household operating system

The phrase “sandwich generation” used to describe Gen X: caring for children and aging parents at the same time.

Now Millennials are moving into that role too.

They had children later, bought homes later, moved into management later, and now their parents are aging. That means many Millennials will manage children, homes, careers, parents, retirement planning, insurance, and healthcare during the same life window.

This belongs in a larger household-operations market.

On healthcare and insurance, CVS Health (CVS), UnitedHealth Group (UNH), and Humana (HUM) connect to pharmacy, health insurance, medical services, and senior care. Addus HomeCare (ADUS) is a more direct home-care exposure. Bright Horizons Family Solutions (BFAM) represents employer-sponsored childcare and early education. Duolingo (DUOL) represents digital learning and education products.

The Millennial household is software-coordinated. It needs reminders, payments, insurance portals, childcare scheduling, care coordination, learning tools, document storage, shared calendars, and family budgeting.

These companies may not all look glamorous. But they sit on a long trend: household life is getting more complex, and Millennials will pay to reduce the chaos.

AI work: Millennials may be the first AI middle managers

One of the most overlooked Millennial investment themes is AI.

Boomers lived through the PC era. Gen X built the internet workplace. Gen Z is native to short video and mobile social life. Millennials sit in the middle: young enough to adopt new tools quickly, old enough to control budgets, teams, and processes.

That makes them a crucial group for AI adoption inside companies.

They may never build the models. They will still decide where AI enters workflows: sales, marketing, customer support, recruiting, finance, legal, content, analytics, project management, and client communication.

The biggest platform names are Microsoft (MSFT), Alphabet (GOOGL), and Meta Platforms (META). They control office software, cloud/search/AI infrastructure, advertising, and social distribution.

Enterprise software adds another layer. Salesforce (CRM), ServiceNow (NOW), Adobe (ADBE), HubSpot (HUBS), and Intuit (INTU) are embedding AI into concrete workflows. Snowflake (SNOW) and Palantir (PLTR) sit in data and decision infrastructure. CrowdStrike (CRWD) and Palo Alto Networks (PANW) represent the cybersecurity budgets that become more important as AI adoption expands.

Millennials will not be impressed by every AI demo. They have lived through too many software hype cycles. But they will pay for tools that save time, reduce repetitive work, and improve output.

For this cohort, AI shows up less as science fiction and more as a productivity layer.

Stop asking what they killed. Ask what they are buying.

Millennials were once reduced to the “avocado toast generation.”

Markets get into trouble when they confuse a cohort’s youth stereotype with its lifetime economic role.

Today’s Millennials are moving into the center of the U.S. economy. They are buying homes or renting for longer. They are investing or restructuring debt. They are traveling or budgeting for family life. They are buying health products or caring for parents. They are using AI tools or deciding which AI tools their companies buy.

They are no longer just participants in consumer trends. They are becoming the main variable in many industries over the next decade.

If I had to summarize the Millennial investment opportunity in one sentence, it would be this:

They still consume, but they punish friction. They still invest, but they distrust old financial entry points. They still want housing, but the market stretched that demand across a longer cycle. They still spend on experiences, but the deeper purchase is control over scarce time.

So investors should stop asking which traditional industry Millennials have supposedly killed.

A sharper question now: as this generation earns more, raises families, invests, buys homes, manages teams, and cares for parents, which companies are becoming the infrastructure of its life?

No single company or sector will capture the whole shift.

It will be distributed across housing, finance, convenience, health, travel, credit, family services, and AI software.

That is why Millennials deserve a fresh look from investors.

Ticker map

Housing and household formation: D.R. Horton (DHI), Lennar (LEN), PulteGroup (PHM), Toll Brothers (TOL), NVR (NVR), Builders FirstSource (BLDR), Home Depot (HD), Lowe’s (LOW), Trex (TREX), Masco (MAS), Rocket Companies (RKT), UWM Holdings (UWMC), Fidelity National Financial (FNF), First American Financial (FAF), AvalonBay (AVB), Equity Residential (EQR), Mid-America Apartment Communities (MAA), Camden Property Trust (CPT), Invitation Homes (INVH), American Homes 4 Rent (AMH).

Digital finance and investing: Robinhood (HOOD), Coinbase (COIN), Interactive Brokers (IBKR), Charles Schwab (SCHW), BlackRock (BLK), Intercontinental Exchange (ICE), CME Group (CME), Nasdaq (NDAQ), Bank of New York Mellon (BK), SoFi (SOFI), PayPal (PYPL), Block (XYZ).

Convenience consumption and e-commerce: Amazon (AMZN), Walmart (WMT), Costco (COST), Target (TGT), DoorDash (DASH), Uber (UBER), Maplebear/Instacart (CART), Shopify (SHOP), MercadoLibre (MELI).

Health, wellness, and digital midlife: Hims & Hers (HIMS), LifeMD (LFMD), Eli Lilly (LLY), Novo Nordisk (NVO), Life Time Group (LTH), Planet Fitness (PLNT), Lululemon (LULU), Estée Lauder (EL), Abbott Laboratories (ABT), DexCom (DXCM).

Travel and experiences: Booking Holdings (BKNG), Airbnb (ABNB), Expedia (EXPE), Marriott (MAR), Hilton (HLT), Hyatt (H), Delta Air Lines (DAL), United Airlines (UAL), American Express (AXP), Visa (V), Mastercard (MA).

Debt, credit, and cash-flow management: Capital One (COF), Synchrony Financial (SYF), American Express (AXP), LendingClub (LC), SoFi (SOFI), Enova International (ENVA), Encore Capital Group (ECPG).

Household operations, children, and care: CVS Health (CVS), UnitedHealth Group (UNH), Humana (HUM), Addus HomeCare (ADUS), Bright Horizons (BFAM), Duolingo (DUOL).

AI work and enterprise software: Microsoft (MSFT), Alphabet (GOOGL), Meta Platforms (META), Salesforce (CRM), ServiceNow (NOW), Adobe (ADBE), HubSpot (HUBS), Intuit (INTU), Snowflake (SNOW), Palantir (PLTR), CrowdStrike (CRWD), Palo Alto Networks (PANW).

Source notes

• Federal Reserve Distributional Financial Accounts / SmartAsset / Statista: U.S. generational wealth distribution.

• St. Louis Fed: 2025 analysis of household wealth by age cohort.

• Apartment List: 2025 Millennial Homeownership Report.

• Bank of America Private Bank: 2024 Study of Wealthy Americans.

• Goldman Sachs Asset Management: 2024 Retirement Survey & Insights Report.

• Northwestern Mutual: 2024 Planning & Progress Study.

• Experian: 2024 U.S. credit-card debt data.

• McKinsey: 2025 Future of Wellness research.

• Deloitte: 2025 holiday travel survey.

Disclaimer: This article is for research and educational purposes only and should not be read as investment advice, a recommendation to buy or sell securities, or personalized financial advice. The tickers mentioned are illustrative examples of industry exposure. Investors should do their own research on company fundamentals, valuation, risk tolerance, and time horizon.

That does not make every prediction of his correct. It does make his opinions harder to ignore. Hassabis has spent his career moving between theory and deployment: from memory research to reinforcement learning, from games to protein structures, from frontier models to drug discovery. When he talks about AGI, AI safety, or the future of science, he is usually speaking from systems his teams have actually built.

To find his most notable ideas, I watched 43 hours of interviews he had or lectures he gave, 172 academic papers he authored or co-authored, and 108 non-academic resources including interviews, official posts, articles, and social posts. I looked for opinions that repeat across years and across formats, then filtered out comments that now look dated, especially older AGI timelines and short-lived product remarks.

The result is a list of 37 insights that worth reading.

1. The mission is still: solve intelligence, then use it to solve everything else

Hassabis’s founding line for DeepMind has not really changed. In older talks, he describes the aim as building a general learning system. In newer interviews, he says the practical reason for doing that is to accelerate science, medicine, energy, and discovery.

That sentence can sound grandiose until you look at the research trail - from human memory and imagination, to Atari and Go, to AlphaZero, to AlphaFold, to AI systems for mathematics, plasma control, drug discovery, genomics, and scientific co-pilots. The mission was not a slogan pasted on after the fact. It was a map.

2. AGI is general learning, not a bag of narrow tricks

His definition of AGI keeps returning to adaptability. A true general system should learn new domains, transfer knowledge, plan, reason, and operate outside the exact setting it was trained for.

This is why Hassabis has always cared about games, simulation, memory, and planning. A narrow classifier can be useful. It can even be superhuman on one task. But for him, intelligence means a system can face a new environment and work out what matters.

3. The AGI timeline has moved closer, but he still talks like a scientist, not a prophet

In older material, Hassabis often treated AGI as far away. In recent 2025 and 2026 interviews, he talks about AGI as plausibly arriving around 2030, sometimes saying five to ten years, sometimes “around 2030, plus or minus a year.”

The important part is the shape of the claim. He does not frame AGI as a single cinematic switch-flip. He says it may arrive gradually. The threshold will probably be messy. We may only agree afterward that the line has been crossed.

4. His default stance is cautious optimism

Hassabis is not a doom spokesman and not a salesman pretending risk does not exist. The phrase that fits him best is the one he uses himself: cautious optimist.

He thinks AI could unlock a better world, but only if people handle the transition well. That caveat is not decorative. It shows up whenever he talks about safety, politics, work, energy, and distribution. The upside is enormous. So is the responsibility.

5. The best use of AI is science

He keeps pulling the conversation away from chatbots and toward science. AI can write, search, summarize, code, and entertain. But those are not the applications that seem to animate him.

The prize, in his telling, is an engine for discovery: new medicines, new materials, fusion, climate tools, mathematical insight, and eventually new theories about how the world works. AlphaFold is not an isolated success story. It is the prototype.

6. AlphaFold is his proof that AI can do more than automate human work

AlphaFold matters in his worldview because it did something practical and scientific at once. It solved a long-standing bottleneck in biology, released the results broadly, and gave millions of researchers a new piece of infrastructure.

That is different from building a tool that makes office work faster. AlphaFold changed what scientists could attempt. Hassabis repeatedly uses it as evidence that advanced AI can produce public goods rather than only products.

7. Open science is part of the model

The AlphaFold database is central to how he talks about impact. DeepMind did not merely publish a paper and keep the useful part private. It released predicted structures at large scale and let the scientific community use them.

This is one of the more important constraints on his AI-for-science vision. If AI systems become instruments of discovery, the output cannot sit only inside one lab or one company. The scientific value compounds when other researchers can build on it.

8. Biology is especially suited to AI because it is an information problem hiding inside a physical system

Hassabis often describes biology as an information-processing system. That framing explains why he saw protein folding as a good target. DNA sequences, amino acid chains, molecular interactions, and cellular behavior all contain structure, but the structure is too complex for simple rules.

AI is useful there because it can learn patterns that are real but hard to write down. In that sense, AlphaFold is a biology project and an argument about nature.

9. The next biological target is not one protein. It is the cell

In recent talks, Hassabis keeps pointing toward a virtual cell. Protein structure was one layer. Protein interactions, genetic regulation, cell state, disease mechanisms, and drug response are deeper layers.

The dream is a simulation good enough to let scientists run experiments in silico before going to the lab. That will not replace biology. It would change the search process. Fewer blind alleys. Better hypotheses. Faster iteration.

10. AI should remove scientific drudgery first

Before AI becomes a Nobel-level collaborator, Hassabis expects it to help with the work scientists already know they need to do: reading literature, spotting patterns, analyzing data, generating candidate hypotheses, writing code, and designing experiments.

This sounds modest compared with AGI, but it is probably where much of the near-term value sits. Science contains a lot of waiting, searching, cleaning, and checking. Removing that friction can change the pace of a field.

11. The hard part of science is often choosing the question

A recurring Hassabis point is that solving a well-posed problem is not the same as doing great science. Great scientists choose questions. They develop taste. They sense which weird result matters and which one is noise.

That is why his “Einstein test” is useful. A system with a 1901 knowledge cutoff should not merely solve textbook physics. It should be able to find the conceptual jump that leads to 1905. For Hassabis, that kind of theory-making is closer to full AGI than another benchmark score.

12. AI must eventually generate new theories, beyond better answers

This is the sharper version of his AI-for-science thesis. A good scientific assistant can summarize papers. A stronger one can propose experiments. A deeper one can discover a law, a mechanism, or a theory that humans did not already have.

He is careful here. Today’s systems are not there. But he does not see a reason in principle that future systems cannot get there.

13. Games were never the destination

Chess, Go, Atari, StarCraft, Stratego, and simulated 3D worlds appear throughout the research record. The mistake is to see them as stunts.

For Hassabis, games are controlled worlds with rules, goals, feedback, search spaces, and measurable progress. They let researchers test learning, planning, exploration, memory, and multi-agent behavior. Games are wind tunnels for intelligence.

14. Self-play is powerful because it can escape imitation

AlphaGo learned from human games. AlphaGo Zero and AlphaZero pushed further: start from the rules, play yourself, and discover strategies humans missed.

Hassabis returns to this because it is one of the cleanest examples of AI producing novelty. Move 37 in the Lee Sedol match became the symbol, but the deeper point is that self-play can search beyond the human record.

15. Search still matters

The current AI conversation often treats scaling as the whole story. Hassabis’s research history says otherwise. AlphaGo combined neural networks with tree search. AlphaZero used search. Newer systems such as AlphaEvolve combine language-model proposals with evolutionary or search procedures.

His implied view is simple: generation gives you candidates, but search, evaluation, and iteration turn candidates into discoveries.

16. Scaling is necessary, but not sufficient

Hassabis does not dismiss scaling. DeepMind builds frontier models, and he clearly sees compute, data, and model size as important. But he keeps saying that new algorithms and architectures are still needed.

That is one of the more durable differences between his worldview and a pure scale-maximalist view. Scaling may get you far. Planning, memory, world models, tool use, reinforcement learning, and search may decide how far.

17. World models are one of the missing pieces

A system that can predict how the world changes has a different kind of intelligence from a system that only predicts text. Hassabis connects world models to video generation, robotics, planning, and AGI.

He has said recent video models surprised him because passive observation appears to teach more physical structure than he expected. Still, the direction is clear: AGI needs a model of how the world works, not merely a model of how people talk about the world.

18. Imagination is a computational tool

This is one of the strongest bridges between his neuroscience work and AI work. His early research on hippocampal amnesia, memory, scene construction, and imagination feeds directly into later AI themes.

Imagination, in this view, is not daydreaming. It is internal simulation. Remember the past, construct possible futures, test actions before taking them. An intelligent agent needs that loop.

19. Memory is not storage. It is part of reasoning

The academic papers return again and again to memory: episodic memory, complementary learning systems, fast and slow reinforcement learning, external memory, catastrophic forgetting.

For Hassabis, memory is not a database bolted onto intelligence. It is part of how agents learn quickly, generalize, avoid repeating mistakes, and build models of the world. This is why long-context models alone do not settle the problem. Remembering is not the same as understanding what to do with memory.

20. Neuroscience gives hints, not a wiring diagram

Hassabis does not argue that AI should copy the brain neuron by neuron. His position is more pragmatic. Neuroscience can suggest useful principles: replay, attention, memory systems, reinforcement learning, imagination, dopamine-like value signals, scene construction.

The brain is proof that general intelligence is possible. It is also a library of design hints. But engineering still has to do its own work.

21. Intelligence needs compositional concepts

Several strands of the research record point toward compositionality: grounded language in simulated worlds, hierarchical visual concepts, concept discovery, and human-AI knowledge transfer.

This matters because a system that cannot compose ideas will struggle to generalize. It may memorize patterns, but it will not easily build new structures from old parts. Scientific discovery depends on that ability.

22. Evaluation shapes progress

Hassabis likes problems with clean feedback. Atari gave scores. Go gave wins and losses. CASP gave a rigorous protein-folding benchmark. Scientific problems become attractive to AI when there is a way to tell whether the answer is right.

This is more than a research-management habit. It is a theory of progress. If you can define the target, measure performance, and iterate, AI can improve very fast.

23. The best AI problems have structure, feedback, and room for surprise

AlphaGo and AlphaFold look different, but they share a pattern. The search space is enormous. Human intuition matters but is incomplete. There is hidden structure. Better predictions unlock real value.

That pattern helps explain why Hassabis keeps naming materials, fusion, mathematics, drug discovery, and biology. They are not random examples. They are domains where nature gives feedback and where better search could matter enormously.

24. AI can make human knowledge more legible

A strange thing happened with AlphaGo and AlphaZero. They did not merely beat humans. They gave humans new ideas. Chess and Go players studied their moves and changed their own play.

That pattern shows up again in AI for mathematics and science. The most interesting systems may not replace experts. They may expose useful structure that experts can then understand, debate, and extend.

25. The future scientist may be a human-AI pair

Hassabis often describes near-term AI as a tool for scientists, then leaves open the possibility that it becomes more like a collaborator. That distinction matters.

A tool waits for instructions. A collaborator notices things, proposes directions, challenges assumptions, and helps choose questions. His current view seems to be that we are moving from the first category toward the second, but have not arrived yet.

26. Agents will be useful because they can act, but action raises the stakes

He talks about assistants and agents as the natural next step. A system that can use tools, remember preferences, plan tasks, and act across digital environments is far more useful than a passive chatbot.

It is also riskier. Once AI systems take actions, safety becomes less abstract. Cybersecurity, monitoring, permissions, evaluation, and guardrails become part of the product itself.

27. Good assistants should push back

One of his more revealing recent comments is about the personality of Gemini. He does not want an assistant trained to maximize engagement or flatter the user. He wants something warmer than a command line but more scientific than a social-media algorithm.

That means the assistant should sometimes say no, challenge a premise, or point out that a request does not make sense. In Hassabis’s worldview, alignment is not sycophancy. A good intelligence helps you see more clearly.

28. AI risk has two main buckets: misuse and loss of control

His public safety comments usually sort into two categories. First, bad actors can repurpose powerful models for harmful ends. Second, increasingly autonomous systems may behave in ways their builders cannot control or predict.

This framing is useful because it avoids a false choice. AI safety has to handle malicious users and runaway behavior at the same time.

29. Safety has to be technical, institutional, and international

Hassabis talks about safety teams, evaluations, cybersecurity, frontier-lab responsibility, safety institutes, and international coordination. He has compared the need for AI-risk assessment to climate-style scientific processes and floated institutions resembling CERN or the IAEA for certain functions.

The thread running through all of this is that AI governance cannot be purely national or purely corporate. The technology is too general, the race is too fast, and the effects cross borders.

30. The labs need to remember their responsibility to the world

He is blunt that frontier labs are in a competitive race. But in recent 2026 remarks, he also says their leaders need to remember the responsibility they have to the world, especially as the final steps toward AGI get closer.

That view is easy to say and hard to execute. The commercial incentives point one way. The safety obligations point another. Hassabis’s own preferred history, by his account, would have kept more of the technology in the lab longer and produced more AlphaFold-like scientific applications before the consumer race accelerated.

31. AI’s energy use is a real cost, but he thinks the scientific payback can outweigh it

Hassabis does not deny that AI will use enormous energy. His argument is that AI may also help solve the energy and climate problems that make that cost frightening: better materials, batteries, fusion, grid optimization, climate modeling, and other scientific advances.

That is an optimistic bet, not a settled fact. But it is a consistent one. He thinks the right comparison is not energy consumed by AI versus zero. It is energy consumed versus the discoveries AI may enable.

32. The future could be radically abundant, if politics does its job

Hassabis uses phrases like radical abundance, golden age of discovery, and new renaissance. He imagines medical breakthroughs, clean energy, new materials, and maybe eventually space exploration.

But he usually adds the harder part: distribution. Technology can increase the pie. It does not automatically decide who eats. He treats fair distribution as a political and social question, not a machine-learning problem.

33. Work will change, but replacement is an unimaginative goal

In recent interviews, Hassabis has pushed back on the crude version of the AI-layoff story. If AI makes engineers or researchers several times more productive, a good organization can do more ambitious work rather than simply cut the team.

That does not mean job disruption is fake. He says nobody really knows how many jobs will be created or destroyed. But his preferred frame is augmentation first: make people better at using the tools, then rethink the systems around them.

34. Post-AGI society needs philosophers and economists as well as engineers

Hassabis repeatedly says the social questions are bigger than the technical community. If AI creates abundance, what happens to meaning, work, ownership, purpose, education, and status? If people have more time, what do they do with it?

His answer is not a detailed political program. It is a call for other disciplines to take the problem seriously now. The engineers may build the system. They should not be the only people designing the society around it.

35. Human qualities will matter more, not less

He does not describe a future where human life becomes obsolete. He talks about empathy, sport, art, meditation, games, family, philosophy, and purpose. He has said he would not want a robot nurse in place of human empathy.

That part can sound soft next to AGI timelines and protein databases, but it is central to his optimism. If AI handles more utility, humans may lean harder into meaning.

36. The transition may be faster than society is ready for

Hassabis’s recent comparison to the Industrial Revolution has two parts: bigger impact and faster speed. The speed is the scary part. Institutions adapted slowly to the Industrial Revolution, and the adaptation was painful. AI may compress that kind of social shock into a much shorter window.

That is why he keeps returning to preparation. Safety, education, labor policy, international governance, and public understanding cannot wait until after the tools arrive.

37. The deepest bet is that reality is learnable

Underneath the interviews, papers, and products sits one philosophical bet: the world has structure, and intelligence can discover it.

Go looked too large to search. Protein folding looked too complex to solve at scale. Biology looks messy. Physics is hard. Human imagination is mysterious. Hassabis’s career keeps circling the same possibility: if nature produces patterns, learning systems may find them; if systems can find them, science can move faster; if science moves faster, civilization gets new options.

That is the through-line. Not chatbots. Not benchmark theater. Not a single product cycle.

The Hassabis view of AI is that intelligence is a discovery instrument. First we build it in games. Then we test it against biology. Then we aim it at the hardest parts of science. If we are careful, it gives us abundance. If we are careless, it gives us power before wisdom.

That is why his optimism never feels entirely comfortable. It comes with a clock.

Tether — the same company that created the $140 billion stablecoin USDT — just led a $1.4 billion investment round into a German robotics company called NEURA. And they’re not just handing over cash. The plan is to embed crypto wallets directly into humanoid robots.

If the integration works as advertised, we’re looking at something the world hasn’t seen before: robots designed to hold their own private keys. Machines built from the ground up to earn, spend, and transact entirely on their own.

That’s the roadmap. Not a press release bubble, but a funded, engineered, and investor-backed product plan. If it sounds small, think again. This is the kind of quiet infrastructure shift that, ten years from now, people will point to and say “that’s when things started to change.”

The German Robotics Company You’ve Never Heard Of

NEURA Robotics is headquartered in Metzingen, Germany — a small town about 30 minutes south of Stuttgart that most people know for its factory outlet stores, not its cutting-edge robotics. The company was founded in 2019 by David Reger, and it has quietly built one of the most ambitious Physical AI platforms on the planet.

They don’t just make one type of robot. They make humanoids, precision robotic arms, autonomous mobile robots, and service robots — a whole portfolio designed to operate in factories, warehouses, hospitals, and eventually homes. Think of them as building the operating system for machines that can see, hear, feel, learn, and act in the physical world.

The core of their platform is called the Neuraverse. It’s an open ecosystem where multiple robots share what they’ve learned. A robot in a Bosch factory in Stuttgart picks up a task, and that knowledge flows to every other NEURA robot on the network. They learn from each other, in real time, across continents. It’s the difference between a thousand isolated machines each learning the same thing from scratch, and a thousand machines where every success makes everyone smarter.

NEURA also operates something called the NEURA Gyms — large-scale training environments where robots practice physical tasks in simulation and real-world conditions before being deployed. Think of it as a robot trade school, but one where the “graduate” immediately uploads everything it learned to every other robot on the network.

And they already have over a billion dollars in orders.

That’s what attracted Tether. That’s what attracted Amazon, NVIDIA, Qualcomm, Bosch, Schaeffler, and the European Investment Bank all to co-invest in the same round. Because the pieces are real. The demand is real. The only question is how fast it scales.

Why a Stablecoin Company Cares About Robots

This is the part that’s hard to grasp at first. Why does Tether — an issuer of digital dollars used mostly by crypto traders in emerging markets — care about German factory robots?

The answer is simple: if machines become economically autonomous, they need financial tools designed for machines, not humans.

Think about what it takes for you to pay someone today. You open a banking app, you approve a transfer, you wait for settlement. Now imagine a factory robot that needs to pay another robot for a completed task. The robot doesn’t have a phone. It doesn’t have a bank app. It doesn’t have a manager to approve spending. It needs money that moves at the speed of software.

Tether is bringing two technologies into the NEURA ecosystem to solve exactly this. The first is the Wallet Development Kit, or WDK. It’s an open-source toolkit that lets anyone build self-custodial crypto wallets — for people, for apps, or in this case, for robots. Each NEURA machine would carry its own wallet, hold its own private keys, and be capable of sending and receiving payments without a human pressing “approve.” The kit is deliberately designed to be embedded in everything — from a smartphone to an IoT sensor to a full-size humanoid robot.

The second is QVAC, Tether’s edge AI runtime. Instead of sending data up to the cloud for processing, QVAC runs AI models directly on the device. In a factory environment, where milliseconds of latency can mean the difference between a smooth operation and a costly error, local processing isn’t a nice-to-have. It’s a requirement. QVAC runs on everything from Node.js servers to the Bare runtime for embedded systems. It even exposes an OpenAI-compatible API, meaning existing AI tools can plug directly into it.

Put them together and you get the blueprint for a robot that can think locally, act autonomously, and transact independently. The machine wouldn’t need to phone home for permission. It wouldn’t need a bank account with a human signatory. It would carry its own keys, run its own models, and settle payments as part of its workflow.

Paolo Ardoino, Tether’s CEO, put it plainly: “Autonomous machines need the ability to process information locally, make decisions, and transact without relying on centralized intermediaries.”

The Machine Economy Isn’t Coming — It’s Being Built

Here’s the frame that matters.

Today, global commerce runs on a financial infrastructure designed entirely for humans. Banks have branch hours. Payment processors have settlement windows. Corporate accounts require authorized signatories. Wire transfers take days. None of this works at the speed and scale of machine interactions.

A fleet of a thousand robots in a distribution center might need to execute millions of micropayments per day. Paying for electricity usage, leasing compute time from each other, settling fees for task handoffs, charging for data access, compensating for maintenance prioritization. Traditional banking rails would grind to a halt under that load before the first transaction even cleared.

This is where stablecoins enter the picture in a way most people haven’t considered. Yes, stablecoins are useful for sending money across borders cheaply. Yes, they’re useful for trading. But their most underappreciated property is that they’re programmable by default. A stablecoin transfer isn’t just a transfer — it can be a smart contract execution, a conditional release, a time-locked payment, or a revenue share split across a hundred recipients automatically.

Transactions that cost dollars using traditional wires cost fractions of a cent on EVM-compatible blockchains. Settlement happens in seconds, not days. And because the settlement happens on a public ledger, the entire history is auditable by any participant — human, machine, or regulator.

This is where Ethereum — and the broader ecosystem of EVM-compatible chains like Arbitrum, Optimism, and Base — becomes the invisible backbone of the machine economy. Not as a speculative asset, but as the trust layer that machines use to verify each other’s transactions. Think of it as a notary, escrow agent, and settlement system rolled into one, running 24/7/365 without a single human employee.

Smart contracts can act as automated dispute resolvers between machines that have never met and don’t share a corporate parent. They can govern shared resource pools where a fleet of robots from different manufacturers bid for compute time or charging slots. They can implement reputation systems where reliable machines earn better payment terms, all enforced in code.

You don’t need to have ever traded a token to see the logic. Programmable money plus autonomous machines equals a new category of economic activity that literally could not exist before.

What This Actually Looks Like

Let me sketch what the roadmap points toward.

Picture a NEURA humanoid working on an assembly line at Bosch. It completes a precision task — inserting a component, running a quality check, updating a digital twin of the product. When the task finishes, a smart contract releases a micro-payment from the manufacturer to the robot’s wallet. Not to NEURA Robotics as a company. To the robot itself, held in self-custody.

The robot later needs to recharge. It has a choice of three charging stations on the factory floor. One costs more but charges faster — the robot can complete more tasks in a shift if it picks that one. The robot queries the stations’ prices, checks its own wallet balance, evaluates the opportunity cost of slower charging against its task schedule, and makes a decision. It negotiates with the charging station — another machine, perhaps from a different manufacturer — pays for the energy using USDT, and the charging station logs the transaction. All machine-to-machine, all settled on-chain, all without a single email approval chain or human accountant.

Now scale this. Across a fleet of a thousand robots in a single facility. Across ten thousand facilities, each with robots from multiple manufacturers, running on different software stacks, but all settling on the same EVM-compatible chains because that’s where the economic activity has naturally converged.

None of this is deployed today. But it’s all buildable. The WDK is shipping. QVAC is open-source. NEURA has hardware in the field and a billion-dollar order book. What makes this round different is the integration thesis — the conscious decision to embed financial agency into the machine itself, as a core design principle rather than an afterthought.

David Reger calls this “the next economy.” If the integration lives up to the vision, he’s right. And I’d go further: it would be the first economy that doesn’t require humans at every transaction node.

Who Else Is Betting on This Direction

It’s worth looking at the investor list again, because the composition tells you something about where this is heading.

NVIDIA invested. That makes sense — they provide the compute hardware for AI inference, and edge robots running QVAC need NVIDIA Jetson-class hardware. More robots means more chip sales.

Amazon invested. That makes sense too — Amazon already runs one of the world’s largest logistics networks. They have a direct use case for warehouse robots that can manage their own economic relationships on the warehouse floor. And AWS wants to be the cloud layer that Neuraverse runs on.

Qualcomm invested. Edge AI needs efficient mobile-class processors. Qualcomm’s Snapdragon and Robotics platforms already power autonomous drones and mobile robots. On-device inference is their sweet spot.

Bosch and Schaeffler invested. These are German industrial giants — Bosch alone is one of the world’s largest automotive suppliers. They see NEURA’s robots as the next generation of factory automation. They’re not here for the crypto angle. They’re here for the productivity angle.

And Tether led the round. Because they see something the others might not be saying out loud: if you control the financial layer of the machine economy, you control the most important new payments infrastructure since the credit card network.

This combination — hardware, cloud, AI chips, industrial manufacturing, and programmable money — is what makes this deal different from a typical robotics funding round. It’s not just capital. It’s the entire stack coming together.

The Real Shift Nobody’s Talking About

Most of the coverage around this deal focused on the dollar amount — $1.4 billion, largest robotics round ever. Some focused on the crypto angle — “Tether is putting wallets in robots!” A few dug into the edge AI piece.

But the real story is deeper.

We’ve spent the last two decades building an internet where information flows freely. Now we’re building an internet where value flows freely — and it won’t just be between people. It’ll be between people and machines, between machines and other machines, between autonomous systems that manage supply chains, energy grids, logistics networks, and eventually entire micro-economies.

Consider what happens when a robot can optimize its own economic output in real time. It doesn’t just complete tasks — it decides which tasks to prioritize based on market pricing. It doesn’t just consume energy — it negotiates the best rate. It doesn’t just work — it participates in a marketplace of machine labor that prices itself dynamically.

This is the part that changes the economics of manufacturing and logistics fundamentally. Today, robots are a fixed cost on a balance sheet. You buy them, you depreciate them, you hope they produce more value than they cost. In the machine economy, robots become variable-cost economic participants. They earn their own keep. They optimize their own schedules. They participate in a decentralized labor market where every machine competes on efficiency.

Tether saw this coming. That’s why they built WDK to be “AI-native” from day one — their documentation explicitly says the toolkit is designed so that “AI agents and robots can access and self-manage their own resources.” That’s not an afterthought. It’s the thesis.

NEURA saw it too. When Reger talks about the Neuraverse, he’s not just describing a robot network. He’s describing an economic network. Robots that share intelligence, skills, and data aren’t just more capable — they’re more valuable as a collective. Add programmable money, and those relationships become self-sustaining.

The Caveats (Because There Are Always Caveats)

Let me be clear about what this isn’t.

No robot legally owns a wallet today. This integration is planned, not deployed at scale. The full $1.4 billion is contingent on NEURA hitting specific performance milestones. We don’t know what those milestones are. The company declined to comment on them. The valuation of around $7 billion is based on a single anonymous source, not a disclosed number.

The regulatory landscape for robot wallets is unsettled. If a robot enters into a smart contract that turns out to be fraudulent, who’s liable? The manufacturer who programmed the wallet? The owner who deployed the robot? The entity that programmed the smart contract? The robot itself? These aren’t academic questions. They’ll determine whether this technology spreads to regulated industries like healthcare and finance, or stays confined to experimental factory floors.

There are also the perennial caveats around blockchain UX for non-human actors. Key management is the first: if a robot’s private key is stored on a physical device, what happens when that device fails? How do you rotate keys across a fleet of thousands of machines without creating a security hole? Gas fees are another: a robot executing a million micro-transactions per day can’t afford to pay $0.10 in gas per transaction. L2s solve the cost problem, but they add complexity around sequencer reliability and state commitment. And recovery — if a robot’s wallet is compromised, what’s the recovery mechanism for an autonomous entity that can’t call customer support?

All of these are solvable with existing technology (deterministic key derivation from fleet IDs, sponsored transaction relays, social recovery for machines). But none of them are trivial, and none of them have mature production solutions today.

And hardware is still the bottleneck. NEURA targets multi-million unit production by 2030. That’s ambitious. Manufacturing at that scale for humanoid robots has never been done before. The order book is real, the partners are serious, but execution is everything. The robotics industry has a long history of over-promising on timelines.

Tether itself carries its own baggage. The company has faced regulatory scrutiny for years. Its stablecoin reserves have been questioned, investigated, and litigated. For the machine economy thesis to fully play out, USDT needs to remain operational and trusted. Any disruption to Tether’s core business would ripple through the entire stack.

Why I’m Optimistic

With all those caveats on the table, here’s why this deal matters more than most people realize.

First, look at the scale. The year 2026 is already a record year for robotics investment — $55.8 billion globally, nearly double the previous record. The capital is flowing because the technology is finally ready. Vision-language-action models can now reason about physical spaces. Edge hardware can run them locally at usable speeds. And programmable money can let the resulting machines participate in the economy directly.

Second, look at the alignment. Hardware, AI, cloud, industrial manufacturing, and financial infrastructure — all five layers have a vested interest in making this work. When NVIDIA needs more robot chips sold, Amazon needs cheaper warehouse automation, Bosch needs next-gen factories, and Tether needs the next use case for its stablecoin beyond trading, you end up with everyone pushing in the same direction.

Third, look at the trend curve. The World Bank estimates that over 60% of global GDP comes from physical work. Agriculture, manufacturing, construction, logistics, healthcare, hospitality — all require physical manipulation of the material world. If even a fraction of that GDP moves through machine-operated economies, the addressable market is measured in tens of trillions of dollars.

Every major technological shift in history follows the same pattern: first the infrastructure gets built quietly, then the applications explode. The internet had TCP/IP and HTTP. Mobile had the iPhone and 4G. AI had transformers and GPUs.

For the machine economy, the infrastructure being built right now is a stack: physical robots from NEURA, local intelligence from QVAC, and programmable money on Ethereum and L2s, enabled by self-custodial wallets from WDK.

None of this makes headlines today. When the robot economy is worth a trillion dollars in annual transactions, nobody will remember the German press release from June 2026. But that’s how all transformative infrastructure works. It sneaks up on you.

The machines aren’t just getting smarter. They’re getting their own bank accounts.

If the vision holds, that changes everything.

In June 2026, NewLimit, the anti-aging company co-founded by Coinbase founder Brian Armstrong, Blake Byers, and Jacob Kimmel, announced a $435 million Series C led by Founders Fund. Other backers included Thrive Capital, Greenoaks, and Eli Lilly’s venture arm.

Reported valuation: roughly $3.1 billion.

No approved product. No mature clinical data. No consumer longevity pill you can buy tomorrow morning.

And yet the money keeps coming.

The lazy explanation says billionaires are simply afraid of dying.

Maybe. If you have already won capitalism, biology starts to look like the final boss.

But that explanation is too small.

Jeff Bezos did not become Jeff Bezos by buying expensive fantasies. Brian Armstrong did not build Coinbase because he liked safe, linear markets. Sam Altman did not put $180 million into Retro Biosciences because he wanted a fancy supplement brand.

Their real wager goes far beyond “live forever.”

They are betting that aging might become programmable.

Programmable does not mean solved, conquered, or magically deleted. It means biology starts to look less like fate and more like an engineering problem.

If that turns out even partly true, longevity stops looking like a wellness category, a biohacking trend, or a rich-person hobby. It starts looking like a new biology platform.

The weird idea at the center of the bet

Think of epigenetic reprogramming like a corrupted settings layer.

Every cell in your body has the same basic DNA instruction book. A liver cell, a skin cell, a neuron, they carry the same genome. What makes them different comes down to which pages get read, which pages stay locked, and which instructions the cell ignores.

That control layer is called the epigenome.

As we age, the genome does not simply “run out.” The deeper problem is that the control system gets noisy. Some genes that should stay quiet become active. Some genes that should work smoothly shut down. The cell still knows what it is supposed to be, but the operating system gets corrupted.

A liver cell is still a liver cell.

It just starts acting like an old liver cell.

Epigenetic reprogramming asks a radical question: what if you could reset part of that control layer without erasing the cell’s identity?

A liver cell should stay a liver cell. DNA replacement misses the point. The goal is narrower: restore enough youthful instructions for the cell to behave more like its younger version.

This idea comes from one of the most important biology discoveries of the last twenty years. Shinya Yamanaka showed that a small set of transcription factors could reprogram adult cells back toward a pluripotent stem-cell state. That work helped win the 2012 Nobel Prize.

The problem is obvious: full reprogramming is too powerful. If you push a cell too far, it may lose its identity. It may become tumor-prone. It may stop being the kind of cell the body needs.

So the modern longevity companies are chasing a narrower, more difficult target.

Partial reprogramming.

The promise sounds more modest, and harder: restore youth-like function while preserving identity.

Everyone in the field is trying to thread that needle.

Bezos is funding the cathedral

Altos Labs is the most spectacular version of this bet.

When Altos formally launched in 2022, it did so with about $3 billion in initial funding. Multiple reports linked Jeff Bezos and Yuri Milner to the company’s backers. Its scientific roster looked less like a startup and more like a private biology institute assembled by someone who had decided the usual academic system was too slow.

Jennifer Doudna. Frances Arnold. David Baltimore. Shinya Yamanaka in a senior scientific advisory role. Hal Barron, formerly of Roche/Genentech and GSK, as CEO.

Nobody builds a quick biotech trade this way. You build a cathedral this way.

Altos has been unusually quiet about specific drug programs. Most biotechs have to show a pipeline, a timeline, and a story investors can model in a spreadsheet.

Altos seems to be doing something different.

The company wants to understand cellular rejuvenation at the deepest possible level. The company has built major research hubs and hired scientists at compensation levels that reportedly far exceed typical academic salaries. The message is clear: if the biology is real, first build the deepest map of the territory. Products can come later.

Bezos makes a useful example for exactly that reason.

Amazon looked irrational for years because outsiders kept asking the wrong question.

They asked: “When will this company maximize profit?”

Bezos was asking: “How large can the platform become if we keep reinvesting?”

Altos may be the same kind of question, translated into biology.

Not: “Where is the first pill?”

But: “If cellular age can be modified, what kind of medical platform becomes possible?”

Armstrong is running the Silicon Valley version

NewLimit feels different.

Altos is the cathedral. NewLimit is the machine shop.

Brian Armstrong comes from crypto, not traditional pharma. Crypto founders are used to weird primitives becoming real markets very quickly. They are used to skepticism. They are used to building infrastructure before the mainstream understands what it is looking at.

NewLimit’s approach is more explicitly computational.

The company is trying to use AI, synthetic biology, and high-throughput experimentation to discover payloads, combinations of transcription factors and related interventions, that can push old cells toward a younger functional state without destroying their identity.

According to company materials and reporting, NewLimit’s Ambrosia AI engine is designed to search enormous biological design spaces. The company also uses experimental platforms that can test many candidate combinations in parallel, read the results at single-cell resolution, and feed that data back into the model.

The important part: NewLimit frames rejuvenation as an optimization loop, not a belief system.

Design. Test. Measure. Learn. Repeat.

That is why the NewLimit story feels so Silicon Valley.

The company is trying to compress biological discovery cycles the way software compressed product cycles.

In 2026, NewLimit said it had discovered a prototype drug that reversed aspects of aging in human liver cells and that it planned to initiate its first human trial the following year. That is still early. Company-reported cell data still sits miles away from a safe, approved medicine.

But it changes the emotional temperature of the field.

Suddenly the field feels less like an academic idea and more like a clinical race.

The other players are not background characters

Life Biosciences may be the closest to the clinic. Its ER-100 program uses a partial epigenetic reprogramming approach built around OSK, Oct4, Sox2, and Klf4, delivered locally for optic neuropathies such as glaucoma and NAION. In 2026, the company announced FDA IND clearance for a Phase 1 trial.

That is a big milestone.

The eye is a logical first battlefield. It is local. It is measurable. It gives researchers a cleaner way to test safety and biological effect than trying to rejuvenate the whole body at once.

Turn Biotechnologies has taken another path: mRNA delivery. Instead of permanently installing genetic instructions, mRNA can be transient. It appears, produces its effect, and fades. In theory, that gives better control over dose and timing, exactly the kind of control partial reprogramming needs.

In 2026, Daewoong Pharmaceutical acquired Turn Bio’s core assets and technology rights. That detail is easy to miss, but it says something important: Asian pharma is also buying into the age-reversal platform idea.

Retro Biosciences, backed by Sam Altman, is broader and stranger. It is working on multiple longevity pathways, including blood stem-cell reprogramming, autophagy, and neurodegeneration. Retro also collaborated with OpenAI on GPT-4b micro, a model designed for protein engineering.

That part should make investors sit up.

Altman brought more than a check into biology. He is connecting AI capability to biology. If AI can help design better proteins, better transcription factors, or better delivery systems, then longevity becomes one of the most obvious places for AI to matter outside software.

Shift Bioscience is trying to reduce the risk another way. Instead of using a multi-factor Yamanaka-style cocktail, Shift is looking for more precise targets. In 2025, the company announced work around SB000, a single-gene target discovered through AI-driven screening. The claim is attractive: rejuvenation-like effects without pushing cells toward pluripotency.

That research is still early and needs careful validation. But the direction makes sense.

The safer the intervention, the larger the possible market.

In this field, safety does not sit in the footnotes. Safety is the whole game.

Why the richest people care before everyone else does

Technology investing has a familiar pattern.

The best investors often arrive before the market has language for the opportunity.

Before smartphones, people saw phones.

Before cloud computing, people saw rented servers.

Before crypto, people saw internet money for nerds.

Before AI became obvious, people saw autocomplete.

Longevity has the same problem. Most people still hear “anti-aging” and think of face cream, supplements, gym routines, and rich men with blood tests.

That mental model misses the point.

A better model starts here:

Aging is the largest risk factor behind many of the most expensive diseases in the world.

Alzheimer’s. Cardiovascular disease. Liver disease. Immune decline. Muscle loss. Frailty. Many cancers.

Modern medicine usually attacks these diseases one by one, after the damage is visible.

Longevity biology asks a more uncomfortable question: what if some of these diseases share upstream mechanisms? What if we can intervene earlier, closer to the root, instead of waiting for each organ system to fail separately?

The upside looks asymmetric for that reason.

If most of these companies fail, the losses are painful but finite.

If even one platform works, the market is enormous.

The upside does not require everyone to buy an immortality drug. Every healthcare system already drowns in age-related disease.

A medicine that safely improves tissue function, delays degeneration, or restores organ resilience would not be a luxury product. It would be one of the most important medical categories ever created.

The super-rich are buying exposure to something more practical than eternal life: a call option on the biology of aging.

Why now?

The timing matters.

Anti-aging research has existed for decades. Most of it never became investable in the venture-scale sense. It was too fuzzy, too hard to measure, too dependent on slow animal models and uncertain biomarkers.

Something changed.

First, AI became good enough to search biological possibility spaces that are too large for humans to explore manually.

NewLimit’s whole model depends on this. Shift’s virtual-cell approach depends on this. Retro’s protein-engineering work with OpenAI depends on this.

Second, epigenetic clocks and single-cell tools made aging more measurable. If you cannot measure biological age and cell identity precisely, you cannot run a serious reprogramming company. You are just telling stories.

Third, delivery technology improved. AAV, mRNA, local delivery, tissue-specific expression, these are not solved problems, but they are far more mature than they were fifteen years ago.

Fourth, the COVID-era mRNA wave changed the imagination of biology. Suddenly, programmable medicine was not a TED Talk phrase. It was something hundreds of millions of people had experienced.

These trends are converging.

The smartest money is moving now because the possibility space has opened, even with no guarantee of success.

The uncomfortable truth

Most of these companies will probably not become the next Genentech.

Some will fail in animal models. Some will fail in safety. Some will discover that the biology works in a dish but not in a body. Some will run into delivery problems. Some will simply run out of time and capital.

Biotech is brutal.

Epigenetic reprogramming belongs nowhere near the supplement aisle. It is powerful biology. Powerful biology can heal, and it can also break things.

So the risk is real.

The risk does not shrink the story. It makes the story more honest.

Every platform shift begins as a field full of fragile claims, strange companies, and overconfident believers.

Then most of them die.

A few survive.

And one day everyone says, “Of course this was obvious.”

The bet

The bet, stated plainly:

The super-rich are trying to buy more than extra years for themselves.

They are trying to buy early ownership in the idea that cellular age can be measured, modeled, and modified.

Bezos is funding the deep science.

Armstrong is funding the AI-driven discovery loop.

Altman is connecting frontier AI to biology.

Life Biosciences is pushing the idea into human trials.

Turn Bio is testing whether transient mRNA expression can make reprogramming more controllable.

Shift is searching for simpler targets.

Retro is trying to turn longevity into a multi-pipeline company.

Different routes. Same destination.

A world where aging does not equal treated as one inevitable wall, but as a collection of biological programs that can be studied, delayed, and maybe partially reset.

That explains the money flow.

Nobody has conquered death. The money is moving because serious people now believe the operating system of aging might be editable.

And if they are even a little bit right, this will not be remembered as a vanity project.

It will be remembered as the moment biology started to look like software.

Disclaimer: This article is for informational and educational purposes only. Treat it as education, not investment advice, medical advice, or a recommendation to buy or sell any security. The companies discussed are mostly private, early-stage, and scientifically risky. Epigenetic reprogramming remains an emerging field, and clinical outcomes are uncertain.

Sometimes the rotation begins more quietly. A few crowded trades stop working. Good news gets sold. Portfolio managers start trimming winners, not because they hate the story, but because the position has become too large. Cash piles up for deals that are too important to ignore. Then, before anyone declares a new cycle, the old leadership begins to feel heavy.

That is how I would think about the next phase of the AI trade.

The obvious story is AI. The more useful story is capital rotation.

According to media reports, SpaceX has been preparing for a possible public listing at a target valuation of about $1.77 trillion, with a potential raise around $75 billion. Anthropic reportedly raised $65 billion on May 28 at a valuation near $965 billion. OpenAI reportedly raised $122 billion on March 31 at a valuation around $852 billion.

Put those reported valuations together and you get more than $3.5 trillion of implied value.

The exact numbers may change. The direction is what matters. These are not normal financing events. These are gravity wells. If even part of this capital demand hits the market in a compressed window, investors have to make room.

And making room usually means selling something else.

The question is not whether AI is important

AI is important. That part is not interesting anymore.

The market already knows the story. It has bought Nvidia. It has bought data centers. It has bought power, cooling, chips, defense, automation, cloud software, and anything that could plausibly attach itself to AI.

From 2023 through 2025, AI became the dominant risk asset narrative. Every model release, every Nvidia earnings beat, every enterprise pilot, every story about jobs being automated made the trade feel bigger. Money likes that kind of story. It gives investors a reason to pay up.

But every strong theme eventually runs into the same problem: positioning.

At first, a theme is under-owned. Then it becomes consensus. Then it becomes mandatory. By the time everyone agrees the theme is real, the trade may already be crowded.

That does not mean AI is fake. It means the price of AI exposure can get too high.

There is a difference between a technology being transformative and a basket of related assets being attractive at today’s price. The internet was transformative in 2000. Many internet stocks were still terrible investments at the peak.

That distinction matters now.

When a market theme becomes too dominant, it starts starving everything else. Investors stop asking what is cheap. They ask what gives them more exposure to the winning story. That is when the next rotation starts to form, usually in the assets nobody wants to talk about.

Mega deals create a liquidity vacuum

Saudi Aramco raised $25.6 billion in its 2019 IPO. At the time, that was the largest IPO in history.

Now compare that with the reported numbers around the AI and space infrastructure names. A $75 billion SpaceX raise would be almost three Aramcos. A $65 billion Anthropic raise would be more than two Aramcos. A $122 billion OpenAI raise would be almost five.

These comparisons are imperfect, of course. Private rounds, public listings, float, secondary sales, index inclusion, and actual liquidity are different things. But the point is simple: the capital requirement is enormous.

On June 4, S&P Dow Jones Indices made clear that it would not waive seasoning rules just because a company is huge. A new public company still needs to trade for at least 12 months before it can enter the S&P 500.

That creates a strange gap. A company can be large enough to dominate every financial headline, but still not receive automatic S&P 500 index demand on day one.

Nasdaq may treat the situation differently. Depending on methodology and float treatment, a mega IPO could receive faster index exposure through the Nasdaq-100. The details matter, but the bigger point is the tension. Some pools of money may have to wait. Others may be forced to react earlier.

Either way, discretionary investors do not wait for the index committee to tell them what matters. If they want allocation, they need cash.

Where does that cash come from?

From the parts of the portfolio that can be sold.

That is the vacuum. Not a dramatic one-day event. More like a pressure change. Capital gets reserved for the sacred names. Second-tier private deals get less attention. Public growth stocks lose some marginal buyers. Funds sell liquid winners to prepare for illiquid opportunities. A few crowded trades stop feeling effortless.

Then people look around and say the market feels tired.

Rotation usually has three phases

The mistake is assuming money jumps directly from one hot theme into the next.

That is not usually how it works.

After a crowded trade breaks, capital tends to move in stages. The stages are messy, and they overlap, but the pattern is familiar.

First, money hides.

Cash, short-term Treasuries, gold, defensive equities, quality balance sheets. This is the boring phase. It can feel like nothing is happening because the most exciting assets are no longer leading. Investors are not trying to get rich in this phase. They are trying to avoid explaining another drawdown.

Second, money buys what the mania ignored.

This is where the rotation becomes interesting. The old winners may still be good businesses, but their stocks have too much expectation built in. The ignored assets, meanwhile, have spent years being neglected. They do not need perfection. They only need investors to notice that they are cheap, under-owned, or less exposed to the old narrative.

Third, money finds the next liquidity story.

This is the phase people like to front-run. It is also the easiest phase to be early on. A new story needs more than a chart bounce. It needs liquidity, flows, and a reason for institutions to reallocate.

The order matters.

If you skip the defensive phase and buy the next speculative asset too early, you may be right about the destination and still lose money on the sequence.

The 2000 playbook was not just a tech crash

The dot-com bubble is usually remembered as a tech-stock collapse. That is only half the story.

The Nasdaq fell from roughly 5,000 in March 2000 to about 1,100 in 2002, a decline of nearly 78%. Many companies disappeared. Some real businesses survived but took years to recover. If you bought the Nasdaq at the top, you waited roughly 15 years to get back to even.

But capital did not vanish forever. It moved.

At first, it hid in cash and government bonds. That is normal. When the leading story breaks, investors do not immediately trust the next one. They need time to figure out whether they are buying bargains or traps.

Then money went into assets that had been neglected during the internet mania. Housing, commodities, energy, emerging markets, and small-cap value stocks started working. From 2002 to 2007, oil moved from around $20 to more than $100. Copper had a huge run. Emerging markets came alive. Value investors, who looked obsolete in 1999, suddenly looked patient rather than stupid.

The internet still changed the world. That did not stop capital from leaving internet stocks and rewarding other parts of the market for years.

That is the lesson I care about now.

A technology can win while its first public-market leadership group stops leading. When that happens, money does not retire. It rotates.

2021 showed the same sequence in a faster market

The 2021 cycle compressed the same movie into a shorter timeline.

Crypto, meme stocks, SPACs, unprofitable software, and anything with a good enough future story benefited from cheap money. Bitcoin ran from under $10,000 in early 2020 to around $69,000 in November 2021. NFTs became dinner-table conversation. DeFi yields looked fake because many of them were fake.

Then the Fed started hiking.

In March 2022, it raised rates by 25 basis points. Then came four consecutive 75-basis-point hikes. Liquidity drained out of the system. The speculative parts of the market broke first.

Bitcoin fell from roughly $69,000 to around $16,000. FTX collapsed. Three Arrows Capital collapsed. High-growth software sold off. SPACs became punchlines.

Again, the important part was not simply that one asset fell. The whole risk stack repriced.

When liquidity is abundant, money pays for duration, imagination, and optionality. When liquidity tightens, money stops paying for distant promises. It wants cash flow, safety, collateral, and time.

Only after the panic burns out does capital ask a better question: what did we sell too hard?

Bitcoin’s recovery later came from several things at once: easier financial conditions, the survival of the network after the frauds washed out, and the January 2024 approval of spot Bitcoin ETFs, which gave institutions a familiar wrapper. The wrapper mattered because flows matter.

That is a broader lesson, not just a crypto lesson. A rotation needs a vehicle. Investors need a clean way to express the trade.

What AI may starve next

If the AI trade stops leading cleanly, I would not expect the market to immediately crown one replacement.

The more likely path is a basket rotation.

Some capital goes defensive first. Some moves into assets that were starved while AI dominated every conversation. Some stays in the AI supply chain but shifts from glamorous model labs to the physical infrastructure behind them.

Traditional software could catch a bid again. Companies like Adobe, Salesforce, and Intuit looked old during the model-lab frenzy, but they still have customers, margins, distribution, and pricing power. If the market becomes less willing to pay unlimited multiples for frontier AI, boring software may look less boring.

Small caps could benefit if investors start looking beyond mega-cap concentration. They have lagged while institutional capital crowded into the obvious winners. If rates fall and breadth improves, some of that neglect can reverse.

Industrial infrastructure may be one of the cleaner bridges between the old story and the next rotation. AI still needs electricity, data centers, cooling, copper, transformers, and grid upgrades. Even if AI valuations compress, the physical buildout does not disappear overnight.

Energy and utilities deserve more attention than they get. Data-center demand has made power availability a real constraint. Nuclear, gas, grid equipment, and storage all sit close to the bottleneck.

Biotech and medical technology have also been left out of the main market conversation. Demographics did not pause because everyone started talking to chatbots.

Real estate can work if rates fall. Emerging markets can work if the dollar weakens. Commodities can work if the infrastructure cycle stays alive.

Digital assets may also become part of the later rotation, but I would put them in the liquidity-sensitive bucket rather than treating them as the only destination. Bitcoin, crypto equities, stablecoins, and tokenized assets all need the same basic ingredients: easier liquidity, improving flows, and less correlation with stressed tech selling.

That is the more balanced view. Bitcoin can be part of the next phase without being the whole thesis.

Why the first move probably is not the final move

The first reaction after AI exhaustion is likely defensive.

That does not mean a crash. It means the marginal buyer changes. Investors who were chasing upside begin protecting gains. Funds reduce exposure to crowded winners. Some cash gets reserved for the biggest private or public AI allocations. Some investors move toward quality, duration, gold, or short-term bonds.

Gold is worth watching here because it often sniffs out discomfort before the high-beta assets do. It does not need a product launch. It does not need an app store ranking. It only needs investors to distrust the current story a little more than they did yesterday.

If AI leaders wobble while gold holds up, that tells you something.

It suggests capital is not just rotating from one growth stock to another. It is looking for a different kind of protection.

But protection is not the same as a new bull market. The defensive phase can last longer than people expect. The old leaders can bounce. The new leaders can fail their first breakout. There may be several false starts.

That is why I would rather watch the sequence than guess the exact date.

That later phase could include gold, small caps, commodities, emerging markets, infrastructure, old software that everyone forgot about, and digital assets. Bitcoin belongs in that list, but it should not sit above it.

Its setup probably improves if three things happen. Liquidity loosens. Its correlation with stressed tech selling weakens. Flows return through ETFs, stablecoins, and crypto-related equities.

If those show up together, Bitcoin becomes one expression of the rotation. Not the only one. Maybe not even the first one.

The signals that matter

I am watching six things.

First: AI leaders stop rising on good news. This is one of the oldest exhaustion signals in the market. When strong earnings, product launches, or financing headlines no longer move the stocks higher, the trade may be saturated.

Second: breadth improves outside mega-cap tech. If small caps, value, industrials, software laggards, biotech, or emerging markets begin working while AI leaders flatten, that is rotation, not random noise.

Third: defensive assets hold up. Cash yields, Treasuries, gold, and quality equities tell you whether investors are reducing risk or simply switching themes.

Fourth: the Fed moves from talk to action. Markets can price cuts for months. A real easing cycle, falling real yields, and a weaker dollar would change the opportunity set.

Fifth: liquidity-sensitive assets stop trading like pure Nasdaq beta. This includes Bitcoin, crypto equities, unprofitable growth, and other long-duration assets. The key is not whether they go up for three days. The key is whether they stop breaking every time tech sells off.

Sixth: flows confirm the story. ETF inflows, stablecoin supply, fund flows into neglected sectors, credit spreads, IPO demand, and secondary-market appetite all matter. Narratives are cheap. Flows are harder to fake.

No single signal is enough. The rotation becomes interesting when several of them line up.

Disclaimer: This article is a market-cycle framework, not investment advice. Any discussion of future market behavior is uncertain. Investing involves risk. Make decisions based on your own financial situation and risk tolerance.

An S-1 is the registration statement a company files with the SEC before selling shares to the public. It is part sales pitch, part legal risk dump, part financial x-ray. In a normal IPO, you read it to understand revenue, margins, ownership, dilution, risk factors, and what the company plans to do with the money.

The SpaceX S-1 is worth reading a little differently because the company is not coming public as a neat single-business story. This filing is trying to package rockets, Starlink, xAI, X, AI compute, chips, satellites, debt, related-party arrangements, and a future orbital data-center idea into one public security.

The number I keep coming back to is $74.4 billion, which is the net cash SpaceX expects to raise from the offering before the underwriters exercise their option. If they do exercise it, the number rises to $85.7 billion.

Most IPO coverage will orbit the valuation because that is the easiest headline to write: $1.75 trillion, $2 trillion, whatever number gets people to click. The more useful way to read this S-1 is as a capital allocation memo for a company that already has an extraordinary launch business, a real Starlink cash engine, and a new AI segment whose funding needs suddenly look less like software spending and more like national infrastructure.

So I would not start with the lazy question, “Is SpaceX a great company?” That part is almost boring. The harder question is whether public shareholders are being invited into the best aerospace business in the world, or whether they are being asked to finance one of the most expensive AI infrastructure experiments ever attempted. Later in the piece, I also bring in Campbell Harvey’s market-structure argument because this is where the IPO stops being only a company story and starts becoming an index-flow story.

That is the angle I would watch.

The IPO is an AI capex raise wearing a rocket-company costume

The use-of-proceeds section is blunt once you strip away the prospectus language. SpaceX expects about $74.4 billion in net proceeds from the offering, or $85.7 billion if the underwriters fully exercise their option, and the company says the money will fund its growth strategy, including AI compute infrastructure, launch infrastructure and vehicles, satellite constellation scale, and general corporate purposes.

That sounds broad because prospectuses always sound broad. Then you reach the capex table, and the story gets much sharper.

In Q1 2026, SpaceX spent $1.052 billion of capital expenditures in Space, $1.332 billion in Connectivity, and $7.723 billion in AI. The AI segment alone spent more than three times the Space and Connectivity segments combined. For full-year 2025, AI capex was $12.727 billion, compared with $3.832 billion for Space and $4.178 billion for Connectivity.

This is the hidden financial pivot. The public story is reusable rockets and global broadband, but the cash story is AI compute. If you annualized Q1 2026 AI capex, you would get roughly $30.9 billion. I do not mean that as a forecast; I mean it as a gut check on scale. At that run rate, the entire $74.4 billion IPO proceeds would cover less than ten quarters of AI capex before you even talk about Starship, satellites, working capital, debt, or whatever comes next.

That is why the proceeds matter more than the valuation headline. SpaceX is raising war-chest money, and a lot of that war happens far from the launchpad.

The “space data center” idea has moved into the filing

The strangest line in the filing is easy to miss because it appears in the definitions and business description, the sort of section most investors skim while looking for revenue tables.

SpaceX defines “orbital AI compute” as AI infrastructure deployed in space, with satellite constellations acting as orbital data centers that use solar energy for power and the space environment for cooling. The company says it expects to begin deploying orbital AI compute satellites as early as 2028. Elsewhere, the filing says SpaceX’s reusable rockets, satellite manufacturing, and operating expertise could enable massive AI compute satellite constellations, “with potentially millions of satellites,” for orbital data centers.

That word, millions, changes the mental model.

Starlink today is already enormous, with roughly 9,600 broadband and mobile satellites in low Earth orbit as of March 31, 2026, according to the S-1. Investors can understand that model well enough: build satellites, launch satellites, sell connectivity. Orbital AI compute is a different animal. It asks investors to believe SpaceX can move part of the data-center stack off Earth, using solar power, space cooling, Starlink connectivity, and Starship-driven launch economics to solve bottlenecks that are becoming painful on the ground.

The vision is wild, but it does have a kind of internal logic. If AI becomes mostly a fight over power, chips, land, permitting, and cooling, SpaceX can argue that the physical bottleneck eventually moves to orbit. The catch is that a credible option is still only an option. There is no current revenue here, and this is no ordinary adjacency like enterprise Starlink.

What the S-1 gives investors is a 2028-and-beyond engineering promise attached to a company already spending billions per quarter on terrestrial AI infrastructure. I would not dismiss it as fantasy because SpaceX has made a career out of turning fantasy into hardware, but I also would not value it like a cloud business with proven margins.

The milestone that matters is not a prototype, a launch, or even one successful satellite. The proof would be paying workloads, recoverable unit economics, and a reason customers prefer compute in orbit over compute on Earth. Until then, orbital AI compute is narrative capital.

Terafab sounds like a moat, but the filing keeps it in pencil

Terafab is another buried clue. The S-1 describes it as a chip manufacturing initiative with Tesla and Intel, aimed at producing one terawatt per year of compute hardware. The goal is to extend vertical integration into chip design and manufacturing, reduce future chip shortages, optimize compute performance, and potentially lower compute costs.

You can see why that line matters. If xAI needs compute, compute needs chips, and chips are the constraint, then Terafab becomes the dream answer. It suggests that SpaceX is trying to push vertical integration all the way down into the silicon layer.

But the S-1 adds a sentence investors should sit with for a minute. SpaceX says it has agreed with Tesla on a general framework for the future development of Terafab, while any specific projects under that framework will be subject to separate negotiations and agreements, including development timelines, milestones, and capital expenditures. Those details have not yet been determined.

That distinction is bigger than it looks. A framework is not a fab, a concept is not capacity, and a related-party collaboration is not the same thing as owning a finished supply chain.

This matters because the SpaceX AI thesis leans heavily on control of the physical stack: chips, data centers, power, launch, satellites, and distribution. Terafab is supposed to help solve the chip layer, but the document itself tells you that the important commercial details are still future negotiations. That does not make the project fake. Early industrial projects often begin exactly this way. It does mean investors should treat Terafab as a watch item rather than a completed moat.

If future filings show binding commitments, capex budgets, production milestones, Intel manufacturing terms, Tesla economics, and actual compute hardware output, the story gets stronger. If Terafab remains a beautiful phrase with no hard numbers behind it, then it is a supporting character in the valuation fantasy.

The satellite accounting assumption is quietly worth hundreds of millions

SpaceX’s financials depend on hardware lasting as long as management thinks it will last, which sounds obvious until you see the sensitivity. The S-1 says that if the average useful life of satellite assets changed by one year, operating income would move by about $480 million for 2025 and $170 million for Q1 2026.

That is a serious footnote because Starlink is the cleanest business in the filing. It has scale, recurring revenue, real demand, and operating income. But satellites are not SaaS servers sitting in a rack that you can baby for a decade. They live in orbit, degrade, get replaced, and sometimes become economically stale before they are physically dead because the network improves by launching newer generations.

The filing says SpaceX considers on-orbit performance, orbit-raise timing, service capability, constellation density, and technology evolution when estimating satellite lives. That is the right accounting framework, but it also means a lot of reported profit lives inside estimates. If Starlink’s future depends on faster replacement cycles, larger mobile constellations, newer V3 satellites, and eventually AI compute satellites, depreciation becomes part of the margin story.

This is where retail investors can get fooled by clean segment numbers. They see Connectivity income from operations of $4.423 billion in 2025 and think, “Great, this is the cash machine.” It may be, but for a satellite network, the useful-life assumption is one of the levers that decides how much of that machine shows up as profit today versus replacement cost tomorrow.

If you want to track Starlink like an owner, watch satellite useful lives, satellite capex, churn in older hardware, and whether depreciation starts catching up with the growth story.

SpaceX says it does not insure its in-orbit satellites

The insurance disclosure surprised me more than some of the flashier AI language. In the risk factors, SpaceX says it generally does not maintain as much insurance as many other companies do, and in some cases it does not maintain any at all. Then it gets specific: the company says it currently does not insure its in-orbit satellites and does not expect to insure them in the future.

That can sound reckless until you think like SpaceX. If you launch constantly, manufacture satellites internally, and treat the constellation as a replenishable system, insurance may be less attractive than self-insuring. Traditional satellite operators protect a small number of extremely expensive assets; SpaceX operates a swarm.

That may be rational, but it also moves the risk directly onto shareholders. A solar storm, debris event, design flaw, launch anomaly, regulatory grounding, or unexpected replacement cycle does not get softened by an insurance recovery if the assets are uninsured; it hits the business.

This is another reason the IPO is harder to value than a normal tech listing. SpaceX has built a system where speed, scale, and vertical integration reduce some risks while concentrating others. The company can absorb losses that would kill a slower competitor, which is the bull case. The bear case is that investors may be buying a business where the operating philosophy is “move fast because we can replace the hardware,” while the valuation assumes those replacement economics remain friendly for a very long time.

Those two ideas can coexist, but they should not be priced as if they were the same thing.

The bridge loan tells you the company already used private-market oxygen

The balance sheet also has a timing clue. As of April 30, 2026, SpaceX had $20 billion outstanding under the SpaceX Bridge Loan, which matures on September 2, 2027, subject to extension. The company also had no borrowings outstanding under its SpaceX Credit Facility as of April 30, and that facility was amended in May 2026 to increase borrowing capacity to $5 billion and extend maturity to May 19, 2031.

This does not read like a liquidity panic. The company had significant cash and marketable securities, and it expects to add a massive amount of IPO proceeds. What it does show is the funding rhythm.

SpaceX is already operating like a mega-cap industrial AI company before public investors get a full public-company track record. It uses equity, debt, bridge financing, credit facilities, sale-leaseback-like obligations, and related-party arrangements, which is what you would expect from a company trying to build rockets, satellites, data centers, AI models, and maybe orbital compute all at once.

The question is whether public investors understand what kind of balance sheet they are buying. A normal software investor thinks in gross margin and operating leverage. A SpaceX investor has to think in launch cadence, satellite replacement cycles, AI capex, debt refinancing, energy infrastructure, spectrum transactions, and whether each new moonshot can keep feeding the next one without making the capital stack too heavy.

That is a different skill set.

Campbell Harvey’s index warning makes the float structure more interesting

Campbell Harvey is a finance professor at Duke’s Fuqua School of Business, best known in mainstream market circles for his work on the yield curve as a recession signal and for a long career studying asset pricing and portfolio construction. He belongs in a SpaceX IPO discussion for a simple reason: one of his recurring critiques of market-cap-weighted investing applies almost perfectly to a giant, low-float IPO.

His broader argument is that passive money does not ask whether a stock is cheap; it buys more of whatever the market has already made large. If a company enters the public market at a huge valuation and then gets pulled quickly into major indexes, the buying can become mechanical at exactly the moment price discipline matters most.

That matters for SpaceX because the float is tiny relative to the headline valuation. The offering is expected to raise roughly $74.4 billion against a company people are already discussing in trillion-dollar terms. In plain English, public investors may only get a small slice of the company at first, while the valuation of the whole enterprise is set by that small slice.

This is where Harvey’s warning becomes practical rather than academic. If SpaceX trades well after listing, index committees and passive vehicles can become forced buyers. The faster the index path, the more the market structure starts to matter. A stock can be expensive, become more expensive because passive demand has to buy it, and then use that very price action as proof that the IPO was “obviously” a success.

None of that makes SpaceX a bad company. It means the public-market setup may be unusually favorable to the sellers and early holders. Private investors captured the long compounding arc from impossible rocket startup to dominant space infrastructure company; retail and passive investors may be arriving when the story is already enormous, the AI capex burden is already visible, and index-driven demand could make valuation discipline harder rather than easier.

This is the part I would connect to the $74.4 billion raise. The IPO does two things at once: it gives SpaceX capital for the next infrastructure layer, and it creates a public security that large pools of passive money may eventually have to own. That is a powerful combination, but it is not automatically a bargain for the investor who buys after the first-day excitement.

The controls section matters because the company is becoming a public conglomerate overnight

There is a dry section in the risk factors about internal controls, and most people will skip it even though they should not.

SpaceX says that, as a private company, it was not required to evaluate internal control over financial reporting under public-company Section 404 standards. It says its internal controls currently do not meet all of the standards it will eventually have to meet. It also says it does not yet have comprehensive documentation of internal controls and has not yet tested those controls in accordance with Section 404, so it cannot conclude that it does not have a material weakness or a combination of deficiencies that could become one.

That is careful legal wording, not an admission that the numbers are wrong. Still, it matters because this is not a simple company becoming public. This is a company that just absorbed xAI and X into the financial story, reports across Space, Connectivity, and AI, operates across 164 countries and markets, uses complex cost-to-cost accounting for contracts, depreciates reusable rockets and satellites based on estimated lives and flight counts, and is asking investors to underwrite long-horizon orbital infrastructure.

In a business this complicated, controls are more than back-office housekeeping. They are how investors know what they own. A 2026 buyer should watch the first two annual reports like a hawk: material weaknesses, segment disclosures, related-party accounting, capex classification, useful-life changes, and whether the company becomes more transparent or less transparent after the IPO pop.

The actual hidden bet

Dami’s piece is right to focus on valuation, xAI losses, ARPU pressure, retail allocation, and governance. Harvey’s concern sits on the market-structure side of the same trade. Those are obvious red flags once someone points at them, but the deeper bet may be even stranger.

The S-1 asks for more than belief in launch dominance or Starlink growth. It asks whether Elon Musk’s companies can turn physical infrastructure into the control layer for AI: launch lowers the cost of orbit, Starlink creates distribution, X creates data and consumer surface area, xAI creates models, COLOSSUS creates terrestrial compute, Terafab is supposed to attack the chip bottleneck, orbital AI compute is supposed to attack the power and cooling bottleneck, and Starship is supposed to make the whole system cheap enough to scale.

That is the pitch hiding underneath the rocket-company branding.

If it works, SpaceX becomes one of the strangest companies ever listed: part aerospace prime, part telecom carrier, part cloud infrastructure provider, part AI lab, part social platform, part planetary industrial project. If it fails, the profitable and semi-profitable pieces may spend years funding experiments whose economics never quite catch the story.

So I would not frame the IPO as “SpaceX good or SpaceX bad,” which is too childish for a company this unusual. I would frame it this way: are you buying the cash flows that exist, or are you financing the infrastructure Musk needs for the next version of the empire?

Both can be valid, but they deserve different prices.

What I would track before touching the stock

I would watch six things: AI capex per quarter, orbital AI compute milestones, Terafab commitments, satellite depreciation, internal-control disclosures, and the index-inclusion path.

On AI capex, the question is whether spending stays anywhere near Q1 2026 levels, because then the IPO proceeds are fuel rather than a cushion. On orbital AI compute, I would want to see real customer workloads and unit economics instead of more language about solar power and space cooling. On Terafab, a framework with Tesla is interesting, but binding agreements, production milestones, capex budgets, and chip output would matter more. On Starlink, satellite depreciation and replacement cycles will tell you whether reported profitability keeps matching the physical life of the network. On controls, the first public-company reporting cycles will show whether this thing can be understood from the outside. And on market structure, I would watch float, lockups, index eligibility, passive-fund flows, and whether early price action is being driven by owner-like conviction or by funds that have to buy because the index says so.

That is the trade, at least to me. Forget Mars, memes, and the opening-day pop for a minute. The trade is whether the world’s best launch company can become the physical operating system for AI before the capital intensity eats the upside.

For the better part of a year now, the stock market moves less on earnings reports or Fed statements and more on one thing: whatever Donald Trump says next.

I’m not picking a side here. But look at the data from his second term, which began January 2025, and the pattern jumps out. The volatility is one thing. What’s more interesting is how several of Trump’s public statements, read a certain way, acted almost like signals. For investors paying close attention, those signals may have created real opportunities.

Let me walk through what happened, what it means, and what a close listener might learn.

The April 9 Episode: “THIS IS A GREAT TIME TO BUY!!!”

On the morning of April 9, 2025, the S&P 500 was coming off one of the worst weeks in modern market history.

It started with Liberation Day, April 2, when Trump announced sweeping tariffs that raised effective U.S. rates from around 2.5% to well over 20%. That is the highest level since 1910. Markets panicked. Over the next four trading days, the S&P 500 lost roughly $4 trillion. The Nasdaq entered bear market territory. The kind of sell-off that makes you question whether you understand the market at all.

At 9:37 a.m. on April 9, Trump posted on Truth Social: “THIS IS A GREAT TIME TO BUY!!! DJT.”

At that moment, stocks were wavering between gains and losses. Nobody outside the White House knew what was coming next.

Less than four hours later, Trump announced a 90-day pause on nearly all his tariffs. Stocks exploded. The S&P 500 closed up 9.5%, its best single day since the 2008 crisis. The market regained roughly $4 trillion in a single session.

Here’s the uncomfortable question: did Trump know what he was about to do when he made that post? He told reporters he’d been thinking about it “over the last few days” and decided “fairly early this morning.” Suspicious timing. Ethics experts called for an investigation. Proving insider trading by a president using his own platform is nearly impossible.

Regardless of intent, the result is what matters. Anyone who saw that post, believed it, and bought before the tariff announcement made a lot of money in a single day.

As for the stock ticker, well, there’s another layer. DJT is also the symbol for Trump Media and Technology Group. The stock closed up 22.67% that day, more than double the broader market’s gain. A company that lost $400 million the previous year, seemingly disconnected from whether tariffs would be paused or not. Trump’s 53% stake, held in a trust managed by his son, rose by $415 million in a single session. Was he talking about stocks in general or his own stock? The White House didn’t clarify.

This is the clearest example so far of what I’ll call a Trump public signal.

The Pattern That Followed

April 9 was not an isolated event.

On May 8, with markets still recovering, Trump told reporters “it’s time to buy” again. Days later, the U.S. and China announced they would slash tariffs for 90 days. Markets rallied hard. The S&P 500 gained roughly 14% from the April 9 low through late May, the strongest 21-day rally of either Trump term (excluding the pandemic era).

Trump kept going. On May 6, 2026, he posted on Truth Social that the stock market hit “an ALL-TIME HIGH TODAY.” A few days later he told reporters the market “is going to go a lot higher.” He talked about an “explosion of investment and jobs.”

By late May 2026, the Dow closed above 51,000 for the first time. The S&P 500 had gained more than 33% in total return since the November 2024 election. All that chaos, and the market kept climbing.

Fundstrat data shows something startling: Trump has been responsible for all five of the best market days and all five of the worst in his second term. Without those five best days, the S&P 500 would be just 1% higher since he took office. With them, it is up 23.5%. The market is effectively a one-man show.

Hardika Singh, an economic strategist at Fundstrat, said something I keep thinking about: “The only strategy investors need to follow is don’t fight the White House, because you’re going to lose and you’re not going to make any money. Throw out your old investing playbook.”

The Other Side: One Post, $2 Trillion Gone

But signals work both ways.

On October 10, 2025, the S&P 500 was a few points from another all-time high. At 10:57 a.m., Trump posted a 500-word Truth Social message about China becoming “very hostile” over rare earth metals. The key line: “One of the policies that we are calculating at this moment is a massive increase of tariffs on Chinese products.”

That single post wiped out roughly $2 trillion in market value. The S&P 500 lost 2.7%. The Nasdaq dropped 3.56%. Nvidia fell 5%. AMD dropped nearly 8%. Apple lost 3%.

The market had been pricing in a Trump-Xi meeting at the upcoming APEC summit with hopes for a trade detente. One post changed everything. Within hours, the consensus flipped from “things are improving with China” to “all-out trade war is back.”

This volatility defines Trump 2.0. If you can lose $2 trillion in a day from a single social media post, can you also profit from reading the signals right?

Some investors are starting to think so. The pattern has created a strange dynamic on Wall Street. Carson Group’s chief market strategist Ryan Detrick told CNBC: “News trumps charts. We’ve been in a very headline-driven world, headline-driven market, and investors have just had to kind of strap on and get on the roller coaster and go along with it.”

Interactive Brokers’ chief strategist Steve Sosnick found that investors who sold on Trump’s Liberation Day announcement and were slow to buy back underperformed those who didn’t. That has created what he calls “a general reluctance of institutions, broadly speaking, to sell too aggressively.” The fear of missing out is now institutional, not just retail.

The Iran Wildcard

In early 2026, a new variable entered the picture: war with Iran.

The U.S.-led military conflict that began in late February 2026 sent oil prices soaring. The Strait of Hormuz, where about 20% of the world’s oil flows, was effectively shut down. U.S. gasoline prices pushed above $4 per gallon. Markets swung between hope and panic.

Then on April 7, 2026, Trump posted on Truth Social that he was suspending bombing for two weeks. The Dow surged more than 1,000 points in early trading. Oil prices plunged. European travel stocks rallied 7%.

The ceasefire was extended, then put on life support. Markets rose on each extension, fell on each threat. By late May, all three major U.S. indexes hit simultaneous intraday records on Iran deal optimism and a surge in AI-related tech stocks.

For the attentive investor, the pattern was clear: Trump’s statements on Iran moved oil, defense, and broad market indices in predictable directions. If you could read the timing, you could position accordingly.

Sectors That Moved

Several sectors showed clear reactions to Trump policy signals throughout his second term.

Energy swung violently with the Iran conflict. Oil stocks rose on war escalation, fell on ceasefire. The long-term tailwind from domestic production deregulation stayed intact.

Defense and industrials benefited from increased military spending and a renewed focus on domestic manufacturing. Tariff protection of U.S. industry created a persistent bid.

Financials and banks gained from deregulation signals and the One Big Beautiful Bill Act, which lowered corporate tax rates. Bank stocks broadly outperformed during tariff reprieve announcements.

Crypto and digital assets found a friend in the White House. Trump’s pro-crypto stance, including executive orders on digital asset regulation and his media company’s forays into the space, kept the sector bid.

Small caps outperformed during the recovery from the April 2025 low. They rose more than 66% through mid-2026, as investors bet that tariff and deregulation policies would benefit domestic-oriented companies.

Big Tech and AI remained the dominant force. The S&P 500 rally was increasingly an Nvidia rally, or at least a Big Tech rally. AI capital expenditure kept growing, and earnings for mega-cap tech names kept beating expectations.

What Happens If Someone Listens Closely?

Let’s start with the upside.

An investor who followed Trump’s April 9 “great time to buy” signal and bought the S&P 500 at the bottom would be sitting on substantial gains. Someone who bought the dips during Iran ceasefire announcements and sold into the extensions would have captured significant short-term moves. Someone who monitored tariff-related social media posts and positioned ahead of policy pivots could have navigated the whipsaw with better timing than the crowd.

Now the downside.

Whipsaw risk is enormous. Trump’s posts create violent two-way moves. Buy on a signal, and the next post reverses the whole trade. October 10 is the textbook example: stocks at all-time highs, one post erased $2 trillion, anyone who bought the pre-post rally was underwater.

False positives are real. Trump posts about the market constantly. Most is bluster. Only a subset correlates with actual policy shifts. Distinguishing signal from noise is harder than it looks.

Crowded trades form quickly. When thousands of retail investors pile in after a Trump post, the easy money gets compressed. By the time you act, the move may already be priced in.

Policy reversal risk is baked into the structure. The 90-day tariff pauses are temporary. The structural tensions with China haven’t gone away. The ceasefire with Iran is fragile. What works today can reverse tomorrow.

Event timing risk means you don’t control the clock. Trump posts at random hours. Policy announcements come without warning. You can’t set alerts for something that doesn’t follow a schedule.

Legal and ethical caveats matter. Trading on a president’s public statements is legal. But following a political figure’s market calls raises questions: are you benefiting from non-public information? Are you comfortable with the implications? Is the strategy sustainable when administrations change?

The Monitoring Playbook

If someone wanted to watch for these signals, here is how they might do it.

Feeds to monitor: Truth Social (Trump’s account is the primary channel), White House press briefings, public remarks at rallies and press conferences, and the administration’s official trade policy announcements.

Keywords to track: “buy,” “great time,” “massive” (tariffs), “pause,” “deal,” “talks progress,” “all-time high,” “Liberation Day,” names of countries (China, Iran, Vietnam, EU).

Timing windows: Major tariff announcements cluster around deadlines and summits. Trump tends to make market-moving posts in the morning before or during trading hours. The Iran ceasefire was announced just before an 8 p.m. deadline.

Sector mapping: Iran and oil signals point to energy. Tariff escalation signals point to defense, domestic manufacturing, small caps. Tariff de-escalation points to tech and China-exposed stocks. Deregulation points to financials and crypto. General bullish market calls point to broad index plays.

Confirmation signals: Watch for follow-through. A single Trump post is noise. A post followed by a policy announcement within hours or days is a signal. Multiple posts on the same theme increase the odds of an actual policy move.

Risk controls: Don’t go all-in on one signal. Size positions knowing reversal is possible. Use trailing stops if trading individual sectors. The best trades are often the ones where the signal aligns with underlying economic fundamentals, not just political theater.

The Bigger Picture

This is a structural change in how markets operate.

Previous administrations communicated through official channels, carefully worded statements, and scheduled press briefings. Markets processed information slowly. Predictability was built into the system.

Trump changed that. His communication is direct, frequent, and unpredictable. It moves markets in ways that would have been unthinkable a decade ago. One strategist put it simply: “Don’t fight the White House, because you’re going to lose and you’re not going to make any money.”

Another analyst called it the end of the old investing playbook.

Maybe that overstates it. Earnings, interest rates, and economic fundamentals still matter. The S&P 500’s 28% earnings growth in Q1 2026 wasn’t driven by Twitter. It was driven by actual business performance. The AI boom is real. Consumer spending remains strong.

But here’s what I keep coming back to. In Trump’s second term, the five best market days and the five worst were all driven by his actions. Without those five best days, the S&P 500 would be just 1% higher since he took office. With them, it’s up 23.5%.

That is not coincidence. That is concentration of market-moving power in one person.

The question for investors isn’t whether this is good or bad. It’s whether you’re prepared to operate in a market where the most important variable is what one person says next. If you can monitor, interpret, and act on those signals with discipline, risk controls, and a clear understanding of the limitations, the opportunities are real.

If you can’t, the volatility will eat you alive.

Either way, the market has changed. Pretending it hasn’t is the riskiest position of all.

This is not investment advice.

Source Framework

Categories of sources used:

• Major financial news organizations: CNBC, NPR, Bloomberg, Reuters, The Associated Press, PBS NewsHour, NBC News

• Investment research firms: Fundstrat Global Advisors, CFRA Research, U.S. Bank Asset Management, Morgan Stanley

• Policy research institutes: Peterson Institute for International Economics, Council on Foreign Relations, Center for Strategic and International Studies

• Market data sources: S&P 500 index performance, Dow Jones Industrial Average, sector performance data via CNBC and U.S. Bank reporting

• Direct primary sources: Donald Trump’s Truth Social posts (quoted via news reporting), White House press statements, U.S. Trade Representative documents

They call it Jane Street.

Back then, exchange-traded funds were not a revolution anyone was watching. The SPY — the first U.S. ETF tracking the S&P 500 — had been around since 1993, but by 2000 the entire global ETF market sat at roughly $70 billion in assets under management. That is less than 1% of what mutual funds held. To most of Wall Street, ETFs were an oddity: a hybrid structure that seemed to combine the worst of both worlds — the complexity of a mutual fund basket with the relentless volatility of a stock ticker.

Nobody understood them. Nobody built systems for them. Nobody knew how to price them when the underlying basket was moving faster than the ETF itself, or when an obscure sector ETF drifted into a 2% premium because a flood of retail buyers piled in and the authorized participants had not caught up. The established firms looked at ETFs and saw complexity without scale — a product that could not possibly justify the operational overhead.

Jane Street saw the opposite: a structural inefficiency that would only grow as the product itself grew. If you could price it better, execute faster, and manage the inventory smarter than anyone else, each trade was a near-riskless arb. And since nobody else was doing it, the spreads were wide enough to make the unit economics work even at modest volume.

The Creation-Redemption Machine

The beauty of an ETF lies in its creation-redemption mechanism — a structural arbitrage that keeps the ETF price tethered to the value of its underlying assets. When demand pushes an ETF to a premium above its net asset value, an AP can buy the basket of underlying securities, deliver them to the ETF issuer in exchange for newly created ETF shares, and sell those shares at the higher market price. When the ETF trades at a discount, they reverse the flow: buy the cheap ETF shares, redeem them for the underlying basket, and sell the individual securities.

The spread captured in each cycle was often tiny — fractions of a cent. But none of the big banks wanted to touch it. The operational complexity was absurd: you needed to price the basket in real-time, execute across multiple venues, manage settlement risk, track corporate actions on every single name, and do it all faster than anyone else. It was un-sexy, infrastructure-heavy work that required custom systems, quantitative models, and a tolerance for operating in a market so early that the rules were still being written.

Jane Street built those systems. They wrote their own tools, optimized their own compilers for latency, and developed pricing models for every ETF on the American Stock Exchange. When ETFs exploded — first into sector funds, then international, then fixed income, then smart beta, then active — Jane Street was there with the infrastructure already in place. They went from a tiny office to a firm trading tens of billions daily across 200+ venues, generating trading revenue that would peak above $30 billion in a single year.

The pattern is a familiar one in financial history: a structural innovation that the incumbents dismiss as too small, too niche, or too complicated; a small group of players who build the plumbing before anyone else; and then the wave hits. When it does, the early builders own the infrastructure, the relationships, and the economic intuition. They scale. Everyone else plays catch-up.

The Same Pattern, Twenty-Five Years Later

Tokenized real-world assets — RWAs — sit today where ETFs sat in 2000.

The numbers are strikingly parallel. By the first half of 2026, the total value locked across all tokenized assets on-chain (excluding stablecoins) had grown to roughly $31 billion, according to RWA.xyz and CoinGecko. That is up from around $6 billion at the start of 2025 — a 5x increase in sixteen months. Tokenized U.S. Treasury products alone crossed $15 billion in May 2026, with BlackRock’s BUIDL fund nearing $2.5 billion, Franklin Templeton’s BENJI at over $400 million, and Circle’s USYC becoming the single largest on-chain Treasury product at roughly $2.9 billion. On-chain private credit — loans originated off-chain and tokenized on-chain — has grown to roughly $5–6 billion in outstanding value, with protocols like Centrifuge, Maple Finance, and Goldfinch collectively financing over $3 billion. The numbers are still small compared to the $70 trillion-plus global asset management industry. But so were ETFs in 2000.

Boston Consulting Group projects that the tokenized asset market could reach $16 trillion by 2030. McKinsey offers a more conservative estimate. Even the lower end of those projections implies a market that grows by orders of magnitude — not unlike what ETFs delivered.

RWAs are not a crypto-native curiosity anymore. They are the frontier where traditional finance’s biggest structural bottlenecks — settlement delays, illiquid private markets, high minimums, fragmented clearing — meet blockchain’s native capabilities: 24/7 settlement, programmable ownership, composable collateral, global accessibility. The creation-redemption parallel for ETFs maps directly onto the mint-and-burn cycle of tokenized funds. An authorized participant delivers a $1 million T-bill to a custodian; the issuer mints a corresponding number of RWA tokens on-chain. The AP can then trade, lend, or use those tokens as collateral in DeFi protocols while the underlying Treasury earns yield. The structural arbitrage that Jane Street exploited in ETFs — pricing gaps between the instrument and its underlying — already exists in RWAs, but with fatter spreads and fewer competitors.

Where the Edges Are Today

Tokenized Treasuries and the Liquidity Stack. The most mature RWA category is also the most analogous to early ETF market making. Products like BUIDL, OUSG, BENJI, and USYC offer daily redemption windows and trade on secondary markets across Ethereum, Solana, and other chains. The spreads between on-chain price and NAV can be wider than any equivalently sized ETF because liquidity is thinner and the redemption mechanism is still manual or T+1 for many funds. For a builder, the opportunity is not just to make markets but to build the infrastructure layer that makes tight market making possible: real-time NAV oracles that price the underlying basket faster than the competition, smart-contract hooks that automate the mint-burn cycle with custodians, and settlement rails that handle the handoff between blockchain and traditional clearing. The teams that own this plumbing will capture a compounding advantage — each new tokenized fund that launches becomes another venue to trade, another data feed to optimize, another client relationship to deepen.

Private Credit and the Origination-to-On-Chain Pipeline. This is where the economic potential is largest. The global private credit market is estimated at over $2 trillion. Tokenization converts illiquid, lock-up-based loan portfolios into tokens that can be traded, used as collateral, and tracked transparently. The structural friction today is enormous: due diligence, legal documentation, custody, compliance. For market makers and liquidity providers, the arbitrage opportunity lives in the gap between the yield earned on the underlying private credit pool (often 8–15%) and the yield required by token holders in secondary markets. A firm that can price the risk of a pool of fintech receivables better than the market can earn a persistent structural edge — just as Jane Street earned an edge pricing ETFs against their baskets. For builders, the hard work is upstream: building the origination pipeline that produces clean, audit-ready pools; standardizing the legal wrappers; connecting on-chain capital to off-chain loan origination systems. The protocols that solve these integration problems — and there are not many yet — will be the ones that attract both institutional supply and DeFi demand.

On-Chain Collateral and The DeFi Flywheel. Tokenized Treasuries are increasingly used as collateral in DeFi lending markets. Aave Horizon, Morpho, and Spark are all actively integrating RWA collateral. This creates a hybrid arbitrage opportunity: borrow stablecoins against tokenized T-bill collateral at one rate, deploy the stablecoins into higher-yielding strategies, and capture the spread. The entire loop is programmable, which means automation can shrink it to milliseconds. The infrastructure to do this at scale — oracles for fair-value pricing of tokenized funds, liquidation engines that work across traditional and on-chain settlement, multi-chain bridges for collateral mobility — is still being built. The teams building it now are the ones writing the standardized AP agreement for a market that does not yet exist in final form. For investors, the opportunity is subtler: tokenized Treasuries offer a crypto-native way to earn risk-free-ish yield — currently 3–5% — that can sit in a wallet, be used as collateral, and be moved between protocols without banking hours. That simple composability unlocks strategies that are impossible with a traditional money market fund.

Custody, Compliance, and the Regulatory Bridge. The single biggest unlock for RWA market making will be regulatory clarity. The U.S. has made meaningful progress in 2026, with the SEC, CFTC, and various state-level frameworks moving toward definitions that accommodate tokenized securities. The European Union’s MiCA framework is already live. Singapore, the UAE, and Hong Kong have all established regulatory sandboxes. The players who invest early in compliance infrastructure — KYC/AML integrations between on-chain identity and off-chain custodians, legal frameworks for cross-jurisdictional token transfers, tax reporting for tokenized fund flows — are not sexy. But they own the bottleneck. Every AP in the ETF ecosystem needs a prime broker, a custodian, and a legal team. The RWA equivalent is not yet standardized. The protocols and service providers that build these bridges — connecting TradFi custody rails like BNY Mellon or State Street to on-chain transfer agents, or building wallet infrastructure that satisfies both SEC custody rules and smart-contract composability — will capture structural rents for a long time.

Cross-Chain Liquidity and Settlement. This is the RWA equivalent of Jane Street trading across 200+ venues. A tokenized Treasury fund may trade on Ethereum at one price and on Solana or Avalanche at another. The bridging costs today are high, the settlement times are slower than pure on-chain transfers, and the risk of bridge hacks is real. But infrastructure for cross-chain atomic settlement is improving rapidly — projects building intent-based bridging, canonical bridges for institutional-grade assets, and settlement layers that abstract away the underlying chain entirely. The firms that build the fastest, safest cross-chain market-making engines will capture the same multi-venue edge that defined Jane Street’s dominance. For market makers, this is the most directly analogous opportunity to 1999-era ETF arb — except the venues are blockchains instead of exchanges.

Issuer and Platform Economics. For the protocols and platforms that issue tokenized assets, the long-term opportunity resembles the ETF issuer business. Once an issuer — BlackRock, Franklin Templeton, Ondo, or a newer entrant — establishes a tokenized fund with meaningful AUM, switching costs are meaningful. Integrations get built around that fund’s specific contract address. DeFi protocols write liquidations engines calibrated to that fund’s redemption schedule. Custodians build workflows for that fund’s compliance rules. The early issuers that reach escape velocity create moats that are hard to cross. For crypto-native protocols like Centrifuge or Ondo, the question is whether they can retain their first-mover position once traditional asset managers fully enter the space. For a builder, the window to integrate deeply with these growing protocols is open now, before the integration patterns harden.

Who Is Playing

The cast of characters is telling. BlackRock — the world’s largest asset manager, with over $11 trillion in AUM — launched BUIDL in 2024 and has since expanded it to nine blockchains. Franklin Templeton runs its BENJI fund on Ethereum and Stellar. JPMorgan operates Kinexys (formerly Onyx), a blockchain platform that has processed over $1 trillion in repo transactions and now handles tokenized money market funds on Ethereum. Ondo Finance has built a bridge between tokenized Treasuries and DeFi, with its OUSG and USDY products serving as the primary on-chain collateral for multiple lending protocols. Figure Technologies has originated over $1 billion in HELOCs per month on its Provenance blockchain and operates what it calls the On-chain Public Equity Network (OPEN). Centrifuge, backed by Coinbase, provides the tokenization infrastructure for institutional funds. Together, these are not fringe experiments — they are the largest names in global finance placing active bets.

The pattern is unmistakable: when the largest asset manager, the largest bank, the largest ETF issuer, and a cohort of crypto-native protocols all converge on the same infrastructure thesis, the market is past the pilot phase.

What History Suggests

ETFs went from $70 billion in 2000 to over $1 trillion by 2010, $7 trillion by 2020, and beyond $20 trillion today. The CAGR from 2008 onward was over 20% — a multi-decade compounder that turned early infrastructure bettors into the dominant firms in global markets. Jane Street, Citadel Securities, and Optiver all grew into their current scale largely because they built for ETFs before the wave hit.

Tokenization follows a similar structural logic: it reduces friction in markets with the deepest inefficiencies — private credit, real estate, fund distribution, cross-border settlement. Each of those verticals is measured in trillions. A technology that reduces settlement time from T+2 to instant, or makes a $100 million private credit pool as tradable as a stock, does not just improve existing markets. It creates new ones.

The risks are real and should not be papered over. Smart contract vulnerabilities remain a concern — a single exploit on a major RWA bridge could set adoption back a year. Regulatory fragmentation across jurisdictions creates uncertainty for issuers and market makers who need to operate across borders. Redemption delays are an open issue: some tokenized funds advertise daily redemptions but execute them off-chain with a manual review step, creating a gap between the promise of instant settlement and the reality of operational friction. And the base layer is still volatile — a sustained crypto bear market would dry up a significant portion of the demand side, even if the underlying assets remain sound.

But these are the same kinds of risks that surrounded ETFs in their early years: uncertainty about how the creation-redemption mechanism would hold up under stress, questions about whether index-tracking would ever replace active management at scale, fears that a liquidity crisis would expose structural flaws in the ETF wrapper. Each time, the market adapted. The infrastructure hardened. The products grew.

The Window Is Open

The analogy is not perfect. ETFs were a distribution innovation wrapped in a regulatory vehicle. RWAs are an infrastructure innovation wrapped in a technology stack. The regulatory path for RWAs is murkier, the technology is newer, and the market is far more fragmented. But the structural similarity — a product with built-in creation-redemption arbitrage, serving an enormous latent demand, operating in a market where the infrastructure is being built in real-time by a small group of early movers — is close enough to be instructive.

Twenty-five years from now, we may look back at the mid-2020s as the moment when a handful of firms built the rails for a market that went from $30 billion toward tens of trillions. The firms that understood the analogy — that saw tokenized RWAs not as a crypto fad but as a structural market evolution, the way Jane Street saw ETFs — stand a strong chance of being the ones who built the infrastructure, wrote the playbooks, and captured the compound advantage.

A close reading of the ETF precedent, the institutional momentum visible today, and the economic logic underpinning tokenization all point in the same direction — but analogies are directional, not deterministic. Every structural shift carries forks where adoption stalls, regulation bifurcates, or a better technology emerges. What made Jane Street’s bet work was not just that they were right about ETFs, but that they were early, they were relentless about infrastructure, and they kept compounding their edge across market cycles.

The question that matters for anyone reading this — builder, investor, market maker, institution — is the same one the Jane Street founders asked themselves in 1999: if this product is going to be bigger than anyone thinks, what should I be building today? Not everyone who answers that question will win. But the ones who do not ask it at all have already decided their outcome.

“Ethereum is weak af.”

“ETH is finished, I’m leaving this shit.”

“Ethereum is falling apart.”

By the end of May, ETH was trading around $2,000, down roughly 60% from its August 2025 high near $5,000. The ETH/BTC ratio had fallen to around 0.027. Gas fees were below 2 gwei, close to cycle lows. The depression in the Ethereum community felt real. I haven’t seen this kind of exhaustion in a long time.

But here’s the strange part.

In the middle of that same ugly sentiment, something else was happening.

BlackRock’s tokenized funds were expanding across Ethereum and other compatible networks.

JPMorgan had just launched its second tokenized money market fund on Ethereum.

A tokenization standard called ERC-7943 had just reached Final status in the Ethereum ecosystem.

Stablecoin value on Ethereum had climbed past $170 billion.

Ethereum plus its L2 ecosystem was processing around 27 million transactions a day.

When I look at those numbers next to that level of despair, I don’t see death.

I see opportunity.

Sentiment collapsed. Adoption did not.

Ask anyone who has been in crypto over the past six months what went wrong with Ethereum, and they’ll give you ten different answers.

Technically, some people say Solana and Sui are better software. Narratively, people say the “ETH is money” thesis is dead. On governance, Ethereum Foundation departures have been framed as a “generational handoff.” On price, even Bankless co-founder David Hoffman said something brutal in late May:

“Ethereum got the ETH price it deserves.”

He even joked, in effect, that maybe the move happened because he had just sold the last of his ETH.

When the true believers start doubting themselves, you know sentiment has gone below freezing.

But there’s one distinction most people are missing.

The market is pricing ETH like a company. It looks at fee revenue, onchain activity, and short-term active users. When those numbers cool down, the price follows. That’s intuitive. It’s also linear thinking.

What Ethereum is becoming cannot be understood through the lens of quarterly revenue.

Why would BlackRock use Ethereum for tokenized funds? Why would JPMorgan come back a second time? Why did Standard Chartered’s analyst say in January 2026 that “2026 will be the year of Ethereum, much like 2021 was”?

None of these institutions showed up because ETH gas fees were rising.

They showed up because Ethereum is becoming financial infrastructure.

TradFi is turning every asset into a token

This is the part people keep underestimating.

RWA.xyz data shows that by May 2026, the total value of tokenized assets globally had already passed $360 billion. Stablecoins made up the largest share, close to $300 billion. But the real story is not today’s number. It’s the direction of travel.

U.S. Treasuries are being tokenized. Money market funds are being tokenized. Private credit is being tokenized. Real estate is being tokenized. BlackRock’s BUIDL fund has grown past $2.4 billion and runs across Ethereum, Arbitrum, Optimism, Polygon, Avalanche, BNB Chain, Aptos, Solana, and other networks. JPMorgan put its second tokenized money market fund on Ethereum that same month.

You don’t need to exaggerate this.

The important point is simple: Wall Street has started treating Ethereum as a pipe that can carry real assets.

Think about what that means.

Traditional finance has barely changed its basic structure since the New York Stock Exchange was founded in 1792. Brokers take fees. Exchanges take fees. Custodians take fees. Clearinghouses take fees. Every layer sits in the middle. Every layer extracts something.

Ethereum offers a different model: a global, permissionless, programmable ledger. Many actions that used to require several intermediaries can be compressed into automated smart-contract workflows. Brokers, clearinghouses, and custodians will not disappear overnight. But their roles will be repriced.

That is the move from a 19th-century rhythm to a 21st-century rhythm.

It won’t happen in one night. But when JPMorgan launches a second tokenized fund on Ethereum in May 2026, that is not a little experiment. That is pipe-laying.

AI agents need dollars. The kind that live onchain.

There’s another piece many people have not connected yet.

Agentic AI, AI that can make decisions and execute tasks on its own, is quickly becoming real. And AI agents need money.

Imagine an AI agent managing your supply chain. It needs to pay suppliers automatically. Or a trading bot that needs to settle positions. Or a DePIN node that needs to receive rewards based on its contribution.

All of those paths lead to the same thing:

Programmable dollars.

That is what stablecoins are for. And that is why Ethereum sits in such an important position.

Visa is tracking stablecoin adoption. PayPal has issued PYUSD. Assets like USDC, PYUSD, and BUIDL, the ones that live more naturally in institutional and compliance conversations, have deep ties to the Ethereum ecosystem. USDT is also huge on Tron, so it would be wrong to say all stablecoins live on Ethereum. But if you look at the chains institutions are willing to name in public materials, Ethereum remains one of the most important.

Why stablecoins?

Because the dollar is the global reserve currency, and a stablecoin is the dollar with an API.

Any AI agent that needs to settle in dollars needs a place to hold, send, and receive those dollars.

Ethereum provides that place.

This does not mean other chains cannot matter. Solana is fast. Base is growing. But institutions choose Ethereum for a very simple reason: the longest operating record, high security, and the most mature ecosystem.

When you are managing billions of dollars in assets, you do not choose “newer and cooler.”

You choose battle-tested.

L2s are not competition. They are expansion.

Ethereum bears have one favorite argument: L2s are stealing activity and value from Ethereum.

It sounds reasonable.

It is also wrong.

Look at the numbers. In May 2026, Ethereum plus its L2 ecosystem was processing around 27 million transactions per day. Ethereum mainnet handled roughly 2.3 million. Base handled about 8.7 million. Polygon PoS handled about 7 million. Arbitrum handled about 1.3 million.

Activity did not disappear.

It modularized.

Ethereum’s strategy was never to run every transaction on mainnet. Mainnet is the settlement and security layer. L2s are the execution layer. Ethereum gives up some direct mainnet transaction volume in exchange for a massive increase in total ecosystem throughput.

This reminds me of Amazon in 2001. The stock fell 95% from its 2000 high. Everyone said the internet was a bubble and Amazon was finished. But what was Jeff Bezos doing? He was turning Amazon from an online bookstore into a platform. Standard Chartered made that comparison directly in May 2026: today’s ETH looks like Amazon in 2001.

While everyone is complaining about ETH’s price, Ethereum’s infrastructure is expanding: more L2s, more developers, more stablecoins, more institutional adoption. The gap between price and adoption will not stay open forever.

Now, the value-capture question is real.

ETH is not a stock. It is the native asset of the Ethereum network. It secures the network through staking. It pays for execution through gas. It is collateral across DeFi. It is an ETF and treasury asset. It is the anchor asset of the ecosystem.

Low L2 fees have weakened the old deflation narrative for ETH. But that narrative was too narrow anyway. Treating ETH as “fee revenue divided by supply” is like treating the dollar as “Federal Reserve profit divided by money supply.”

You miss the whole point of a monetary network.

Vivek Raman said it well: “Ethereum is not a company. It is global infrastructure.”

Why this deserves your attention

I want to be clear about something: Ethereum can succeed and ETH can still underperform. That is a real risk. It is possible Ethereum becomes a global financial settlement layer while ETH captures less value than investors expect.

But I think the more likely path looks different.

As more real-world assets settle on Ethereum, hundreds of billions, then trillions, and eventually tens of trillions of dollars in tokenized assets, the network’s security needs rise exponentially. The only way to secure Ethereum is to stake ETH. Staking rewards come from network activity. That creates a flywheel: more assets require more security, more security requires more staked ETH, more staked ETH reduces circulating supply, and more activity increases the value of participating in the network.

That flywheel does not show up in one month or one quarter.

But over 5 years, 10 years, 15 years, it becomes a structural trend.

Tom Lee said in May 2026: “If one is wondering why Ethereum has been under selling pressure, to me, rising oil prices is the biggest headwind.”

Do you see the point?

Short-term price action may have nothing to do with crypto fundamentals. Oil prices rise. Macro uncertainty rises. Risk assets get sold. Those forces can dominate daily and weekly moves.

But they are not the fundamental story.

Fundstrat’s conclusion was: “Crypto Spring, in our view, has commenced.” A close above $2,100 would help confirm that view.

I cannot predict tomorrow’s price. Nobody can.

But when an infrastructure network is being adopted by the world’s largest financial institutions, and sentiment is sitting at absolute despair, that is often one of the best moments of the decade to pay attention.

The last thing I’ll say

On May 1, a user named @Cryptotarzan19 wrote something that stuck with me:

“Ethereum is still being valued too much like a company, and not enough like global public infrastructure.”

He also wrote:

“$8,000 ETH in 2026 looks less like a crazy target and more like a conservative repricing.”

I do not know whether ETH reaches $8,000 in 2026. Maybe it does not.

But maybe five years from now, the important thing will not be whether that exact target was right. Maybe the important thing will be that this debate existed at all.

During DeFi Summer, nobody saw that by 2026 Ethereum would carry more than $170 billion in stablecoins while global tokenized assets would reach the $360 billion range.

In the same way, in 2026, while everyone is complaining about ETH, very few people can see that Ethereum is becoming a settlement layer for global finance.

That is how nonlinear change works.

There is a threshold between “interesting” and “obvious.” Once the world crosses it, it does not go back.

The people who make real money are not the ones rushing in when everyone is euphoric. They are the ones who can sit through the doubt, see the structural direction, and stay seated.

Risk note and disclaimer: Crypto assets are highly volatile and risky. This is personal opinion, not investment advice. Do your own research and assess your own risk before making any decision. For investors with a 5-year horizon or longer, short-term volatility may be noise, but only if you can actually hold for 5 years.

What if the market is looking at the wrong oil shortage?

Most people hear “oil shortage” and think crude. Tankers. OPEC. Gasoline. Some guy on CNBC standing in front of a chart of WTI.

That is the obvious trade.

The better trade may be smaller, uglier, and buried one layer deeper in the machine.

Lubricants.

Base oils.

Additives.

Re-refined supply.

The fluids that keep engines, turbines, compressors, hydraulics, factories, trucks, ships, farms, mines, and military equipment from turning expensive metal into glitter.

This is the part of the economy nobody talks about at dinner. Good. That is where mispricings live.

The public spark was an alleged AutoZone memo reported by Carscoops. The memo said AutoZone was facing what it called the largest supply shortage of lubricating fluids in modern American history, with average available supply in the category potentially down 40%.

I do not need the memo to be perfect for the thesis to matter.

The stronger signal comes from the trade group behind the scenes. The Independent Lubricant Manufacturers Association, ILMA, has been warning about a global Group III base-oil crisis. Its customer brief says base oils make up roughly 75% of crankcase lubricants and up to 98% of many industrial formulations. ILMA describes a nasty triangle: Persian Gulf Group III disruption, South Korea unable to fully backfill the gap, and Group II feedstock getting pulled toward diesel and jet fuel economics.

That is not internet gossip.

That is a supply chain saying: the cheap workaround is not working.

And when the workaround breaks, prices start doing strange things.

The machine has a hidden bloodstream

A car can run without a new infotainment screen.

A factory can run without a better logo.

A truck fleet can survive a bad quarter.

But rotating metal needs lubrication. Bearings need films. Engines need viscosity. Hydraulic systems need pressure. Gearboxes need protection. Refrigeration compressors need specialized oils. Wind turbines need gear oils. Mining equipment needs grease. Aviation and defense systems need fluids that meet spec, not vibes.

That is why this shortage is interesting.

It does not sit in one cute consumer category. It touches the maintenance layer of the physical economy.

Maintenance is boring until it fails. Then it becomes the whole story.

I keep thinking about the old saying from industrial people: downtime is the most expensive product in the plant.

A manufacturer can argue about raw material costs. It can negotiate labor. It can delay capex. But if a $40 lubricant problem risks a $4 million production stoppage, the buyer pays. Maybe grudgingly. Maybe angrily. Still pays.

That is where pricing power hides.

Why Group III matters

Group III base oil is a high quality base stock used in many synthetic and high performance lubricants. It is not the whole lubricant market, but it sits in the premium part of the stack.

When Group III gets tight, blenders usually try to reformulate or substitute where specifications allow. That sounds easy until you remember that lubricants are not just oil in a jug. They are recipes. They have viscosity requirements, OEM approvals, API standards, additive packages, cold start behavior, oxidation stability, volatility limits, and warranty implications.

You cannot always swap molecules like LEGO bricks.

ILMA’s warning matters because it says the normal substitute, Group II, is also under pressure. Refiners can route vacuum gas oil toward diesel and jet fuel when those margins look better. Refineries are not moral philosophers. They are margin machines.

So the bottleneck has two layers:

First, the premium base oil is tight.

Second, the substitute is not freely available.

That is when a shortage moves from annoying to investable.

The opportunity is not “buy oil”

This is where investors get lazy.

They hear petroleum-product shortage and go straight to Exxon or Chevron. Those may be fine stocks. They may even benefit. But the lubricant thesis is more specific.

The opportunity sits in the companies that touch the molecules after crude becomes specialized.

Who has base-oil capacity?

Who sells finished lubricants?

Who controls additive chemistry?

Who can re-refine used oil into useful supply?

Who owns distribution when customers panic?

Who has pricing power without losing volume?

That is the map.

And the map is much more interesting than “oil up, buy oil stocks.”

The direct plays: CLMT, DINO, PSX

Calumet (CLMT) is the spicy one.

It lives in the unglamorous parts of the barrel: specialty oils, base oils, process oils, waxes, finished lubricants, transformer oils, refrigeration oils. Normal investors read that list and fall asleep. I read it and think: there is probably a margin story hiding here if the shortage persists.

Calumet is also messy. Debt. Refinancing. Renewable fuels. Feedstock. Execution. It can be right on the theme and still wrong as a stock if the balance sheet eats the story.

That is why I think of CLMT as the high-beta expression, not the clean one.

HF Sinclair (DINO) may be the more institutionally comfortable version.

DINO has a real Lubricants & Specialties segment. Petro-Canada Lubricants, Sonneborn, white oils, waxes, base oils, finished lubricants. This is not a footnote to the thesis. It is the thesis living inside a larger refiner.

That matters because the market can understand DINO without having to underwrite a tiny pure-play special situation.

Phillips 66 (PSX) belongs in the same conversation. PSX is not a pure lubricant story, but it has Marketing & Specialties exposure, base-oil relevance, refining leverage, and enough liquidity for larger investors. If the theme goes mainstream, PSX is one of the names that can absorb money quickly.

That is how themes move. First the weird names. Then the liquid names. Then the ETFs and tourists arrive late.

The overlooked winner may be the recycler

Clean Harbors (CLH) might be the most intellectually satisfying name in the basket.

Through Safety-Kleen, Clean Harbors collects used oil and re-refines it into base oil and lubricants.

This is the kind of business Wall Street ignores until it suddenly becomes strategic.

Every commodity cycle eventually rediscovers secondary supply. Scrap metal. Used cooking oil. Recycled batteries. Waste gas. Reclaimed water. Re-refined oil.

When primary supply is abundant, secondary supply is a sustainability story.

When primary supply is tight, secondary supply is inventory.

That shift can change how investors value the asset.

CLH is still an environmental services company. Waste volumes, industrial demand, labor, disposal capacity, and execution all matter. But the Safety-Kleen angle gives CLH a real seat at this table.

If virgin base oils get scarce, used motor oil stops being waste. It becomes feedstock.

That is a better story than most people realize.

The quiet compounder: NEU

NewMarket (NEU), through Afton Chemical, is the additive angle.

Base oil is the bulk of the lubricant. Additives make the lubricant perform.

Anti-wear. Detergents. Dispersants. Friction modifiers. Viscosity modifiers. Oxidation control. The boring chemistry that turns slippery liquid into something an engine manufacturer will approve.

A shortage can create two different opportunities for additive companies.

One is pricing.

The other is formulation complexity.

When blenders need to stretch supply, qualify alternatives, or manage changing base-stock mixes, additive expertise becomes more valuable. If the world had infinite clean base oil, chemistry would still matter. In a constrained world, chemistry matters more.

The risk is volume. If base-oil scarcity reduces finished lubricant production, additive shipments can get hit. But NEU belongs on the watchlist because it owns one of the less obvious tollbooths in the system.

Sometimes the best commodity trade is not the commodity.

It is the chemical that lets the commodity meet spec.

Retail is the emotional accelerator

AutoZone (AZO), O’Reilly Automotive (ORLY), Advance Auto Parts (AAP), Genuine Parts (GPC), and Valvoline (VVV) sit closer to the consumer.

They are not the bottleneck.

They are the place where the bottleneck becomes visible.

A consumer does not buy Group III base oil. A consumer buys a five-quart jug, an oil filter, an oil change, transmission fluid, grease, coolant, and whatever else is on the shelf next to the thing he came in for.

If inventory holds, retailers can benefit from higher tickets and stronger urgency. DIY customers stock up. Professional mechanics lean on distributors with reliable supply. Quick-lube shops reprice service packages.

If allocation gets ugly, retailers get a different outcome: empty shelves, substitution, annoyed customers, and lost units.

So I would not make retail the center of the trade. I would use retail as the signal.

Watch shelves.

Watch online availability.

Watch private-label pricing.

Watch what the store associates say when you ask for synthetic 5W-30.

ORLY is probably the best operator. AZO has the cleanest narrative link. VVV has the service-ticket angle. AAP is the risky turnaround version. GPC gives you NAPA distribution with a broader business wrapped around it.

The retail names tell you whether the shortage has crossed from industry problem to consumer psychology.

That crossing matters.

The broad refiners are the second wave

If the thesis expands beyond lubricants into broader petroleum products, the classic refiners enter.

Marathon Petroleum (MPC).

Valero (VLO).

PBF Energy (PBF).

Delek (DK).

These are not precise lubricant trades. They are crack-spread trades, diesel trades, regional fuel trades, product tightness trades.

But the lubricant story is connected to them because base-oil supply competes with other uses of refinery streams. If diesel and jet fuel economics stay strong, refiners have less incentive to maximize base-oil output.

That is one of the sneaky parts of this thesis.

The lubricant shortage may persist not because nobody can make the stuff, but because the refinery system is being paid to make something else.

In markets, incentives beat intentions.

Every time.

The market is bad at middle-layer shortages

The market understands crude.

The market understands gasoline.

The market understands a product on a shelf.

It is worse at pricing middle-layer shortages: the weird inputs that sit between raw commodity and final consumer product.

Base oil is one of those inputs.

Too technical for the retail investor.

Too small for the macro tourist.

Too downstream for the crude-oil crowd.

Too industrial for the consumer analyst.

Perfect.

That is exactly the kind of place where a thesis can sit for a while before the market gives it a name.

Uranium had that phase. LNG had that phase. Transformers had that phase. Data-center power has that phase right now. The first people who make money are usually the ones willing to stare at a boring bottleneck before it becomes a CNBC segment.

This does not have to become a generational trade to be useful.

It only has to be mispriced for a few quarters.

My shortage basket

If I were building a research basket, I would split it this way.

Direct and spicy: CLMT, DINO, CLH, NEU.

Liquid and institutional: PSX, CVX, XOM, SHEL.

Retail and service: ORLY, AZO, VVV, GPC.

Broad product tightness: MPC, VLO, PBF, DK.

My favorite part of the basket is the first line. CLMT, DINO, CLH, NEU. That is where the lubricant thesis is most alive.

PSX is the bridge between specificity and liquidity.

The majors are ballast.

Retail is confirmation.

The refiners are the second-wave trade if the shortage spreads.

I would rather own the bottleneck than the headline.

What I would monitor now

I would watch five things.

First, ILMA language. If the trade group keeps talking about allocation, substitutions, emergency relief, and normalization pushed into 2027, the thesis is not fading.

Second, base-oil price reports from Argus, ICIS, Lubes’n’Greases, and industry distributors. The exact numbers matter less than the direction and the language around availability.

Third, earnings calls from DINO, CLMT, CLH, NEU, PSX, AZO, ORLY, and VVV. I would search transcripts for base oil, lubricant, allocation, additive, re-refined, Safety-Kleen, pricing, feedstock, and supply.

Fourth, shelf checks. Not fancy. Just real-world inventory. AutoZone. O’Reilly. Walmart. Costco. Amazon. Local quick-lube shops. Sometimes the best channel check is a bored person in aisle seven.

Fifth, diesel and jet fuel margins. If those stay attractive, they can keep pulling refinery economics away from base-oil relief.

This is how a serious shortage thesis develops.

It starts with trade-group language.

Then pricing services confirm it.

Then companies mention it carefully.

Then retailers show it.

Then analysts pretend they saw it coming.

The risk is timing, not imagination

The biggest risk is not that the thesis is crazy.

The thesis is not crazy.

The risk is timing.

Supply chains can heal. Emergency waivers can loosen specs. OEMs can approve substitutions. Retailers can over-order and then discount later. A Middle East disruption can fade. A demand slowdown can make the shortage disappear on paper because customers buy less.

And stocks are never pure.

CLMT has balance-sheet risk. DINO and PSX have refining cycles. CLH has waste-volume exposure. NEU has additive-volume risk. Retailers have valuation and same-store sales. The majors are too diversified to move much on a lubricant story alone.

That is why the basket matters.

One ticker can betray you. A well-built theme gives you more ways to be right.

The opportunity

Here is the opportunity as simply as I can say it.

The market may still be treating this as an oil-change inconvenience.

The supply chain is describing a base-oil bottleneck that touches transportation, manufacturing, agriculture, industrial maintenance, power systems, and defense.

That gap is the trade.

I like gaps like this because they start out sounding ridiculous.

A lubricant shortage? Really?

Yes. Really.

The physical economy has a maintenance layer. The maintenance layer has inputs. Some of those inputs are getting tight. The companies that own supply, chemistry, re-refining, distribution, or pricing power may have more leverage than investors expect.

That is the whole game.

Find the tiny hinge.

Then ask what giant door it moves.

This time the hinge may be base oil.

Source notes

• Carscoops report on the alleged AutoZone memo and reported 40% lubricant-supply drop: https://www.carscoops.com/2026/05/autozone-motor-oil-shortage/

• ILMA March 2026 release on Group III base-oil supply disruptions and emergency relief request: https://ilma.org/ilma-seeks-immediate-relief-amid-group-iii-base-oil-supply-disruptions/

• ILMA May 2026 customer brief, “The 2026 Global Base Oil Supply Crisis — What It Means for You”: https://ilma.org/wp-content/uploads/2026/05/ILMA-Customer-Info-Base-Oil-Supply-Crisis.pdf

• Company filings and public disclosures for Calumet, HF Sinclair, Clean Harbors/Safety-Kleen, Phillips 66, Chevron, Exxon Mobil, Shell, NewMarket/Afton, AutoZone, O’Reilly, Advance Auto Parts, Genuine Parts, Valvoline, Marathon Petroleum, Valero, PBF Energy, and Delek.

Disclaimer: This article is for information and research only. Nothing here should be treated as investment advice or as an offer or solicitation to buy or sell any security. The shortage thesis is speculative and depends on supply conditions, pricing, demand, and company-specific execution.

That was the pitch. Decode the three billion letters. Find the bad genes. Fix disease at the source. A clean story. A beautiful story. Also incomplete.

Because DNA is not destiny. DNA is closer to a script locked in a drawer. What matters is which pages the cell reads, which lines it ignores, which proteins it actually builds, which metabolites pile up like exhaust, which immune cells show up late, which microbes whisper from the gut, and where all of this happens inside real tissue.

That is multiomics.

Not one layer of biology. Many layers, stacked together until the body stops looking like a parts list and starts looking like a city at night: roads, electricity, water pressure, traffic jams, police reports, restaurant receipts, and heat maps all blinking at once.

My view: multiomics today feels a lot like genomics did 10 to 15 years ago.

The science is real. The commercial plumbing is uneven. The early revenue lines do not yet capture the size of the eventual market. Some public stocks will turn out to be monsters. Some will be disasters with beautiful slides. A few boring suppliers may make more money than the glamorous pure plays. That is usually how platform shifts work.

And this one matters because medicine is moving from static genetic clues toward living biological context. AI is becoming good enough to model that context. Quantum computing is not the engine today, but over a 5 to 20 year horizon it could become a second acceleration layer for chemistry, simulation, and optimization.

What multiomics really means

Genomics asks: what is written in the DNA?

Transcriptomics asks: which genes are being read into RNA right now?

Proteomics asks: which proteins are present, modified, folded, degraded, and doing work?

Metabolomics asks: what small molecules and chemical byproducts reveal the cell’s current state?

Epigenomics asks: which DNA switches are open or closed without changing the underlying genetic code?

Microbiome analysis asks: what organisms are living in and around us, and how are they changing immune, metabolic, or inflammatory behavior?

Single cell analysis asks the question bulk biology used to hide: which exact cells are doing what?

Spatial biology adds the missing map: where are those cells inside the tissue, who are their neighbors, and what conversations are happening at the tumor border, in the inflamed gut, or inside the aging brain?

Each layer is useful. Together, they are different in kind. Disease rarely respects the boundaries of a textbook. Cancer involves DNA, but the mutation is only the opening clue. Alzheimer’s involves protein aggregates, but the surrounding cellular neighborhood matters too. Autoimmune disease involves immune cells, but the trigger and tissue context decide the damage. Metabolic disease involves glucose, but the real body is a feedback loop.

For decades, medicine worked like a detective arriving after the crime. A patient is sick. A symptom appears. A blood test or scan catches a clue. Doctors infer what may have happened upstream.

Multiomics tries to move the camera earlier. It wants to see the molecular weather before the storm breaks.

That is why I think the category is still under-imagined.

The genomics movie already played once

Go back to 2010 or 2012 and genomics had the same weird feeling.

The Human Genome Project was old news by then. Sequencing costs were collapsing. Illumina was becoming the default machine inside the lab. Cancer sequencing was starting to move from research into clinical decision making. Consumer DNA had a lot of cultural heat. Every serious hospital wanted to understand precision medicine, even if most of them had no idea how to operationalize it.

The skeptical case sounded reasonable: sequencing was expensive, reimbursement was messy, interpretation was hard, privacy was unresolved, and doctors did not need another 200 page PDF full of variants of unknown significance.

All true.

It still became one of the most important life sciences platform shifts of the last 15 years.

Illumina is the cleanest historical example. Around 2010, the stock traded near $30 on a split adjusted basis. By 2015, it was around $180. By 2021, near the peak of the genomics and life sciences tool boom, it briefly traded above $500. Then the story broke. Growth slowed, competition rose, the Grail deal became a governance and regulatory mess, and the stock fell hard. The lesson is not “buy every sequencing stock.” The lesson is sharper: the platform was real, the adoption curve was real, and the equity path still punished anyone who ignored valuation, execution, and cycle risk.

Thermo Fisher and Danaher tell a quieter story. They were not sexy genomics pure plays. They were diversified life sciences infrastructure companies. Yet they benefited from the same underlying wave: more sequencing, more sample prep, more bioprocessing, more lab automation, more analytical workflows. From the early 2010s to the 2021 life sciences peak, both became much larger and more strategically important. The boring toolchain often compounds while the market argues about the headline technology.

Exact Sciences is another useful case. It turned molecular screening into a commercial product with Cologuard, then pushed deeper into cancer testing. The stock had enormous runs and painful drawdowns. Guardant Health came public later and gave investors a more direct liquid biopsy story. It also showed the other side of the curve: the science can be impressive while profitability, reimbursement, competition, and trial evidence remain brutal.

Then came the more specialized names. PacBio had moments of real excitement around long-read sequencing and then long stretches of investor pain. 10x Genomics came public in 2019 as one of the best known single cell and spatial biology names, rocketed during the 2020-2021 life sciences enthusiasm, and then collapsed with the rest of the high-multiple tool universe. Again: the technology did not become irrelevant. The stock did not get a free pass.

That is the right mental model for multiomics.

A platform can be inevitable and still destroy capital in the wrong vehicle. A platform can be early and still create huge winners in the supply chain. A platform can look like a research tool for years before it becomes a clinical or pharmaceutical workflow. By the time revenue is obvious, the best entry prices may already be gone. By the time the hype is loudest, the risk may already be hiding in plain sight.

This is why I do not want to treat multiomics as a cute subcategory of genomics. Genomics gave medicine the street map. Multiomics is trying to add traffic, weather, power consumption, emergency calls, surveillance footage, and the weird smell coming from the alley.

That is a bigger data problem. It is also a bigger business problem.

The field is early in the way that matters

If you listen only to conference-stage language, you might think multiomics has already transformed healthcare. It has not.

But “not transformed healthcare yet” is not the same as “not investable” or “not important.” That distinction matters.

In research, multiomics is already part of serious biology. Single cell RNA sequencing changed how scientists look at tissue. Spatial transcriptomics and spatial proteomics let researchers see biology without grinding everything into molecular soup. Large biobanks, tumor atlases, clinical sequencing programs, imaging archives, and electronic health records are turning biology into a layered dataset.

In oncology, rare disease, immunology, cardiovascular research, aging, metabolic disease, and drug discovery, the old one-marker-at-a-time model feels increasingly primitive.

The clinic is slower.

Genomic tests are commercial. Some expression based tests are commercial. Some cancer assays already combine DNA, RNA, methylation, protein markers, pathology, imaging, or clinical data into one decision. But full-stack multiomics for routine diagnosis is still held back by cost, sample handling, standardization, reimbursement, regulation, and the boring reality that hospitals are not built like computational biology labs.

That gap is not a reason to dismiss the space. It is where the companies will be made.

The science wants thousands or millions of measurements. The clinic wants one answer that is accurate, reimbursed, explainable, and delivered before the physician loses patience.

Someone has to turn a mountain of molecular noise into a clinically useful sentence.

This patient needs drug A, not drug B.

This tumor is likely to recur.

This target is not worth five years of R&D.

This subgroup of patients, invisible in the old trial design, is where the drug actually works.

That is where the money should concentrate. Not in data for data’s sake. In decisions.

AI is the translation layer

Multiomics without AI is like owning a library where every book is written in a different language and half the pages are missing.

A human researcher can understand a pathway. A team can analyze one dataset. But multiomics quickly becomes too wide, too sparse, too noisy, and too high dimensional for old methods alone. The comparison is no longer gene A versus disease B. It is millions of weak signals across cells, tissues, time, drugs, clinical records, imaging, and outcomes.

AI is the translation layer.

Machine learning can integrate messy data types, impute missing layers, cluster patient subgroups, identify biomarkers, predict drug response, and prioritize targets. Deep learning can learn representations of cells the way language models learn representations of words. Foundation models for biology are the natural extension of this idea.

One clear example is scGPT, published in Nature Methods in 2024. The researchers trained a generative model across more than 33 million cells and showed it could support cell type annotation, batch integration, multiomic integration, perturbation response prediction, and gene network inference. That does not make scGPT a finished commercial product. It shows the direction: biology is moving from handcrafted analysis toward pretrained biological representations.

In plain English: AI is learning a grammar of cells.

If that grammar gets reliable, the consequences are large.

Drug discovery changes because teams can ask better questions earlier. Biomarker discovery changes because models can see patient subtypes hidden inside noisy averages. Clinical trials change because inclusion criteria can be built around biology instead of blunt demographic categories. Diagnostics change because molecular context can follow the patient instead of sitting in a one-time lab report.

The important 5 to 20 year question is not whether every model works this year. Many will fail. Wet labs are merciless. Correlations die. Batch effects bite. Hospital data is ugly. But that is exactly what happened in genomics: interpretation lagged measurement, then workflows caught up, then commercial products emerged.

The investment question is simple: who owns scarce biological data, repeatable workflows, customer access, and a path from prediction to validation?

That is a much smaller list than “everyone with AI in the deck.”

Quantum computing is the far-horizon accelerator

Over the next few years, quantum computing probably will not be the main driver of multiomics. The heavy lifting will come from sequencing, single cell tools, spatial biology, mass spectrometry, proteomics platforms, cloud infrastructure, GPUs, lab automation, and AI models trained on better biological data.

But over 5, 10, or 20 years, quantum belongs on the map.

Molecules are quantum systems. Drug discovery and biology eventually run into problems where classical approximations are expensive, incomplete, or painfully slow: electronic structure, binding energy, reaction pathways, conformational states, protein-ligand interactions, materials for instruments, and certain optimization problems in experimental design. If fault tolerant quantum computing matures, it could become a serious tool for chemistry and simulation.

That does not mean quantum replaces multiomics platforms. It means quantum may deepen the model of what the multiomics platforms are measuring.

Imagine a future workflow. Multiomics identifies a disease state at high resolution. AI proposes the pathway, the target, the subgroup, and the likely response. Quantum accelerated chemistry helps simulate the molecular interaction or reaction space with more fidelity than classical tools can manage alone. Robotic labs test the best candidates. The results loop back into the model.

That is not tomorrow morning. It is not a revenue forecast for IonQ, Rigetti, D-Wave, IBM, Microsoft, Alphabet, or NVIDIA. It is a direction of travel.

And direction of travel matters in platform markets.

The more practical near-term link is hybrid computing. NVIDIA’s CUDA-Q work with Google Quantum AI is a useful signal because it shows the strange loop forming: classical accelerated computing helps design and simulate quantum processors, and those quantum systems may eventually help simulate chemistry. IBM, Microsoft, Alphabet, IonQ, Rigetti, and D-Wave all sit somewhere on that map. Investors should still separate a quantum platform company from a multiomics revenue company. But I would not dismiss the connection just because the first commercial impact is indirect.

The next biology stack may be layered like this: assays create the data, AI interprets the data, accelerated computing trains the models, and quantum eventually attacks the hardest simulation edges.

That is a 20 year sentence. I think it is worth writing down now.

The public watchlist

I would group the public companies into four baskets.

The first basket is the toolmakers: Illumina (ILMN), 10x Genomics (TXG), Thermo Fisher Scientific (TMO), Danaher (DHR), Agilent (A), Waters (WAT), QIAGEN (QGEN), PacBio (PACB), and Standard BioTools (LAB).

These companies sell the picks and shovels. Illumina is still central to sequencing despite its bruised stock chart. 10x Genomics is one of the names most closely tied to single cell and spatial biology, with Chromium, Visium, and Xenium. Thermo Fisher and Danaher are broader, less pure, and deeply embedded in labs. Agilent and Waters matter because mass spectrometry, chromatography, biomolecular analysis, and analytical workflows are part of the proteomics and metabolomics stack. QIAGEN sits in sample prep, molecular assays, NGS workflows, and bioinformatics. PacBio gives long-read exposure. Standard BioTools, especially through the SomaLogic combination, gives exposure to proteomics and high-parameter biology, though execution risk is real.

The second basket is diagnostics and clinical data: Tempus AI (TEM), SOPHiA GENETICS (SOPH), Exact Sciences (EXAS), Guardant Health (GH), and Labcorp (LH).

This basket is closer to the patient. Tempus is one of the more direct public expressions of the thesis: multimodal clinical, molecular, imaging, and text data with AI layered on top. Its 2024 filing described more than 7.3 million de-identified patient records, over 900 million documents, more than 1.3 million records with matched clinical and genomic information, and more than 260,000 with full transcriptomic profiles. Those are company-reported figures, not magic. But they explain why the market pays attention.

SOPHiA GENETICS is another direct name, with a cloud-native platform built around data-driven medicine and multimodal analysis across genomics, radiomics, clinical, biological, and digital pathology data. Exact Sciences and Guardant Health show how molecular signals can become reimbursed clinical products, and also how expensive the road can be. Labcorp is broader and less pure, but scale, samples, ordering relationships, and clinical lab infrastructure matter.

The third basket is computational biology and AI drug discovery: Schrödinger (SDGR), Recursion (RXRX), and AbCellera (ABCL).

Schrödinger is more physics based computational chemistry than multiomics, but its combination of molecular simulation and machine learning belongs on the adjacent map. Recursion is closer to the high-dimensional biology thesis, with phenomics, transcriptomics, proteomics, patient-centric data, and machine learning inside its operating system. AbCellera is focused on antibody discovery and development rather than broad multiomics, but it fits the same pattern: industrialized biological data plus computation plus a platform business model.

The fourth basket is infrastructure: NVIDIA (NVDA), Alphabet (GOOGL), Microsoft (MSFT), IBM (IBM), IonQ (IONQ), Rigetti (RGTI), and D-Wave Quantum (QBTS).

NVIDIA is the most immediate infrastructure beneficiary because modern biological AI runs on accelerated computing. Alphabet and Microsoft matter through cloud, AI research, health data tooling, and quantum research, though neither is a pure biology stock. IBM has long-running quantum and enterprise research exposure. IonQ, Rigetti, and D-Wave are quantum watchlist names. Their connection to multiomics is indirect today. Over a 10 to 20 year horizon, that indirect exposure may become more interesting if quantum chemistry and hybrid AI workflows mature.

The trick is not to buy a theme. The trick is to understand where the theme touches revenue, margins, data advantage, and customer behavior.

A ticker is not a thesis. But sometimes a theme tells you where to look before the thesis is obvious.

The frontier may leak out before it shows up in public revenue

Some of the most important signals are not clean public-stock stories yet.

In the measurement layer, a few names are public or tucked inside larger companies: Oxford Nanopore trades in London, PacBio trades on Nasdaq, Olink now sits inside Thermo Fisher, and SomaLogic sits inside Standard BioTools. They matter because they show where the instrument race is going: longer reads, cheaper reads, better proteins, better spatial context, and less friction between sample and insight.

The private-company watchlist is different: Element Biosciences, Ultima Genomics, Parse Biosciences, Vizgen, Scale Biosciences, Isomorphic Labs, Generate:Biomedicines, Insilico Medicine, and Owkin.

These companies are pushing either the measurement layer or the AI-biology layer before the story becomes obvious in public filings.

Private leaders matter because they reveal the frontier early. They also create temptation. Fewer filings. Fewer audited numbers. More room for heroic narratives. The right posture is not cynicism. It is aggressive curiosity with a calculator in your hand.

The risks are real, but they are not the whole story

Multiomics can generate gorgeous plots that do not improve outcomes. That is the first risk.

Biology is physical. Samples degrade. Tissues vary. Labs use different protocols. A model trained on one dataset may stumble on another. The boring operational details are not boring; they are the moat.

Reimbursement can also break the dream. A diagnostic can be scientifically elegant and commercially miserable if nobody pays for it.

Then there is stock selection. Large diversified companies may benefit from the trend but barely move because multiomics is only one small part of revenue. Small pure plays may offer more upside to the theme but carry financing risk, adoption risk, and violent drawdowns.

The 2010s genomics lesson is useful here. The wave was real. Sequencing did become central. Precision oncology did grow. Clinical genomics did spread. Tool companies made money. Diagnostics companies built products. Infrastructure companies compounded.

And still, plenty of shareholders got hurt.

That is not a reason to avoid the map. It is a reason to read the map correctly.

My read

Multiomics is not a single product category. It is a direction of travel.

Medicine is moving from one-dimensional tests toward layered biological context. AI is moving from generic pattern recognition toward domain-specific biological models. Drug discovery is moving from artisanal trial and error toward industrialized data loops. Quantum computing sits farther out, but if chemistry and simulation become quantum-assisted over the next 10 to 20 years, the biology stack gets another gear.

The most interesting companies will connect four things: hard-to-get biological data, reliable measurement workflows, models that improve with scale, and a commercial path into decisions people pay for.

That is why I keep coming back to the city-at-night image.

For a long time, genomics gave us the street map. Valuable, yes. Revolutionary, yes. But a street map does not tell you where traffic is frozen, where the power is out, where the hospital is overwhelmed, or where a fire is about to start.

Multiomics is the attempt to turn on the lights.

And once the lights are on, the real competition begins.

That is the sales pitch. The real thing is more interesting, and more complicated.

A tokenized stock is not automatically “a stock onchain.” Depending on the issuer and jurisdiction, it may be a security token, a tracker certificate, a derivative contract, a broker/custodian ledger claim, a synthetic exposure, or a token that is backed by shares but gives you only economic exposure rather than shareholder rights. Two products can both say “tokenized Nvidia” and still give holders very different legal claims.

That distinction matters. If you are buying a tokenized stock, you are taking market risk on the underlying company, plus product-structure risk: issuer risk, custodian risk, transfer restrictions, redemption mechanics, jurisdictional rules, tax complexity, and the possibility that the token tracks the stock price imperfectly when markets are closed or liquidity is thin.

This guide is educational, not personalized financial advice. The goal is to give you a practical map: what tokenized stocks are, where the main live products are as of May 2026, how to place a small first trade if you are eligible, and what red flags should make you stop before clicking buy.

1. What tokenized stocks actually are

The broad definition: a tokenized stock is a digital token or blockchain-recorded instrument that references a public equity or ETF.

But that definition hides the important part: what exactly do you own?

There are several common structures.

A. Tokenized securities or tracker certificates

Some products are issued as securities or structured instruments. xStocks, for example, are issued by Backed Assets (JE) Limited. xStocks’ own legal documentation describes each xStock as a bearer debt instrument classified as a tracker certificate. It provides economic exposure to the underlying equity, but it does not confer shareholder voting rights and is not direct equity ownership.

In plain English: you hold a token that is designed to track a share or ETF. The issuer says the product is backed by the relevant underlying asset, held through regulated custodians or brokers, and governed by product documents. Your rights come from the token/instrument terms, not from being recorded as a shareholder of Apple or Nvidia.

B. Derivative stock tokens

Robinhood’s EU Stock Tokens are an explicit example. Robinhood says these are derivative contracts between the customer and Robinhood. They follow the prices of publicly traded stocks and ETFs, are recorded on a blockchain, and give exposure to the U.S. market. Robinhood also says customers are not buying the actual stocks, cannot currently send the tokens to outside wallets, and do not get rights to the underlying securities.

This is a cleaner mental model: you are buying a blockchain-recorded derivative contract, not a share.

C. 1:1-backed tokenized equities distributed through platforms

Dinari’s dShares are described in Dinari’s documentation as tokens 1:1 backed by a security, commonly a U.S. equity. The mint/burn flow happens after a corresponding brokerage order is completed. Gemini’s EU tokenized-stock materials describe Dinari-powered dShares as digital derivatives linked to public equity securities and note that the product provides indirect exposure rather than ownership of the underlying asset.

That “1:1 backed” language is useful, but it does not eliminate the need to read the legal wrapper. Backed by shares is not the same thing as being the shareholder of record.

D. Synthetic exposures, CFDs, and perpetuals

Some venues also offer stock-linked CFDs or perpetual futures. These are not tokenized stocks in the strict sense, even if they trade inside a crypto app. A CFD or perpetual is usually a leveraged or margin-based contract that references a stock price. It may not be asset-backed at all. It may have funding rates, liquidation risk, and different tax treatment.

If a product has leverage, margin, funding payments, liquidation prices, or “perp” in the name, treat it as a trading derivative, not as a tokenized share substitute.

E. Tokenized funds are related, but separate

Ondo’s tokenized U.S. Treasury funds, money-market-style products, and other RWA funds are part of the same tokenization world, but they are not tokenized stocks. Ondo Global Markets, however, is directly relevant because it offers tokenized U.S. stocks and ETFs. The distinction is important: a tokenized Treasury fund and a tokenized Nvidia exposure have different risks, disclosures, market behavior, and investor protections.

2. Why people are interested

The appeal is obvious: fractional access, extended trading hours, crypto-native funding, faster settlement, wallet withdrawal in some products, and access for eligible non-U.S. investors who want U.S. equity exposure through crypto-native rails. Those benefits are real in some products. But each one has an asterisk.

“24/5 trading” does not mean U.S. equity markets are open 24/5. It means the token can trade while the underlying market may be closed. During those hours, the token price may rely on market makers, oracles, indicative prices, or issuer mechanisms. Spreads can widen. Liquidity can vanish. Corporate actions can pause trading. A token can keep moving after-hours even though the underlying share’s primary market is closed.

“Onchain” does not always mean withdrawable. Robinhood EU currently says its Stock Tokens cannot be sent to other wallets or platforms. Kraken’s xStocks page, by contrast, advertises withdrawal to a wallet for eligible users. The same phrase, stock token, can mean very different custody and transfer rights.

“Backed 1:1” does not remove issuer risk. You still need to know who holds the shares, whether collateral is segregated, who can enforce tokenholder rights, what happens in bankruptcy, and whether you can redeem directly or only sell on a secondary market.

3. Where people are trading tokenized stocks in 2026

Availability changes by country, account type, and regulator. Always check the venue’s current eligibility page before assuming you can trade.

Kraken xStocks / Backed-style products

Kraken offers xStocks, a family of tokenized U.S. stocks and ETFs issued by Backed. Kraken’s xStocks page says users can access 100+ companies and ETFs, trade 24/5, start with as little as $1, and, for supported products, receive dividend exposure through balance increases rather than shareholder ownership. Kraken says xStocks are not available in the U.S., EEA, and certain other regions; its support result also indicates they are not available to U.S. persons, and are not accessible in the U.S., Canada, U.K., or Australia at this time.

xStocks’ legal documentation says the issuer is Backed Assets (JE) Limited, a Jersey SPV. Each xStock is a tracker certificate, gives economic exposure, does not confer voting rights, and is not direct equity ownership. The product documents also say collateral is held with regulated custodians and brokers and that distribution is restricted by jurisdiction.

Practical takeaway: this is one of the main crypto-exchange routes for tokenized equity exposure, but it is highly jurisdiction-dependent and should be read as structured exposure, not ordinary stock ownership.

Bybit xStocks

Bybit lists xStocks on spot markets and describes them as tokenized representations of U.S. stocks and ETFs issued by Backed. Bybit’s FAQ says each token is backed 1:1 by the underlying asset and that Bybit acts as a secondary market. It also says users cannot redeem xStocks on Bybit; direct redemption is through Backed for onboarded clients subject to KYC/AML and fees.

Bybit’s own FAQ also warns that holding xStocks on Bybit does not entitle users to dividends, interest, voting rights, shareholder privileges, or rights offerings. That may differ from how another distributor handles dividend economics, so do not assume one xStocks venue’s user experience equals another’s.

Practical takeaway: distinguish the issuer from the exchange. The token may be Backed-issued, but your practical rights on Bybit are shaped by Bybit’s rules, eligibility, wallet support, and secondary-market setup.

Robinhood EU Stock Tokens

Robinhood EU offers Stock Tokens to verified users in the EU. Its support page says these are derivatives tracked on the blockchain that follow prices of publicly traded stocks and ETFs. Robinhood says customers are not buying actual stocks, cannot currently send the tokens to other wallets or platforms, and trade from Monday 02:00 CET/CEST until Saturday 02:00 CET/CEST. Robinhood also says it charges a 0.10% FX fee when converting euros and that Stock Tokens are offered under MiFID II as derivatives.

Robinhood’s support materials also warn that Stock Tokens carry high risk, can lose up to the full invested capital, and depend on Robinhood’s product structure and solvency. The exact list of available tokens should be checked inside Robinhood’s current EU product pages or app before trading.

Practical takeaway: Robinhood EU is a familiar-app route for eligible European users, but the product is a Robinhood derivative, not an externally transferable share token.

Dinari dShares and Gemini EU

Dinari’s dShares are 1:1-backed tokens linked to U.S. equities or ETFs. Dinari’s docs describe a mint/burn process where issuance or redemption occurs only after a corresponding order completes in a brokerage account. Gemini’s EU materials say eligible EU customers can access tokenized stocks powered by Dinari, that the products are digital derivatives linked to public equity securities, and that Dinari is the product manufacturer.

Gemini’s Key Information Document for tokenized stocks describes dShares as bilateral OTC derivative contracts linked 1:1 to an underlying U.S.-listed stock or ETF. It also says the product gives indirect exposure without ownership of the underlying asset, is recorded on Arbitrum, is not freely transferable, and can only be bought from and sold back to Dinari under the stated product terms.

Practical takeaway: dShares are important because they combine brokerage execution, token issuance, and app distribution. But depending on where you access them, transferability and redemption may be limited.

Swarm

Swarm offers tokenized public stocks and bond ETFs through a compliant DeFi-style setup. Swarm’s product pages say its tokenized stocks are issued by SwarmX GmbH, are backed by 100% real stock, have ISINs, are monitored by a trusted auditing firm, and can be traded onchain. Swarm’s FAQ says users purchase security tokens using USDC on Polygon; the tokens are backed by real stocks and bond ETFs held by institutional custodians and verified by a token trustee. The FAQ also says Swarm currently does not have a license to transfer real underlying stocks directly to token holders; redemption transfers the value of the stocks, in USDC.

Practical takeaway: Swarm is one of the more explicitly onchain/DeFi-style routes, but it requires comfort with wallets, Polygon, USDC, KYC, and a security-token framework.

Ondo Global Markets

Ondo Global Markets is a major 2026 entrant. Ondo announced in May 2026 that Global Markets had surpassed $1 billion in TVL, offered 260+ tokenized U.S. stocks and ETFs across Solana, Ethereum, and BNB Chain, and was accessible through wallets, exchanges, custodians, and protocols including Binance, Bitget, MetaMask, and Blockchain.com. Ondo says each token is fully backed by the underlying security held in a U.S.-registered broker-dealer and tracks total return including dividends.

The same announcement also makes the caveat: the tokens have not been registered under the U.S. Securities Act and may not be offered or sold in the U.S. or to U.S. persons unless registered or exempt. Ondo says the tokens provide economic exposure, but are not themselves stocks, ETFs, or ADRs and do not provide holders rights to hold or receive the underlying assets.

Practical takeaway: Ondo is a serious tokenized-equity platform to watch, especially because it is distributed through crypto wallets and exchanges. But it is still economic exposure through a token structure, not ordinary brokerage ownership.

Hyperliquid stock perps

Hyperliquid belongs in this conversation, but with a bright warning label: this is not tokenized stock ownership. It is onchain perpetual futures exposure to stock prices.

Through HIP-3 markets, outside deployers can launch perp markets on Hyperliquid’s infrastructure. CoinGecko’s 2026 explainer describes trade.xyz as an early HIP-3 deployer offering 24/7 perpetual markets for U.S. equities including Tesla, Apple, Nvidia, and Amazon, plus a synthetic Nasdaq index. OneKey’s guide frames the same category as stock perps: derivatives that reference stock prices, settle in crypto rails, and can be traded long or short without a brokerage account.

Practical takeaway: Hyperliquid is useful to mention because many crypto-native traders will encounter “stock” markets there. But put it in the derivative bucket, not the tokenized-share bucket. If someone wants Apple exposure with shareholder-like rights, this is not that. If someone wants a high-risk onchain stock-price perp, Hyperliquid is one of the places they will look.

Coinbase and Binance: useful history, not simple live access

Binance offered stock tokens in 2021 and discontinued them after regulatory scrutiny. Reuters reported at the time that Binance stopped selling digital tokens linked to shares. In 2026, Binance-related access appears through partnerships and venues such as Ondo’s admission on Binance’s ADGM-regulated MTF, not necessarily a simple revival of the old global Binance stock-token product.

Coinbase, meanwhile, has reportedly sought U.S. SEC approval to offer tokenized equities, but seeking approval is not the same as having a live retail product. If you are in the U.S., assume tokenized-stock access remains restricted unless a properly registered or exempt product is explicitly available to you.

4. How to think about “ownership”

Before buying any tokenized stock, answer this question in writing:

If the issuer, distributor, broker, custodian, or smart contract fails, what exactly is my claim, against whom, in which jurisdiction, and under which document?

That sounds boring. It is the whole game.

A normal brokerage share has a familiar chain: broker, clearing system, custodian, customer protection rules, account statements, tax forms. Tokenized stocks add new actors: issuer SPVs, blockchain records, smart contracts, oracles, crypto exchanges, market makers, bridge infrastructure, token trustees, and offchain brokerage accounts. That may improve access, but it also creates unfamiliar failure points.

Some tokens are transferable and can sit in your self-custody wallet. Others are only ledger entries inside an app. Some products track dividends. Some reinvest them into more tokens. Some disclaim dividend rights at the venue level. Some provide voting rights; many do not. Some are redeemable directly; others require you to sell on a secondary market.

Do not buy the marketing noun. Read the legal verb.

5. Practical preflight checklist

Before your first trade, check:

1. Eligibility: Is the product available in your country and to your account type? Are U.S. persons excluded? Are U.K., Canadian, Australian, or EEA users excluded?

2. Product type: Is it a security token, tracker certificate, derivative, CFD, perpetual, or fund token?

3. Issuer: Who issues the token? Is it a broker, SPV, transfer agent, exchange affiliate, or offshore company?

4. Backing: Is it 1:1 backed? By what asset? Held where? Audited or disclosed how often?

5. Rights: Do you get dividends, dividend equivalents, voting, corporate-action treatment, or only price exposure?

6. Transferability: Can you withdraw to a wallet? Can you transfer peer-to-peer? Can the issuer freeze or restrict transfers?

7. Redemption: Can you redeem for cash, stablecoin, or underlying shares? Is redemption direct or only through a secondary market?

8. Protection: Is there SIPC, FDIC, investor-compensation, trustee, segregation, or bankruptcy protection? If not, is that clearly disclosed?

9. Trading hours: Does it trade 24/5 or 24/7? What happens during U.S. market holidays, halts, and corporate actions?

10. Fees and spreads: What are the explicit fees, FX fees, blockchain gas fees, withdrawal fees, and likely spreads?

11. Tax records: Will you get statements? How are dividends, sales, token transfers, stablecoin conversions, and FX handled?

12. Operational risk: What wallet, chain, bridge, oracle, smart contract, and exchange risks are you taking?

If you cannot answer these questions, your first trade should be either zero or so small that a total loss would be educational rather than painful.

6. Choosing a venue

Pick the venue based on your actual need.

If you only want easy price exposure and you are eligible in Europe, a familiar app like Robinhood EU or Gemini EU may be simpler than self-custody. You give up onchain transferability, but you reduce wallet-management mistakes.

If you want crypto-native custody, look at products that explicitly support withdrawal, such as eligible xStocks routes or onchain venues. But then you must understand wallet security, chain support, contract addresses, transfer restrictions, and what happens if you send a token to the wrong chain or address.

If you want DeFi composability, be even stricter. Ask whether the token can actually be used in the protocol you intend to use, whether the protocol accepts it as collateral, what liquidation rules apply, and whether a liquidity pool is deep enough to exit without a bad price.

If you are in the U.S., be careful. Many products explicitly exclude U.S. persons. Do not use VPNs or false residency information to bypass restrictions. That creates legal, tax, account-closure, and asset-freeze risk.

7. Placing a first trade

A conservative first-trade process looks like this:

1. Open the venue’s current product page and legal/risk documents.

2. Confirm you are eligible.

3. Complete KYC honestly.

4. Fund with the smallest practical amount.

5. Choose a boring, liquid instrument for testing, not because it is a recommendation, but because illiquid tokens are bad test cases.

6. Use a limit order if available.

7. Check spread, quoted price, underlying stock price, fees, and settlement.

8. If withdrawal is supported, consider a tiny test withdrawal before moving size.

9. Save confirmations, transaction hashes, statements, and screenshots.

10. Wait through one corporate action or dividend cycle before assuming you understand how the product behaves.

The goal of the first trade is learning the plumbing.

8. Custody and withdrawal considerations

Self-custody changes the risk from “can I trust the app?” to “can I operate safely?”

If you withdraw tokenized stocks to a wallet, verify the chain, contract address, receiving wallet support, and transfer restrictions. Some security tokens require whitelisting. Some tokens may not be freely transferable. Some venues may support deposits but not withdrawals, or withdrawals but not third-party deposits. A token visible in your wallet does not mean every DeFi protocol can legally or technically accept it.

Use a hardware wallet for meaningful size. Keep a transaction log. Do not bridge tokenized securities casually. A bridge may wrap the token and create a new risk layer. Also remember: holding a token in your wallet may still leave you dependent on the issuer, custodian, trustee, transfer agent, or redemption agent.

9. Portfolio sizing and risk controls

Tokenized stocks should not be treated as safer just because the underlying asset is a blue-chip stock. You are stacking risks:

• underlying equity risk;

• token issuer risk;

• exchange or app risk;

• custodian/broker risk;

• jurisdiction and enforcement risk;

• liquidity and tracking risk;

• smart-contract and wallet risk;

• tax and reporting risk.

For most people, that argues for small sizing until the market structure matures. Avoid leverage at the beginning. Do not use tokenized stocks as emergency cash. Do not park money you need for taxes, tuition, payroll, rent, or debt payments in a product whose redemption path you have not tested.

A useful rule: size the position based on the weakest link, not the brand name of the underlying stock.

10. Record keeping

Tokenized stocks can create messy records. You may have fiat deposits, stablecoin swaps, blockchain transfers, token purchases, token sales, dividends or dividend equivalents, FX conversions, wallet movements, and corporate-action adjustments.

Keep a simple spreadsheet with date, venue, ticker, product type, action, amount, price, fees, FX rate, chain/transaction hash, statement links, and notes on dividends or corporate actions. Do not wait until tax season. Your future self will hate you.

11. Red flags

Walk away or slow down if you see any of these:

• The site says “own real stocks” but the legal document says “derivative” or “synthetic exposure.”

• No clear issuer name.

• No clear custodian, broker, trustee, or reserve disclosure.

• No explanation of bankruptcy treatment.

• “Guaranteed tracking” or “risk-free yield” language.

• VPN instructions for restricted jurisdictions.

• Huge APYs for providing liquidity in a tokenized-stock pool.

• Contract addresses shared only through social media.

• No explanation of corporate actions, dividends, delistings, and trading halts.

• No tax documents or exportable trade history.

• Product claims SIPC/FDIC-style protection without a precise explanation of who is covered and for what.

Bottom line

Tokenized stocks are not a gimmick anymore. By 2026, there are real products from Kraken/xStocks, Bybit/xStocks, Robinhood EU, Dinari/Gemini, Swarm, Ondo Global Markets, and others. The market is moving from experiments to infrastructure.

But the category is still young. The phrase “tokenized stock” is doing too much work. Sometimes it means a tracker certificate. Sometimes it means a derivative. Sometimes it means a 1:1-backed token with limited transfer rights. Sometimes it means a CFD or perp wearing an equity costume.

So the practical investor’s approach is simple: start with structure, not ticker. Understand the issuer, the legal claim, the backing, the transfer rules, the redemption path, and the risks before caring whether the token tracks Apple, Nvidia, Tesla, or an ETF.

The future of stocks may be more onchain. That does not mean every onchain stock product deserves your money.